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Preface 
Organ transplantation has saved the life of many people throughout the world, who 
suffered from end·stage organ failure. The University Hospital Rotterdam·Dijkzigt, 
is one of the Dutch organ transplant centers, in which kidney, heart and liver 
transplantation are performed. In close conjunction with hurdles encountered in 
clinical organ transplantation, experimental transplantation research has been for 
a long time one ofthe points ofinterestofthe Department of Surgery. Experimental 
work in small and large animal models to overcome the thresholds to successful 
intestinal transplantation has been of special interest for years. My scientific 
curiosity for the transplantation·field was provoked during participation as a 
student in a research project at the Laboratory for Experimental Surgery to 
investigate xenogeneic islet transplantation as therapy for diabetes mellitus. 
In addition to search for new transplant modalities, we also try to improve 
long. term graft survival as data show that clinical organ transplantation has not 
yet achieved its full potential on the long· term. Beyond one year post· 
transplantation, the half·life of organ grafts has little changed since the 
beginning ofthe transplantation.era. Long·term graft survival is predominantly 
hampered by chronic transplant dysfunction (CTD). So far, no drugs can 
prevent CTD and a therapeutic strategy is not within hand's reach, since causes 
and mechanisms leading to CTD are poorly known. Retransplantation is at 
present the only effective therapy. 
In '995, I first started experiments at the Laboratory for Experimental Surgery 
to gain insight into the etiology of CTD: The role of ischemia and surgery was 
shldied in an aorta transplantation modeL Participating in ongoing experiments, 
at the Departments of Medicine and Surgery, Monash University, Melbourne, 
Australia I investigated the pathogenesis of CTD after small bowel transplantation 
in a rat modeL From a clinical point of view, I continued experiments on the 
pathogenesis in the kidney and studied the effect of ischemia, surgery and 
genetics. TI,ese studies were carried out in close collaboration with the 
Departments of Paediatric Surgery and Pathology, Erasmus University and with 
the Department of Nephrology, University Hospital, Essen, Germany. 
This thesis outlines the problem of CTD, presents the results of the 
experimental studies mentioned above, and finally discusses tl,e results. 
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Chronic transplant dysfunction 
Chapter 1 
1.1 The problem of chronic transplant dysfunction 
Since it was first shown in '954 that successful transplantation of a healthy kidney 
could completely rehabilitate an individual with renal failure, transplantation of 
several organs has become an increasingly successful medical treatment for those 
with end.stage organ failure. In 1998, in only the Eurotransplant area, more than 
3000 kidneys, 750 hearts, about IOOO livers, 230 lungs and about IOO pancreas 
from cadaver donors were transplanted.' Worldwide, 56 intestinal transplantations 
were performed in 1996.' The short-term results after clinical organ 
transplantation have improved progressively, principally due to refinements in 
tissue typing, advancements in organ preservation, operative techniques and 
ancillary care, more effective immunosuppressive agents, and better monitoring 
after engraftment. For example, one year survival of cadaveric kidneys has 
increased from approximately 50% by the end of the 1960s to about 85% 
nowadays,' and for living-related kidneys from 80% to 90-95%.4 
Figure I. 
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Despite the strongly improved early results, clinical transplantation has not 
achieved its potential as a long-term treatment for disease. Beyond one year the 
annual rate of graft loss has not improved as much as one year results. The half-
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life of cadaver kidney allografts, for instance, has remained consistently at 7. 5'9· 5 
years (Figure I),"6 although the most recent data indicate that there is a slight 
improvement in half-life after the first year.' Other organ transplants generally 
show comparable results, with exception of the liver, which shows more 
favourable long-term results.'" 
Although a series of factors including recurrent and de novo disease, drug 
toxicity, acute rejection and non-compliance may contribute to late graft loss, 
chronic transplant dysfunction (CTD) is the most important, single cause oflate 
graft deterioration and failure. Kidney graft loss is in 35 to 58% due to CTD,'"·n 
more than 70% oflung allografts had CTD 5 years post-transplantation," more 
than 50% of the heart transplants had severe coronary arteriosclerosis at five 
years,']'" and about 9-26 % of graft loss of liver transplants was due to CTD."·" 
There is still no treahnent to inhibit or prevent CTD, and a logic therapeutic 
strategy is not within hand's reach, since its etiology and pathophysiology are 
poorly known. Until now, re-entry to dialysis in case of a kidney graft or direct 
retransplantation are the only effective therapies, the latter thereby heavily 
contributing to the problem of donor shortage. 
1.2 Definition of chronic transplant dysfunction: functional 
and histological characteristics 
CTD is the phenomenon in solid organ transplants in which a gradual 
deterioration of graft function occurs months to years after transplantation, 
eventually leading to graft failure, and which is accompanied by characteristic 
histological features. 
Clinically, CTD in kidney grafts manifests itself as a slowly progressive 
decline in glomerular filtration rate, usually in conjunction with proteinuria and 
arterial hypertension."'" In heart transplants, CTD presents itself with congestive 
heart failure, acute infarction, arrythmias and most dramatically, as sudden 
death.'" The diagnosis of liver CTD should be based upon clinical evidence of 
chronic liver disease consisting of persistent enzyme abnormalities, elevated 
bilirubin, diminished synthesis of protein and blood clotting factors." Intractable 
diarrhoea and weight loss are the accompanying symptoms in intestinal 
transplants with CTD." 
The cardinal histomorphological feature of CTD in all parenchymal allografts 
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is fibroproliferative endarteritis." Other terms frequently used for this lesion are 
transplant arteriosclerosis, graft vasculopathy, graft vessel disease or intimal 
hyperplasia. The vascular lesion affects the whole length ofthe arteries, although 
in a patchy pattern. There is concentric myointimal proliferation resulting in 
fibrous thickening and the characteristic 'onion skin' appearance of the intima 
in small arteries." Other findings include endothelial swelling, foam cell 
accumulation, disruption of the internal elastic lamina, hyalinosis and medial 
thickening, and presence of subendothelial T-lymphocytes and macrophages."! 
In addition, a persistent focal perivascular inflammation is often seen. 
Figure 2. Intimal proliferation in small artery of a kidney transplant 
Although intimal hyperplasia is very specific for CTD, the diagnosis of CTD in 
biopsies of allografts is frequently based on other, less specific abnormalities, 
since intimal hyperplasia is very patchy and affects mainly arteries larger than 
those seen in biopsies. 
In the cardiac allograft, concentric intimal hyperplasia is the only histological 
feature of CTD. 11,e myocardium appears to be no primary target in the CTD 
process: The small, triangular-shaped fibrosis in the heart muscle is the 
remainder of an infarction as result of vessel occlusion. 'l 
In addition to vascular changes, a CTD kidney shows parenchymal 
manifestations, including interstitial fibrosis, tubular atrophy and glomerulopathy. 
Chronic transplant glomerulopathy - duplication of the capillary walls and 
mesangial matrix increase - has been identified as a highly specific feature of 
kidneys with CTD." Less specific lesions are glomerular ischemic collapse, 
tubular atrophy and interstitial fibrosis. Furthermore, peritubular capillary 
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basement splitting and laminations are associated with late decline of graft 
function." The criteria for histologic diagnosis of CTD in kidney allografts are 
internationally standardised in the BANFF scheme for Renal Allograft Pathology." 
CTD in the liver is characterised by intimal hyperplasia in medium-sized vessels, 
similar to that seen in other organs. In biopsy samples, diagnostic indicators are 
non-specific hepatocellular changes, centrilobular ballooning, degeneration, 
atrophy, fibrosis and canalicular cholestasis, especially seen in the centrilobular 
zone."·"-" Sometimes overlapping with the vascular changes is the loss of bile ducts, 
called 'chronic vanishing bile duct syndrome' or 'ductopenic rejection'. ,,-"-" 
The histopathological hallmark of CTD in the lung is bronchiolitis 
obliterans," a lesion characterised by submucosal fibrosis and chronic 
inflammation ultimately leading to obliteration of the terminal airway. 
Obliterative endarteritis, if found, is diagnostic of CTD of the pancreas. Acinar 
tissue loss, fibrosis and absence of pancreatic islets are frequently found." In 
human small bowel allografts, CTD is evidenced by patchy intimal hyperplasia 
and parenchymal lesions such as distorted mucosal architecture with focal 
necrosis and ulceration, villous blunting, loss of goblet cells, and focal lamina 
propria fibrosis.3.5.16 
Table I. 
Kidney Heart Intestine 
Low.grade inflammation Low.grade inflammation Inflammation 
Arteriosclerosis Arteriosclerosis Arteriosclerosis 
Glomerular basal Fibrosis Mucosal atrophy 
membrane thickening 
and sclerosis 
Tubular atrophy 
Fibrosis 
Muscular hyperplasia 
Fibrosis 
Histopathology of chronic transplant dysfunction in different organs 
Until now, such typically functional and histologic changes of allografts are 
often di~gnosed as 'chronic rejection'. However, the designation 'rejection' 
presumes a host alloimmune responsiveness to be basis for these changes. Since 
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there are indications that non-alloimmune mediated factors involved in organ 
transplantation can cause similar functional and histopathological changes, 
calling the process on the whole chronic rejection is not satisfactory, both from 
a mechanistic and therapeutic point of view. When seen as a pure immunologic 
process, immunosuppressive drugs are the goal to treatment, whereas non-
alloimmune mediated processes need other treatment. As long as the result -
dysfunction and characteristic histologic changes - cannot be exclusively 
attributed to an alloimmune-mediated pathway, it is recommended to call the 
process CTD that leaves any causative factor out of consideration. 
1.3 Etiology of chronic transplant dysfunction 
In 1963, Porter et al. reported four human cadaveric kidney allotransplants in 
which striking obliterative vascular lesions developed a few months after 
transplantation." All patients had experienced early episodes of acute rejection, 
and the subsequent vascular lesions were thought to have an immunological 
basis. These cases suggested that the process of allograft rejection can evolve 
from early acute cellular infiltration of the engrafted organ to a more chronic 
process, ultimately resulting in intimal arterial thickening, with interstitial 
fibrosis. However, until now the cause of CTD remains ill defined. Two working 
. hypotheses are proposed to understand the process: 1) the phenomenon leading 
to CTD is the result of an ongoing host alloimmune response. 2) Non-
alloimmune responses-to-injury, such as ischemia, can cause or aggravate the 
process. 
1.3.1 A1loantigen-specific factors 
Several clinical and experimental data indicate that CTD is the result of the 
recipient's immune response to incompatible donor tissue antigens. In this 
view, the relationships between the following identified risk factors and CTD all 
reflect an alloimmunologic mechanism: 1) Histoincompatibility, 2) Acute 
rejection, 3) Suboptimal immunosuppression/non-compliance, and 4) Anti-
donor specific antibodies 
16 
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H istoineo III pa tibility 
Antigenic disparity in humans between donor and host is associated with the 
occurrence of CTD, as demonstrated in kidney, heart, and lung transplant 
studies. In these multicenter studies, long. term graft survival appeared to be 
strongly correlated with the degree of histocompatibility between donor and 
recipient.'·'·"·" Cadaveric kidneys with zero HLA·mismatches have a half·life of 
'3.2 years compared to 7.0 years in grafts with six·allelic mismatches.' 
Interestingly, some large unicentre studies are unable to demonstrate the benefit 
of histocompatibility matching for the development of CTD in kidneys and 
hearts, independently of the effect of acute rejection."·' It is presently unclear 
whether matching directly affects the development of CTD or whether this 
results from a decreased incidence of acute rejection episodes."'''''' 
Acute rejection 
Graft survival studies from both uni· and multicentres show a strong correlation 
between acute rejection episodes and the lifespan of a graft. "." For instance, 
Matas et al. showed in a group of 278 cadaver kidney graft recipients that a single 
rejection episode in the first post·transplant year reduces the estimated graft half· 
life from 33 years to 22 years, whereas multiple rejections or a single rejection 
after the first year decreases the half·life to less than 5 years." M ore specific, 
several retrospective analyses of organ grafts with CTD demonstrate that acute 
rejection is strongly related to the development of CTD in all types of organ 
transplants.'l4'·'·'~S4 Basadonna et al. reported that in a cohort of 205 cadaverrenal 
transplant recipients, the incidence of biopsy. proven CTD was 0% in the I09 
patients without acute rejection, 36% in the 69 patients with an acute rejection 
within the first 2 months after transplantation (P<O.001), and 63% in the 27 
patients with acute rejection 60 days after transplantation (P<O.001)." Other 
clinical studies have corroborated and refined these findings: The onset, 
frequency, and severity of an acute rejection episode are independent risk factors 
for CTD.4<"·"·,,·,' Acute rejections Witll complete functional recovery do not have 
a deleterious effect on the long. term outcome."'" whereas an increased baseline 
serum creatinine after treatment of an acute rejection episode is associated with 
CTD."·" In addition, the vascular type of acute rejection appears to be a stronger 
risk factor for the occurrence of CTD than interstitial rejection." Thus from 
clinical studies, the impact of a single acute rejection episode with a complete 
functional recovery in the early posttransplant period is minimal, whereas late 
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and more severe acute rejection episodes are more likely to develop CTD. 
Experimental studies in kidney, heart and lung transplantation models 
confirm these clinical observations."'" For instance, Yilmaz and Hayry showed 
in rat kidney allografts that intimal hyperplasia increased from o.S±o.4 in a scale 
from 0 to 3 in the no-rejection group to I,7±o.9 in the group with one rejection 
(P<O.OI), to 2.2±O.3 in rats with 2 rejections (p~O.OOOI), and to 2.2±O.S for rats 
with 3 or 4 rejections (P<O.OI)." Nonetheless, acute rejection is not a prequisite 
for CTD: patients also develop CTD without prior acute rejection episodes.'o."." 
Reviewing the literature it can be stated that at present acute rejection is the most 
consistently identified clinical risk factor for the occurrence of CTD. 
suboptimal immunosuppression and noncompliance 
A low dose of maintenance Cyclosporin (CsA) medication in some clinical 
studies has been associated Witll CTD:,·GG.6, but not in others." At S years post-
transplantation, the percentage of recipients who were free of CTD as 
demonstrated by biopsy was 86% for those using CsA > smg/kgjday versus 77% 
for those on <S mg/kg/day.6, Additional evidence that CTD may be related to 
inadequate immunosuppression was provided by the histopatllOlogical shldies 
of Isoniemi et al." They found that CTD-lesions were less apparent in patients 
given protocols of triple-versus double-dose immunosuppressive therapy. 
Experimentally, previous investigations at our own institution demonstrated 
that in a rat aortic allograft model both high dose CsA as well as Rapamycin were 
able to abolish the inflammatory response, and concomitantly inhibit the 
generation of intimal lesions during the 4-weeks follow-up period.'o Other 
groups also reported that high dose of CsA alone" or in combination with 
leflunomide" or with methylprednisolone and azathioprine" can prevent CTD in 
allografts. However, in man it would be impossible to maintain high doses of 
immunosuppressants on the long-term, because of toxic side effects of the 
various drugs, e.g. nephrotoxicity caused by CsA and FK s06.74 
Noncompliance also indicates that CTD may result from inadequate 
immunosuppression.''''' In a Shldy by the Minneapolis group 34% patients were 
noncompliant and this was associated witlllate deterioration of graft function." 
Anti-donor antibodies 
Many studies have shown that following renal,"'s, cardiac,"'" or hepatic 
transplantation," the majority of patients produce antibodies. Both preformed 
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antibodies reactive against donor tissue and antibodies after transplantation 
against HLA class I antigens and against tissue (endothelial cells, smooth muscle 
cells) are found. A correlation between antibody and CTD, however, is not 
consistently found. 66.k8J.88·9 l 
No difference in panel-reactive antibody levels was found between patients 
whose grafts were still functioning versus those who lost their graft due to 
CTD.67.,o Likewise, Hosenpud et al. could not demonstrate differences between 
the presence of IgM antibodies against endothelial cells of kidney grafts with and 
without CTD." Other investigators, however, observed significantly more anti-
donor reactivity against both HLA class I and II in sera of patients with biopsy-
proven CTD in kidneys (94-4%) than in sera of patients with a normal 
functioning graft {I2.8%)." Likewise, in 70% of the liver allografts with CTD 
patients had non-HLA anti-smooth muscle and anti-nucleus antibodies, which 
were not present in patients with a healthy liver transplant.'" 
Experimentally, Paul and colleagues demonstrated IgG antibodies against the 
glomerular and tubular basement membrane, the mesangial cell, and 
endothelial cell antigens in sera of rats with a kidney allograft with CTD, whereas 
such antibodies were not found in sera from animals that had received a 
syngeneic graft."·" In other experimental models of CTD, the presence of 
antibodies was noted in areas with intimal hyperplasia.,6.97 
I.3.2. Non-Alloantigen associated factors 
In the late 80-ies, attention has been redrawn to the fact that in the pre-
immunosuppression era even human kidneys transplants between identical 
twins developed late morphologic changes. Two-third of these kidney isografts 
developed glomerular lesions -hypercellularity, increase of mesangial matrix and 
immunoglobulin deposition - between 2 months and I6 years post-
transplantation that was classified as recurrence of the original disease, 
glomerulonephritis." Two of these grafts with glomerular lesions developed in a 
later stage additional vascular lesions. It was also suggested that such changes 
observed in human renal isografts might have been a consequence of the 
transplantation injury per se." 
Nowadays, based upon clinical and experimental data from different organ 
transplants, surgical injury and other, non-alloimmune specific factors related to 
the donor and the graft have been associated to the development of CTD."'''' 
Cliapter 1 
These risk factors include: ischemia, brain death, viral infections, hyperlipidemia, 
hypertension, age, gender, race, and the amount of functional tissue. 
Table 2. 
Ischemia 
Alloantigen specific factors 
Histoincompatibility 
Acute rejection 
Suboptimal immunosuppression 
Anti·donor antibodies 
Non·al1oantigcn specific factors 
Ischemia 
Brain death 
Infection 
Hyperlipedemia 
Age 
Gender 
Race 
Size 
Risk factors for chronic transplant dysfunction 
In clinical transplantation it is still unclear if ischemia participates in the 
development of CTD. Whereas some studies reported that prolonged cold 
ischemia reduces graft survival,H-PO} other centres found no correlation.4~.lo4 For 
instance, the UNOS registry showed that preservation for >24 hours significantly 
impaired late kidney graft survival rates compared to cold ischemic times 
between 0 - 24 hr.' In cardiac transplants, a prolonged ischemic time was a risk 
factor for transplant arteriosclerosis.'" 
Experimental transplant studies have been demonstrated that ischemia can 
cause CTD·like lesions in the absence of allogenicity. Tilney and co·workers 
demonstrated that rat kidney isografts develop the same functional and 
morphologic changes as allografts, including vasculopathy, albeit over a much 
longer time interval.'" 11,ese changes appeared to be triggered mainly due to 
ischemia. Clamping the renal vessels of a unilaterally nephrectomized rat caused 
functional deterioration identical to isografts at I year post-surgery. Similarly, on 
the long-term syngeneic aorta and heart transplants develop intimal 
hyperplasia. ,,6.'07 In isografts the degree of intimal hyperplasia correlates with the 
duration of the ischemia period.lo6.lo7 
Nonetheless, it is much less clear whether the length ofthe ischemic period plays 
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a role in the onset of CTD in allografted organs. Whereas Hayry's group showed 
that in renal allografts a cold ischemic time of 60 minutes led to increased 
intimal proliferation and glomerulosclerosis compared to kidneys subjected to 
30 min cold ischemia,'" in heart and aortic allografts the duration of the cold 
ischemic period did not have an influence on the degree of CTD."'·"9.'" 
It has also been suggested that in allografts the effect of ischemia on CTD is 
indirect: Ischemia might predispose for acute rejection, the latter being the most 
consistent clinical risk factor for CTD. Organ grafts with prolonged cold ischemia 
or with delayed graft function, which is a parameter that correlates with the 
ischemic period, experience more often an early acute rejection episode than 
grafts that functioned immediately,'O).IIH'4 
Brain death 
The striking divergence in clinical long-term results between kidney grafts from 
cadavers and those from living-related and unrelated donors'" has drawn 
attention to the healthiness of an organ before procurement. The hypothesis has 
been put forward that brain death activates surface molecules on peripheral 
organs via cytokines: In brain death donors, increased serum cytokine levels, 
such as IL-If), IL·6, IL·S, TNF-a, and RANTES are found before organ 
procurement.'" In experimental models of brain death, peripheral organs have 
increased endothelial cell activation""'" and a more accelerated tempo of acute 
rejection in organs from brain death animals is observed."9m The relevance for 
CTD still has to be proved. 
Viral infection 
Whereas infection with cytomegalovirus (CMV), a member of the herpes virus 
family has shown to be related to CTD in cardiac, liver, and lung 
transplantation."'"'''''''' its association with CTD in kidney transplants is not yet 
clear. A multivariate analysis on risk factors for CTD performed on 675 renal 
allograft recipients at Hennepin County Medical Centre in Minneapolis showed 
no difference in the incidence of CMV infection in patients who did or did not 
loose their grafts to CTD." 
CMV infection has been experimentally identified as promotor of CTD in 
aorta, kidney and heart transplants.",-.,6 CMV infection directly affects 
intercellular adhesion molecule-I (ICAM-I) expression on endothelial cells'" and 
induction of MHC class II antigens is observed, together with a prolonged and 
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increased acute cellular infiltration of T cells and macrophages.,,6,"7 In both 
hearts and kidneys, a more pronounced intimal hyperplasia was seen."',"7 
Similarly, administration of lipopolysaccharide, an endotoxin of Escherichia coli 
to a rat model of kidney CTD led to an earlier expression of ICAM-, which 
correlated with an accelerated pace ofCTD.""'" 
Hyperlipidemia 
In patients bearing kidney or heart transplants, hyperlipidemia is considered as 
a risk factor for allograft arteriosclerosis."o"" However, different opinions 
exist.'"'''' The relevance of hyperlipidemia in animal transplant models has also 
been a matter of controversy. Alonso et al:" Fellstrom et al:,6 and Tanaka et al'J7 
have reported enhancement of arteriosclerosis by hyperlipidemia, whereas 
Mennander et al:" and Adams et ai'" could not confirm these observations. 
Hypertellsioll 
Systemic hypertension in clinical kidney and heart transplants is associated with 
CTD."o"" In heart transplant recipients, hypertension was associated with an 
earlier onset of CTD.''' In renal allograft recipients, hypertension is a common 
event (75%), although its role as a causative factor or a consequence of renal 
dysfunction is difficult to define since a vicious circle is created where the 
worsening of one parameter leads to worsening of the other.''' 
Experimental studies showed that systemic hypertension accelerates CTD in 
kidney allografts,4' whereas antihypertensive dmgs inhibited the progression of 
chronic allograft dysfunction.',6 Similarly, in rat aortic transplants, hypertension 
was associated with a significant increase of intimal thickness, while ACE· 
inhibitor was able to decrease systolic blood pressure by 30%, and concomitantly 
reduce intimal lesions by 40%.''' 
DOllor age 
Donor age is a controversial risk factor. Some investigators have found that grafts 
from donors over 60 years of age are associated with poorer survival rates.4 ""o 
Cardiac transplants from an older aged donor had an earlier onset of CTD. "','" 
Gender 
In male recipients, solid organ grafts appeared to be more vulnerable for the 
development of CTD. In cardiac allografts the onset of arteriosclerosis was earlier 
22 
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in males than in females'" and another study reported that the prevalence of CTD 
was higher in male than in female recipients: 30% versus 50% free of coronary 
artery disease at 5 years (p = o.or).''' n,e UNOS Transplant Registry reported a 
similar observation for kidney grafts.' 
Experimental shldies have corroborated the observations: In rat syngeneic 
aorta transplants, the female gender protects against myointimal hyperplasia.''' 
This gender effect could reflect oestrogen. Oestrogen protects against 
cardiovascular disease and, it has been demonstrated that oestradiol effectively 
inhibits transplant arteriosclerosis in experimental models.'~·'" 
Race 
Long-term survival of cadaveric renal transplants appeared to be related to race: 
Five.year graft survival rates were 66% for Asians, 6r% for Caucasians and 
Hispanics, and 47% for Black recipients.''' Black recipeints of heart transplants 
developed earlier CTD than non-blacks.''' 
Functional tissue mass 
One risk factor reserved to the kidney is the contribution of reduced numbers of 
nephrons to the progression of CTD. In non-transplant models in the rat, it is 
well established that kidneys with significantly reduced numbers of nephrons, 
such as in the 'remnant kidney model', develop glomerulosclerosis, hlbular 
atrophy and interstitial fibrosis in response to an increased workload of the 
remaining nephrons, i.e. hyperfIltration.',8.,,, In a chronic kidney allograft model, 
Heemann et al. demonstrated that reduction of renal mass led to earlier onset of 
CTD and shortened survival. Moreover, isografts and non-transplanted, ablated 
kidneys haVing only r/6 of total mass experienced proteinuria in a same tempo as 
allografts, whereas 2/6 or 3/6 nephrectomized native and isografted kidneys had 
negligible damage.'" Thus, the reduction of functioning renal mass accelerated 
the changes characteristic for CTD, and after a substancial reduction, 
hyperfiltration plays an overriding role in further deterioration. In the same 
animal model, the inadequate nephron supply was further investigated by 
comparing one allograft plus one retained native kidney, or two allografts with one 
allograft with bilateral nephrectomy. Recipients with 2 kidneys had less allograft 
injury and had no hyperfIltration and normal glomerular pressures whereas 
solitary grafts revealed hyperfIltration and increased glomerular pressures.'" 
Nonetheless, in clinical kidney transplantantion the significance of a mismatch 
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between donor nephron supply and functional metabolic demand of the 
recipient in the development of CTD is unclear. Poorer survival of grafts from 
very young, elderly, black or female donors compared to grafts from donors aged 
15'55, non·black or male donors has been ascribed to hyperfiltration damage.'" 
None of these CTD.prone conditions, however, are uniformly found. Miles et a/. 
did not find that the donor kidney size was different in patients who lost their 
graft due to CTD compared with those with stable function.'" Others also did not 
see differences in CTD between pediatric kidney recipients and adult·kidney 
recipients.'" Paired pediatric kidney transplantation did not improve renal 
function compared to small single pediatric kidneys.'" 
1.4 Pathophysiology of chronic transplant dysfunction 
As outlined in paragraph I.2, CTD is characterized by morphological evidence of 
destruction of the transplanted organ!' The common denominator in all 
parenchymal organs is the development of intimal hyperplasia. Whether the 
parenchymal changes with fibrosis occurs secondary to gradual arterial 
insufficiency and ischemia or develop from ungoing subclinical host 
immunologic attack or other factors remains undefined. 
Immunohistochemistry of allografts with CTD has shown that T cells and 
macrophages are the predominant graft·invading cell types, with an excess of 
CD4+ over CD8+ T cells."·,66.,,, Increased expression of adhesion molecules 
(!CAM'I, VCAM.I),',H" and MHC antigens""" are seen in allografts with CTD. 
Also, complement and immunoglobulin deposits is seen in areas with intimal 
hyperplasia.,6.",.,,, Little consistent information is available regarding the 
expression of growth.regulating factors and their receptors in organ transplants 
with CTD. An increased TGF·j3 expression, however, is frequently found.''''''' 
The histologic lesions, including intimal hyperplasia, the infiltrating cells, 
upregulated adhesion molecules, and cytokines in organ transplants with CTD 
do not necessarily reflect an alloimmune·mediated response. As already 
mentioned, syngeneic transplants, ischemia· or mechanical.injured organs also 
show cell infiltration, upregulation of cytokines and develop CTD·like 
lesions.""'" Notwithstanding, the development of the lesions occurs much more 
rapidly in allografts, suggesting that alloimmtme responses playa role.''' The 
most consistent clinical risk factor 'acute rejection' also indirectly indicates that 
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an alloimmune response is involved in CTD and suggests that CTD is, for the 
main part, the result of insufficient immunosuppression. More evidence to 
support this hypothesis comes from experiments which have demonstrated that 
pretransplant immunizations with donor splenocytes accelerate CTD, ,8, whereas 
manipulations aimed at induction of tolerance delay the process.""'" 
In the following subparagraphs, we postulate the route through which an 
organ transplant may develop CTD. 
I.4.r Initial response-to·injury 
Endothelial cell activation 
The specific adhesion of cells to other cells or to particular tissues is a basic 
function of cell migration and recognition. Under normal conditions, contact 
between leukocytes and vascular endothelium is random if both cell types are 
inactive and at rest, the cells touch vessel walls indiscriminately. 
In organ transplantation, the endothelial cells are activated by ischemia, 
surgical manipulation, and reperfusion injury, events inherent to the procedure. 
After ischemia and reperfusion, endothelial cells produce oxygen free radicals 
predominantly via the xanthine· oxidase pathway, which in vitro activate and 
damage the cells.'" Upon activation, the endothelial cells retract and release 
increased amounts of the cytokines IL-I, IL·6, IFN-y, TNF-a, the chemokines 
IL-8, macrophage chemoattractant protein (MCP)-r, macrophage inflammatory 
protein (MIP)-r and MIP·r, colony stimulating factors, and multiple growth 
factors such as, platelet derived growth factors (PDGF), insulin growth factor-r 
(IGF·r), transforming growth factor (TGF).p, and pro-thrombotic molecules 
(tissue factor, plasminogen activator inhibitor). This secretion enhances 
migration of neutrophils, monocytes/macrophages and T lymphocytes to the site 
of injury.") The release of cytokines also led to upregulation of adhesion 
molecules on the vascular endothelium.")"" The proinflammatory cytokines IL·r 
or TNF·a induce the expression of the adhesion molecules P- and E-selectin on 
the endothelium,""'" by which circulating leucocytes begin to adhere via binding 
to their surface carbohydrates.""'" Leucocytes are then triggered by the 
chemokines released by the endothelium, which causes upregulation of the 
affinity of the p2-integrin receptors LFA-r and MAC-r on their surface. This 
enables a permanent adherence of leucocytes to the endothelial adhesion 
molecules ICAM·r and VCAM-r,""'" which expression is induced by the released 
cytokines IL·rp, IFN-y, TNF·a.'''·''' Activated complement also plays a role in the 
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adhesion of neutrophils and monocytes to endothelium.'96 Finally, extravasation 
of leucocytes occurs to the extracellular matrix and graft tissue, presumably 
facilitated by activated complement'''''9' and oxygen free radicals, which increase 
the permeability between endothelial cells.'" 
The first cells that inmtrate the graft are neutrophils. They further aggravate the 
inflammatory response through release of oxygen free radicals and inflammatory 
mediators, including platelet activating-like factors and leukotrienes. 
Direct evidence that oxygen free radicals, adhesion molecules, and neutrophils 
playa role in the pathogenesis of CTD is shown by interference studies. '99'''' One 
recent study, for instance, revealed that carotid allografts from donor mice deficient 
in ICAM -I had a 52% reduction of intimal hyperplasia compared to controls. "l 
In addition to the increased expression of adhesion molecules on the 
endothelium, after reperfusion of a transplanted organ a drama tical upregulaton of 
MHC class I and II antigens on the endothelium occurs,""'" which appears to be 
induced by release of cytokines IFN-y, TNF-a and TNF-/l.'" Alterations in tissue 
density ofMHC class II antigens are likely to influence the alloimmune response 
against the tissue.'" Parenchymal cells are also activated after ischemia. In non-
transplanted kidneys MHC class I and II antigens are upregulated on the tubular 
epithelium. ",·"9 Epithelial cells in lung autotransplants showed after cold ischemia 
a mild expression ofMHC class II.'" 
CD4+ T-lymphocytes infiltrate ischemic allografts, isografts and non-
transplanted organs.''''''''''" In addition, T cell associated cytokines, such as IFN-y 
and TNF-a are produced'"'''' and blockade of the C28-B7 costimulatory pathway 
decreased early influx ofT cells and expression ofT cell associated cytokines.'" 
The role for CD4+ T-lymphocytes in ischemia has been elegantly demonstrated. 
In a liver ischemia model, CD4+ T cell deficient mice had significantly less 
hepatic damage.'" 
This response to ischemic injury is initially independent from allogenicity: 
Heemann et al. demonstrated that the pattern of cellular inmtration and cytokine 
expression in both syngeneic and allogeneic cardiac grafts was similarly if not 
identically within the first 48-72 hr after engraftment. '" 
Thus as result of the transplant procedure, a complete network of cytokines is 
already activated, even before allogeneic reactions develop. Some pre-transplant 
conditions of both donor and recipient, discussed in paragraph I.3 appear to 
aggravate this initial injury. 
Introduction 
Alloimmune response 
In transplant recipients, the recognition of his to incompatible MHC alloantigens 
will provoke an alloimmune response. Class I antigens, constitutively expressed 
on nucleated cells, interact with CD8+ cells, and class II antigens, constitutively 
expressed on lymphoid cells and inducible on endothelial cells, macrophages and 
fibroblasts are recognised by CD4+ cells.'" Intact foreign MHC molecules on 
donor cells may be directly recognised by T cells, either in combination with an 
allopeptide or a selfpeptide, ", which results in an exceptionally strong immune 
response. Frequencies ofT cell precursors that respond to alloantigens are ro to 
100 fold higher than for other nominal antigens.'" The common pathway of 
antigen presentation also takes place in allotransplantation: In draining lymph 
nodes and spleen, alloreactive T-cells recognise donor MHC as processed 
peptides presented by self-MHC molecules on recipient antigen presenting 
cells. '" TI,is is called 'indirect allorecognition'. 
In allorecognition, the MHC antigen is bound to the T cell receptor. For 
activation of the T-cells, costimulatory pathways as the CD28 receptor on T cells 
with its ligand B7 and CD40 with its T-cell based ligand, CD40L are mandatory 
for the promotion of T-cell effector function and proliferation. The adhesion 
molecules ICAM-I, VCAM-I and LFA-3 have also been shown to co-stimulate T 
cell activation. Once the CD4 + T cell is activated, a cascade of events amplifies the 
alloimmune response: Secreted IL-2 leads to clonal proliferation of alloreactive 
cells and stimulates CD8+ T cells to develop into mature cytotoxic effector cells. 
Release of cytokines such as IFN-y, TNF-a., may further increase the expression 
of adhesion molecules, and MHC antigens on the endothelium, smooth muscle 
cells and parenchymal cells. IFN-y is also responsible for the activation of 
macrophages, which together with CD8+ cells are cytotoxic to the graft cells, 
leading to acute graft failure, when no immunosuppressive intervention is given 
to prevent or to overcome this CD4 + T-cell mediated alloimmune response. 
Despite inhibition ofT cell activation by Cyclosporin, FK 506, or anti-IL-2 
monoclonal antibodies, these therapies do not prevent the development of CTD 
in clinical transplantation, probably due to too low doses of these drugs. In 
experimental models, continuously high dosis of Cyclosporin A or blockade of 
CD28/B7 and CD4o/CD4oL costimulatory pathways decrease early infiltration 
and almost completely inhibit intimal hyperplasia in murine aortic and cardiac 
allografts.'9,o'''''''9 The striking evidence that the CD4+ T cell is involved in the 
genesis of intimal hyperplasia is elegantly exemplified by Shi et al: Carotid 
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allografts in mice which were genetical deficient for the CD4+ T cell developed 
intimal thickening to only 40% of that seen in controls."" 
Anti-donor specific antibodies 
The cytokines IL-4, IL-6, and IL-ro released by activated CD4+ cells are growth 
and differentiation factors for B cells. Activation of B cells may result in 
maturation into plasma cells with allospecific antibody production. Since 
immunoglobulin, complement, antigen-antibody complexes have been found in 
areas of intimal hyperplasia/"'''' humoral activity has long been thought to be 
primarily responsible for CTD. A recent finding of upregulated immunoglobulin 
J chain in arteriosclerotic lesions suggests the presence ofIgM- or IgA-producing. 
plasma cells in such grafts.''"' Donor-specific antibodies are found against HLA 
antigens, endothelial cells, mesangial cells, glomerular and tubular basement 
membrane, smooth muscle cells and the nucleus.""""'''' 
The precise significance of antibody deposition that mitigates over time, as 
shown in many animal models,"""'" remains to be established. In experiments 
with scm mice, which lack T and B cell mediated cellular responses passive 
transfer of anti-donor specific antibody was sufficient to produce graft 
arteriosclerosis with a perivascular mononuclear cell infiltrate in longstanding 
cardiac allografts.'" Whereas some investigators found that the degree ofintimal 
hyperplasia aortic and cardiac allografts in mice recipients with a defect of 
humoral antibody production was comparable to that seen in immunocompetent 
mice,'" Russell et al. showed that cardiac allografts in B-cell deficient mice did 
not develop fibroproliferative arteritis.'" These investigators also demonstrated 
that in two donor-recipient mice combinations in which anti-donor antibodies 
are generally undetectable, intimal fibrosis was uncommon, whilst these 
recipients became capable of producing fibrous lesions in allografted hearts 
when given anti-donor, class I antibody.'" Similarly to Russell's report, Shi et al. 
showed that CD4+ cells, humoral antibodies and macrophages together were 
necessary for intimal hyperplasia in a mice carotid allograft model. Arteries 
allografted into mice deficient in both T-cell receptors and humoral antibody 
showed almost no neointimal proliferation, whereas those grafted into mice 
deficient only in humoral antibody developed minimal intimal hyperplasia. "" 
The mechanism by which antibodies contribute to CTD is rather speculative. 
One recent study has shown that anti-HLA antibodies when sticked to their HLA 
class I antigen on cultured endothelial cells induce increased gene expression of 
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bFG F receptor and ligand binding, and a 4 to 6 fold cell proliferation, as it does 
for smooth muscle cells.'" Marsh et al. hypothetized that IgG induces the 
accumulation, differentiation and subsequent cytokine production by intimal 
macrophages via crosslinking ofFcR thereby preventing apoptosis of monocytes. 
FcR crosslinking induces the production ofMCP-, and IL-8, which can promote 
both macrophage and Iymphocyt accumulation. ,,0.'" 
r.4.2 Chronic response.to.injury 
It is not clear why this response to the initial injury does not disappear over time, 
as seen in normal healing processes. In allografts, it is conceivable that the 
alloantigens are responsible for an ongoing cellular and/or humoral response. 
T cells decline to relatively low levels as the process enters its chronic phase, they 
and their products may continue to provide a persisting low grade immunologic 
response and ongoing subclinical injury to the graft's endothelium and 
parenchyma over time. 'F Since there is a continuous supply of donor allopeptides 
processed and presented by host professional antigen-presenting cells (dendritic 
cells, macrophages, B cells), self-MHC restricted Tcells may perpetuate a chronic 
alloimmune response. Recently, Suciu-Foca and colloboratives demonstrated a 
persistent allopeptide reactivity in patients developing CTD.''' The continued 
alloimmune recognition in long term graft recipients is evidenced by the 
presence of graft reactive cytotoxic T splenocytes in long term recipients of 
cardiac allografts.''' Anti-donor specific antibodies may also persist a chronic 
alloimmunologic injury: Donor reactive alloantibodies in the recipient's 
circulation have been demonstrated long-term after engraftrnent."'no.," 
The significance of donor alloantigens on 'non-professional' antigen 
presenting cells, like the endothelial cells for T cell recognition is unclear. An 
indication that donor MHC class I and II antigens playa role in the chronic phase 
has been recently shown. Carotid allografts from donor mice deficient in MHC 
class II molecules showed a reduction of intimal hyperplasia formation of 33%, 
primarily due to a reduction in smooth muscle cell accumulation.'" 
In this hypothesis, the absence of such a continuous alloantigeneic stimulus 
in syngeneic transplants might explain the much more rapid development of 
CTD in allografts. Nonetheless, non-alloimmune specific factors are involved in 
the process. Ascessory factors mentioned in paragraph r.}2 can accelerate or 
inhibit the progress of the lesions. 
Thus, the strenght of the initial trigger, the length of the trigger, and the presence 
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of additional factors, under which alloantigens, determine the onset and the pace 
of progress of irreversible chronic lesions 
Macrophages 
After activation, T cells produce amongst others the cytokine RANTES 
(Regulated upon activation, normal Tcell expressed and secreted), a macrophage 
chemoattractant.'" Macrophages invade the graft and become activated by IFN-y. 
The continued presence, the activated state and the upregulation of macrophage 
associated cytokines in long-term allografts with CTD and in other chronic 
diseases with fibrotic features suggest a pivotal role for the macrophages.'''·'''·'''·''' 
In organ transplantation, a demonstration ofthe impoltance of the macrophage 
was provided by the prevention of CTD by treatment with gammalactone, a 
synthetic inhibitor of macrophage activity, in a rat renal allograft model,"s and by 
the observation that carotid allografts in mice deficient in macrophages, 
developed only small intimal hyperplasia.»o 
Activated macrophages produce a number of cytokines including TNF-a, IL-II3, 
PDGF, bFGF, and TGF-I3. Conversely, other cytokines, such as IL-8, MCP-I and 
osteopontin released by interstitial cells and smooth muscle cells are chemotactic 
for macrophages, and this together with an upregulation of adhesion molecules 
contribute to their localisation in areas of injury. This perpetuates and amplifies 
the fibrogenic signals. 
Cytokines and growth factors 
Cytokines and growth factors play an important role in the chronic phase. They 
have profound effects on cells of the graft and on the immune system. Cytokines 
and growth factors are pleiotropic, with biological effects on many cell 
subpopulations, are regulated via autocrine, paracrine or systemic pathways, and 
there is a great deal of redundancy in the cytokine networks. The advent of the 
transgenic and knock-out technology has allowed to dissect out molecular 
pathways causally involved in allograft arteriosclerosis.""'" No cytokine has been 
unequivocally identified as specific to alloimmune response. 
The redundancy of the cytokine system has been stressed by gene knockout 
technology: IL-4 is not necessary for the development of graft coronary 
arteriosclerosis, nor does its absence appear to augment the development of 
vascular lesions. In addition, TNF-aRr deficiency in either donor heart or 
recipient does not abrogate the development of graft arteriosclerosis. '" The 
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increased expression ofTGF·I3, has been linked to transplant arteriosclerosis 
both from clinical and experimental shldies, and transfection ofTGF·1l to the 
kidney led to increased accumulation of the extracellular matrix and glomerulo· 
sclerosis.'" Interestingly, cardiac allografts in TGF·Il, deficient recipients 
developed significantly more intimal hyperplasia than controls.'" In 1989, IFN·y 
has already been postulated by Libby et al. to playa central role in CTD because 
of its effects on T cells and macrophages, as depicted above. '" The availabilty of 
IFN·y deficient mice permitted this group to test critically the contribution of 
IFN·y to the development of CTD.""'" Cardiac allografts in IFN·y deficient mice 
developed only minimal or no transplant arteriosclerosis as compared to 
controls. In addition, similar results on graft arteriosclerosis were ·found after 
the administration of IFN·y neutralizing antibody in normal rats. 
1+3. Chronic remodelling 
The process evenhlally becomes irreversible, but the period in which this occurs 
is variable: Retransplantation of allogeneic kidney grafts back into the original 
donor strain prevents CTD, when the retransplant is performed within 12 weeks, 
but not after this period. ,,6 In. aorta and cardiac allografts Mennander et at. and 
Izutani et at. reported a much shorter time interval after which intimal 
hyperplasia continues, when the graft was transplanted back into the donor 
strain. ~7.:148 
Smooth muscle cells 
Once the endothelial cells are injured, the secreted cytokines, i.e. IL· I, PDG F, 
IGF'I, TGF·1l and bFGF, and metabolic products, such as prostaglandin, nitric 
oxide, and oxidized low·density lipoproteins induce smooth muscle cell (SMC) 
proliferation, as reviewed by Ross.'" Activated T cells and macrophages, often in 
close anatomical association with the replicating SMC, produce also a whole 
wealth of these factors. Platelets deposited along the injured vascular wall 
contribute by secreting PDGF, EGF, TGF·1l and tromboxane.A2 • When the SMC 
migrates to the intima, they transform their phenotype from 'contractile' to 
'secretory' and the cells become capable ofreplication."""o In addition, SMC can 
produce many of these growth factors and may generate similar autocrine or 
paracrine loops of stimulation for cell replication, as seen in 'classical' 
atherosclerosis.''' These factors also may modulate extracellular matrix 
synthesis, angiogenesis, and leucocyt adhesion. Moreover, activated SMC can 
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express MHC class I and II and may act as antigen presenting cells. 
Numerous drugs inhibit SMC proliferation, and some have been shown to be of 
some benefit in organ allografts, such as angiopeptin:""" 
Extracellular matrix 
As the endothelium is damaged, the underlying extracellular matrix can become 
activated and act as costimulator for leucocytes to facilitate recruitment and 
extravasation. For instance, exposed collagens and fibronectin may act as 
costimulators for activated CD4 + T-cells:wll Mter antigen activation naive T cells 
synthesize heparanase, which facilitates migration through tissue" The 
cleavage of heparan sulphate by this enzyme also activates and releases 
fibrogenic growth factors, such as basic fibroblast growth factor 'in the 
extracellular matrix:" TG F-ll, produced by the activated T cells and macrophages, 
stimulates the production of ECM molecules and inhibits the matrix degrading 
enzymes. The thickening of basal membranes, such as that of the pericapillary 
and glomerular endothelium in the transplanted kidney, interstitial fibrosis and 
sclerosis, and in intima hyperplasia smooth muscle cell proliferation is 
accompanied by excessive synthesis of connective tissue proteins. 
1.5 Conclusion 
CTD is currently the main cause of late graft failure. CTD is usually associated 
with previous acute rejection episodes, although several non-alloantigen 
associated factors, like ischemia, hyperlipidemia, and hypertension may enhance 
the process. We propose that the process leading to CTD in allografts begins at 
time of graft retrieval, is enhanced by ischemic injury, which provokes an 
alloimmune response to the endothelial cells, the extracellular matrix and 
parenchyma. An ongoing alloimmune response in which several non-
alloimmune factors may interfere, eventually leads to irreversible lesions of the 
organ graft. 
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1.6 Aim ofthe thesis 
Chronic transplant dysfunction (CTD) hampers indefinite survival of solid organ 
grafts, such as kidney, heart and lung. Long-term survival of clinical intestinal 
transplants, which survival until recently was too short to be encountered by 
CTD, appears to be hampered by CTD also. There is still no way to prevent CTD 
and a rational treatment is not within hand's reach, since its etiology and 
pathophysiology are poorly known. At present, retransplantation is the only 
effective therapy. 
Clinical and experimental studies indicate that alloantigen-dependent events 
play an important role in the development ofCTD. Nonetheless, the contribution 
of non-alloantigen specific factors, such as ischemia, has also been suggested. 
Prospective clinical studies to unravel aspects ofCTD cannot easily be realized 
due to the contribution of multiple variables, need of a large patient 
population, and a long follow-up period. From a mechanistic point of view, 
clinical studies cannot discriminate whether an effect of non-alloantigen specific 
factors acts directly or via potentiating alloimmune responses, since allogenicity 
is a conditio-sine-qua-non in the clinical setting. To overcome these difficulties, we 
investigated some etiological or pathophysiological aspects of CTD in 
transplantation models in the rat, with the ultimate goal to obtain new 
therapeutic strategies. 
We investigated the role of non-alloantigen specific factors in the 
development of CTD. At first, we studied the effect of surgical trauma and 
prolonged cold ischemia on the development of transplant arteriosclerosis per se, 
the cardinal histologic feature of CTD, using the well-established aorta 
transplantation model. 
Subsequently, the significance of prolonged cold ischemia on the 
development of CTD was verified in a solid organ transplant, - i.e. the 
vulnerability of intra parenchymal vessels and parenchymal tissue to ischemia 
and to understand a possible relationship between arteriosclerosis and 
parenchymal lesions. TIlerefore, we introduced a kidney transplantation model 
of CTD into our laboratory. 
Using this model, the effect of prolonged cold ischemia on tl,e development 
of CTD was studied in both kidney isografts and allografts, treated transiently 
with the immunosuppressive agent Cyclosporin. Analysis of infIltrating cells at 
different timepoints during the course gives us insight into the mechanism. 
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Without use of any immunosuppressive drug, a relationship between ischemia 
and allogenicity in kidney allografts was investigated. 
In kidney transplantation, complications of urinary tract reconstruction can 
lead to late graft failure. We compared long-term graft function in kidney 
transplants with 2 different surgical techniques of urinary tract reconstruction 
applied: uretero·ureterostomy versus uretero·neocystostomy. 
Genes other than MH C-genes may influence the development of CTD. Some 
transplant studies suggest differences in graft outcome due to donor ethnicity. 
To elucidate whether the descent plays a role, the impact of genetic background 
of donor kidneys on CTD was studied in a syngeneic environment. 
Since we had previously shown that CTD occurs in intestinal transplants a rat 
model was set up to study the pathophysiology of CTD in small bowel 
transplants. Functional, histologic and inflammatory features of CTD in this 
model were characterized. This model was subsequently used to investigate 
growth factor patterns. 
Gene expression ofEGF and TGF'!3, in the small bowel transplants with CTD 
was investigated. 
The gene and protein expression ofbFGF and its localization was studied in 
the small bowel transplants. 
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Summary 
Background: Late graft loss is predominantly attributable to chronic transplant 
dysfunction (CTD). The general histological feature of CTD is transplant 
arteriosclerosis. Although alloantigen·dependent factors are central in the 
development of CTD, it is still a matter of debate whether alloantigen-
independent factors contribute to this process as well. 
Aim: The aim of this study was to investigate the role of two factors, namely I) 
cold ischemia and 2) surgical trauma on the development of transplant 
arteriosclerosis in a rat aorta transplantation model. 
Materials and methods: Aorta grafts (10 mm length) were transplanted 
orthotopically; syngeneic transplantations were performed between inbred BN 
rats, and allogeneic transplantations from WAG to BN rats. The grafts were 
stored at 4 'C in UW-solution, and two cold ischemia times were applied: 0.1 and 
24 hours. To investigate the impact of surgical trauma grafts were anastomosed 
with continuous or interrupted sutures, or were implanted non-stretched versus 
stretched. The stretch model was performed by transplanting 8 mm aorta 
segments into 12 mm dissected recipients. Inversely, 12 mm segments were 
transplanted into the 8 mm recipients to assure non-stretch. The rats were 
sacrificed 4 weeks post· transplantation Histomorphological analysis from the 
midportion of aorta grafts consi~ted of measurement of intimal thickness, 
medial thickness and nuclear density, and adventitial nuclear density. 
Results: Syngeneic grafts preserved for 24 hours had significantly less intimal 
hyperplasia and a significantly higher adventitial nuclear density than aorta 
isografts with 0.1 hr cold ischemia (I6±5 vs. 39±7 /lm, and II3±2 vs. 169±7 
nuclei/o.I mm2, respectively). In allografts, results of all studied parameters did 
not differ between the o.Ihr and 24hr cold ischemia.groups. Continuous 
suturing enhanced intimal thickening significantly compared to interrupted 
suturing (39±7 vs. 14±6 /lm, respectively), wher.eas stretch did not influence 
intimal hyperplasia. On the other hand, aortic stretch significantly reduced 
medial thickness and nuclear density compared to non-stretched aortic grafts 
(83±2 vs. 94±2 /lm and '49±7 vs. 199±9 nuclei/o.I mm2, respectively). 
Conclusions: These results indicate that alloantigen-independent factors 
contribute to CTD: I) Cold ischemia up to 24 hours does not enhance transplant 
arteriosclerosis. 2) Continuous suturing of the vessel aggravates intimal 
hyperplasia and 3) vascular stretch decreases medial thickness. 
isci1emia, Surgical Trauma, Transplant Arteriosclerosis 
Introduction 
One year allograft and patient survival continue to improve, principally due to 
progress in immunosuppressive therapy. Nonetheless, from one·year post· 
transplantation, there is a steady rate of organ failure due to chronic transplant 
dysfunction (CTD), a comprehensive term used to denote several pathological 
events that lead to a gradual, irreversible deterioration of organ function.' TI,e 
cardinal histopathological feature of CTD in all organ transplants is transplant 
arteriosclerosis,'" characterised by concentric thickening of the intima, 
migration and proliferation of smooth muscle cells, medial necrosis and 
adventitial inflammatory infiltrate. 
Some clinical studies showed that prolonged cold ischemia is a risk factor,'" 
whereas others did not,'" Experimental studies of organ transplantation are also 
inconsistent with regard to the role of cold ischemia on CTD.'·' Also, the effects 
of surgery per se are not uniform; One study showed that syngeneic kidney 
transplantation led to a fall of glomerular filtration rate compared to unilaterally 
nephrectomized rats." On the other hand, Tullius et al. could not demonstrate 
adverse effects of manipulating the kidney: clamping, dissecting, dividing and 
consecutively reanastomosing the renal vessels or ureter did not lead to 
functional or histological changes of the kidney." 
The aim of this study was to elucidate the influence of these two factors, 
namely cold ischemia and surgical trauma, on the development of transplant 
arteriosclerosis in a rat aorta transplantation model. To exclude organ specific 
factors on the development of CTD the aorta graft was used, which is a proven 
CTD model." To Shldy these factors in the absence of allogenicity, syngeneic 
grafts were compared \vith allogeneic ones. 
Materials and methods 
Animals 
Adult male Brown Norway (BN) and Wistar-Agouti (WAG) rats weighing 250-
275 g were used. These rat strains differ at the major histocompatibility locus: 
The BN is homozygous for the RT-In haplotype, whereas the WAG strain is 
homozygous for RT-IU haplotype. The animals were purchased from Harlan-
CPB (Austerlitz, The Netherlands), where they were bred under specific 
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pathogen free conditions. All animals were kept under standard conditions and 
given access to standard commercial rat chow (AM II; Hope Farms, Woerden, 
The Netherlands) and tap water acidified to pH 3, ad libitum. The experimental 
protocols were approved by the committee on animal research of the Erasmus 
University, Rotterdam and adhered to the rules laid down in the published 
"Guidelines on the protection of experimental animals' by the Council of the EC 
(I986). 
Aorta transplantation 
All rats were anaesthetised with ether whereafter a laparotomy was performed. 
In the donor a segment of infrarenal aorta (10 mm length) was isolated, excised 
and perfused with University of Wisconsin (UW) solution (Viaspan®, Du Pont 
Pharmaca) of 4·C. The graft was preserved for O.I hr, i.e. the minimal cold 
ischemic period possible with our transplant procedure. In the recipient, the 
aorta was transplanted orthotopically. End·to·end anastomosis was performed 
using a 9.0 monofilament nylon suture (B. Braun, Neuhausen, Germany). The 
perioperative warm ischemic titne was 20 minutes. 
Experimental groups 
Syngeneic transplantations were performed between BN rats, and allogeneic 
transplantations from WAG to BN rats. No immunosuppressive therapy was given. 
To study the impact of cold ischemia on graft arteriosclerosis in both an 
allogeneic and syngeneic setting, the grafts were stored in UW ·solution at 4·C 
for o.Ihr (BN.BN, n~6, WAG·BN, n~5) or 24hr (BN·BN, n~4, WAG·BN, n~4). 
The anastomosis was made with continuous sutures. 
The impact of surgical trauma was studied in isografts by comparing the 
mode of suturing, continuous (n~6) or interrupted (n~5), and by comparing the 
way of implantation, stretched (n~5) versus non·stretched (n~5). The stretch 
model was performed by transplanting 8 mm aorta segments into 12 mm 
dissected recipients. Inversely, 12 mm segments were transplanted into the 8 
mm recipients to assure non·stretch. Aortic transplants were removed at 4 weeks 
post·transplantation, since we previously demonstrated that in the WAG·BN 
model, intimal hyperplasia could not be evaluated beyond 4 weeks due to intense 
intimal thickening, thrombosis and necrosis." 
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Histology 
Formaldehyde-fIxed and paraffin-embedded 5 !-tm-thick straight cross-sections 
from the midportion of the aorta graft were stained with hematoxylin/eosin and 
elastic of Gieson. The following variables were analysed using a calibrated ocular 
micrometer: Intimal thickness, medial thickness and nuclear density, and 
adventitial nuclear density. The average medial thickness and maximal intimal 
thickness were determined. Cellularity of the media and adventitia was assessed 
by counting the number of nuclei at 5 locations using a magnifIcation of 400X. 
The mean score was multiplied to a fIeld of 0.1 mm2 • 
For statistical analysis, one way ANOVA followed by unpaired t test was used. 
The results are expressed as mean ± SD in the text and tables, and as mean ± 
SEM in the fIgures. 
Results 
Cold ischemia 
Syngeneic aorta transplants with the minimal cold ischemic time of 0.1 hr 
developed some intimal hyperplasia, although much less than allogeneic grafts 
preserved for 0.1 hr (Figures Ia and b). In BN isografts preserved for 24 hrs 
intimal hyperplasia was signifIcantly less compared to isografts with o.Ihr cold 
ischemic time. Medial thickness and nuclear density were similar in both 
Figure IA. 
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• WAG·BN,O.1h cold Ischemia 
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The effect of 24 hr cold ischemia on intimal and medial thickness in aortic isografts 
and allografts. * = P<O.OI vs. BN·BN isografts with 0.1 hI cold ischemia 
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Figure lb. 
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Medial and adventitial nuclear density. * = P<O.05 vs, BN·BN isografts with 0,1 hr 
cold ischemia, 
groups, whereas the isografts with 24 hr ischemia had significantly more 
adventitial cellular infIltration. In allografts, prolonged cold storage of the aorta 
for 24 hrs did not lead to significantly more histopathological changes than in 
aortic allografts preserved for 0.1 hr: The intimal thickness, the medial nuclear 
density and the cellular adventitial infIltration did not differ both groups. 
Mode of suturing 
In the BN-isografts, continuous suturing of the aortic anastomosis enhanced 
intimal thickening significantly compared to interrupted suturing. Medial and 
adventitial nuclear density was similar in both groups (Figure 2). 
Figure 2 
150 DBN·BN,continuous suturing 250 DeN·BN,continuous suturing 
• BN·BN,lnterrupted suturing • BN·aN, interrupted suturing 120 ~ 200 
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" • 3D ~ 50 
0 0 
intima media media adventitia 
The effect of mode of suturing on intima, media and adventitia in aortic isografts. 
* = P<o,05 vs, BN·isografts, continolls suhlring 
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Mode of implantation 
Implanting the aorta under stretch did not influence intimal hyperplasia, but 
significantly reduced medial nuclear density and led to a significant increase of 
the adventitial nuclear density (Table r). 
Group intimal thickness medial thickness medial nuclear adventitial nuclear 
(!un) (~m) density(o.lmm2 ) density (0.1 mm2) 
BN·BN non·stretch 16 ± 6 94 ±2 199 ± 20 90 ±7 
BN-BN stretch 10 ±7 8) ±2* 149 ± 15 * II6 ± 18 
Table I. The impact ofthe mode of implantation on intima, media and adventitia in aortic isografts. 
* = P<0.05 vs. non-stretch. 
Discussion 
The etiology of CTD remains poorly understood. Since both alloantigen-
dependent and independent factors, including ischemic time and surgical 
trauma, are thought to playa role, we examined these factors in syngeneic aorta 
grafts by varying the ischemic time, the mode of suturing and the degree of 
stretch. The effect of prolonged ischemic time was also studied in aortic allografts. 
Firstly, the present study demonstrates that cold ischemia during 24 hours 
did not enhance transplant arteriosclerosis in both aortic iso- and allografts. This 
observation conflict with reports using also the aortic graft model in which 
prolonged ischemia produced vascular lesions in syngeneic transplants."'" 
However these investigators preserved the aortas for 24 hr in cold saline" or, 
Frodin/Wolgast perfusion solution." By using UW preservation solution, a 
superior preservation fluid which contains oxygen free radical scavengers as 
allopurinol and gluthatione, we found that cold ischemia had no adverse effect 
on the intimal thickening, suggesting that endothelial integrity was better 
preserved. On the other hand, the prolonged cold storage of the aorta led to a 
significant increase of infiltrating cells in the adventitia. Since studies show that 
adventitial infiltration precedes intimal thickening"'" and that the intensity of 
cellular adventitial infiltrates correlates with the degree of intimal hyperplasia," 
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it is possible that the 28-day follow up was too short to demonstrate adverse 
effects of 24 hr preservation on intimal hyperplasia_ Using the same rat strain, 
we recently demonstrated focal intimal thickening in the interlobular and 
cortical arteries in syngeneic kidney transplants preserved for 24 hr at 52 weeks 
post-transplantation.'6 The impact of cold ischemia in an allogeneic environment 
is also not clear_ Similar to our findings, other investigators could also not 
demonstrate a significant effect of different cold ischemic times in aortic 
allografts_4.~ On the other hand, these data conflict with findings using cardiac 
and renal allografts, in which prolonged cold ischemia led to more graft 
vasculopathy.8 .• , Comparison of different studies is complicated by strain and 
species differences, as well as different preservation solutions, immunosuppressive 
regimens and even dietary manipulation. Moreover, the response-to-injury in 
endothelium of aortas could be different from that of intra parenchymal arteries. 
Secondly, the transplantation procedure per se did lead to some histological 
changes, since isografts with a minimal ischemic time showed intimal 
hyperplasia, which is absent in the native aorta. Results of the present study 
indicate that the mode of suturing influences the development of transplant 
arteriosclerosis. In the mid portion of the I cm aortic transplant, interrupted 
suturing of the anastomosis led to significant less intimal thickening. 
Continuous suturing may lead to invisible torsion of the graft, thereby changing 
flow patterns. Decreased flow and flow separation causes decreased wall shear 
stress, which is known to provoke intimal hyperplasia." Also, the way of 
implantation, i.e. the degree of stretch, influences transplant arteriosclerosis. 
Stretch did not have an impact on intimal thickness, but did significantly 
decrease the thickness of the media. Since mechanical stretch is known to induce 
apoptosis,'" decreased nuclear density in the stretched aortic transplants could be 
the result of apoplosis. 
Finally, the relationship between intimal thickness and decreased medial 
thickness, as a consequence of migration of smooth muscle cells, is very clear in 
allografts, but not in the different subjects presently studied in isografts. 
Mennander et al. also demonstrated that thickening of the intima was not 
accompanied by medial cell destruction in aortic isografts exposed to starch 
before transplantation, thereby suggesting that intima thickness and medial 
necrosis are independently regulated." Therefore the response-to alloimmune, 
ischemia and mechanical-related-injury in the aorta appears to be mediated by 
different mechanisms. 
Iscilemia, Surgical Trcwma, Transplant Arteriosclerosis 
In conclusion, I) Cold ischemia during 24 hours using an optimal preservation 
solution does not enhance transplant arteriosclerosis in aortic grafts. 2) 
Continuous sUhlring of the vessel aggravates intimal hyperplasia, and vascular 
stretch decreases medial thickness. 
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Summary 
Background: Chronic transplant dysfunction (CTD) is the major cause oflate 
graft failure. In unravelling its etiology, non·alloantigen specific factors, as 
ischemia/reperfusion and renal mass have been suggested to playa role in the 
process. 
Aim: To investigate the effect of the transplantation procedure itself on the 
development of CTD in a syngeneic kidney transplant model in the rat. 
Materials and methods: Heterotopic kidney transplantation was performed with 
the BN rat as donor and recipient, in which the recipient kidneys were removed. 
Unilaterally nephrectomised (UNx) and native BN rats served as conqols. Renal 
function was determined monthly (Proteinuria and Glomerular filtration 
rate/IOogr body weight;GFR). The follow-up period was until 52 weeks post-
transplantation. At sacrifice, the systemic blood pressure was measured. 
Histomorphological analysis of CTD according to the BANFF criteria was done. 
Immunohistochemical staining was performed to identify infiltrating cells 
(CD4, CD8, and ED-I) and the expression ofMHC class II, and ICAM-I. 
Results: Isografts had a minor, constant proteinuria during follow-up, which did 
not differ from that of UNx: 27±IO vs. 29±2 mg/24h at week 52. Unilateral 
nephrectomy led to a significant reduction of the GFR, which was about 80% of 
that in native rats at the first measurement 4 weeks post-transplantation. The 
GFR ofisografts did not differ from UNx rats at week 4 post-transplantation. The 
G FR in UNx and isografts did not further change during the next 48 weeks of 
follow-up. Histomorphology of renal isografts was comparable to UNx kidneys: 
some glomerulopathy and hlbular atrophy, leading to a BANFF-score of 2.6±0.5 
vs 2.7±0.8. Native kidneys demonstrated some glomerulopathy, resulting in a 
BANFF score which was similar to that ofUNx. In native BN kidneys few CD4+ 
cells and ED-I+macrophages(M<I» were found; MHC class II was constihltively 
expressed on the proximal tubules and ICAM-I on the glomeruli and peritubular 
capillaries. UNx-kidneys showed a similar pattern. Isografts had significantly 
more CD4+cells and M<I>, mainly localised in the glomeruli, and a more intense 
ICAM-I expression in the glomeruli and interstitium. 
Conclusion: Transplantation of one kidney in itself does not lead to CTD. 
Kidney Transp/'H1tatioll Procedure and Chronic Tramp/(l1It Dysfunction 
Introduction 
Despite progressive improvements in the early success rate of clinical organ 
transplantation, the annual rate of graft loss after the first year has not improved 
significantly over the last 2 decades. The half-life of cadaveric renal allografts 
remains consistently at 7-8 year.' Late failure of renal allografts is largely 
attributable to the poorly understood process of chronic transplant dysfunction 
(CTD). The cardinal histopathological characteristic of CTD is intimal 
hyperplasia;' the chronic dysfunctioning kidney graft also shows less specific 
features as glomerular sclerosis, tubular atrophy and interstitial fibrosis. The 
mechanisms leading to CTD are largely unknown.'" Clinical data indicate that 
the host alloimmune response plays an important role in the development of 
CTD: Acute rejection is the most consistent risk factor for CTD.' 
Nonetheless, there are indications that alloantigen-independent factors can 
cause lesions resembling those seen in chronic rejected allografts. For instance, 
renal ischemia in unilaterally nephrectomised rats can cause late 
histomorphological lesions mirroring those seen in kidney allografts with 
CTD.'·' In syngeneic kidney transplants, Tullius et al. demonstrated late damage 
to the same extent as observed in ischemic non-transplant kidneys.' Others, 
however, did not see functional or morphologic changes in renal isografts.'·' The 
pathway from such early injury to the late morphologic changes is unclear. Since 
reduction of nephron number in non-transplant experiments can cause 
glomerular and vascular changes and thus resembling CTD," it has been 
suggested that ischemic injury leads to a decrease of nephron number. 
To further unravel the etiology and pathophysiology of CTD, the aim of the 
present Shldy was to investigate the effect of the transplant procedure on CTD in 
the rat kidney. To rule out alloimmune mediated effects on CTD, syngeneic 
transplants were shldied. 
Materials and methods 
Animals 
Young adult male rats of inbred Brown Norway (BN; RTrll) weighing 225-25og and 
ro-12 weeks old age were purchased from Harlan (Austerlitz, The Netherlands). All 
animals were kept under standard conditions and given access to standard 
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commercial rat chow (AM II; Hope Farms, Woerden, The Netherlands) and tap 
water acidified to pH 3, ad libitum. The experimental protocols were approved by 
the committee on animal research of the Erasmus University, Rotterdam. 
Kidney transplantation 
Kidney transplantation was performed using a modification of the technique 
described by Fisher and Lee. H The animals were anaesthetised with ether. After 
an intravenous injection of heparin (roo IV), the left donor kidney was flushed 
in situ via the aorta with 5 ml University of Wisconsin (UW) solution of 4 'C at a 
rate of 2 ml Imin. The kidney was excised and stored in UW solution (4'Q for 
about 6 minutes prior to implantation. In the recipient, the kidney graft was 
transplanted heterotopically; donor renal artery and vein were anastomosed end-
to side to recipient aorta and vena cava, respectively, using continuous 9-0 
prolene sutures. During surgery, the graft was wrapped in gauze moisturised 
with 4 'C phosphate buffered saline (PBS). The perioperative ischemia time was 
30 minutes. After revascularization, the ureter was anastomosed end-to·end to 
the distal third part of the recipient's ureter using 4 single IO-O prolene sutures, 
without use of a stent. The left native kidney was removed at time of 
transplantation, while the contralateral one was excised 3 weeks later. 
Experimental groups 
BN isografts were followed up until 52 weeks (n=5) after transplantation. Control 
groups were age-matched unilaterally nephrectomised (UNx) rats (n=8), and 
native non-nephrectomised rats (n=5). Functional, morphological and 
immunohistological evaluations were performed after engraftment. 
• 
Functional measurements 
Urine was collected monthly by placing the rats individually for 24hr in 
metabolic cages. Protein excretion was measured colorimetrically by addition of 
pyrogallol red." The glomerular filtration rate (GFR) per IOOg body weight (BW) 
was based on the clearance of creatinine. Serum and urinary creatinine was 
determined using the Jaffe method ,vithout deproteinization. 
At sacrifice, diastolic and systolic blood pressure (BP) was measured intra-
arterially. Mter anaesthetising the rat, the right carotid artery was dissected, a 
pressure-probe (Baxter, United Kingdom) was inserted into the direction ofthe 
aortic arch, and the BP was recorded continuously for 5 minutes. 
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Histology 
At 52 weeks post-transplantation, kidneys were harvested and weighed. They 
were fIxed by immersion for 48h in a J.G% buffered formaldehyde solution after 
longitudinal bisection, and embedded in paraffIn. Sections (311m) were stained 
with hematoxylin/eosin, periodic acid Schiff (PAS) and evaluated for chronic 
transplant dysfunction according to the BANFF-criteria" by 2 independent 
investigators. Briefly, glomemlopathy, interstitial fIbrosis, tubular atrophy and 
intimal thickening were separately determined with a score ranging from 0 ~ 
normal, I ~ up to 25% affected, 2~ moderate, affecting 25-50%, and 3~ more than 
50% changes. 
Immunohistology 
Representative portions of all kidneys were stained on 5 11m cryostat sections by 
a three-layer immunoperoxidase technique. After fIxation with acetone for IO 
minutes, tissues were dehydrated through graded alcohols to block endogenous 
peroxidase activity by incubation for IO minutes in methanol/0.03% H20 2. After 
rehydration the non-specifIc binding was blocked by preincubation with 10% 
Normal Rabbit serum (Dako, Copenhagen, Denmark), in PBS/Bovine serum 
Albumin 5%. This was followed by one hour incubation with primary 
monoclonal antibodies (Serotec, Oxford, United Kingdom) for identifIcation of 
CD45+ leucocytes (OX-I), CD4+ cells (W3/25), CD8+ cells (OX-8), monocytes 
/macrophages (ED-I), major histocompatibility complex (MHC) class II antigens 
(OX-G), and intercellular adhesion molecule-I (ICAM-I). After each incubation, 
slides were washed in PBS-Tween 20, 0.1%. A second layer, rabbit anti-mouse 
IgG (Dako) was then applied for 30 minutes and after washing, slides were 
incubated with the third layer, mOuse peroxidase-anti peroxidase (Dako) for 30 
minutes. After washing in PBS, the reaction was developed by the addition of 
Diaminobenzidine substrate (Dako) and slides were counterstained in Mayer's 
hematoxylin for 40 sec, washed, dehydrated and mounted. 
The analysis was done blindly as to experimental group. Positive cells were 
counted at400x magnification using a calibrated micro-ocular grid in >rG fIelds 
of view and expressed as number of positive cells /0.1 mm2. MHC class II and 
lCAM-I expression was quantifIed on a 0-to-3 scale (0 ~ none, I ~ mild, 2 ~ 
moderate, 3 ~ dense). 
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Statistical Analysis 
Statistical analysis was performed using the Kruskal-Wallis one way ANOVA 
followed by the Mann-Whitney test and p< 0.05 was accepted to be significant 
The results are expressed as mean ± SD in the text and tables, and as mean ± 
S E M in the figures. 
Results 
Renal function 
Isograft recipients had a minor, constant excretion of urinary protein during the 
52 weeks follow-up, which did not differ from that in UNx or native rats during 
the whole observation period (Figure r). 
The G FR (per roog BW) in native control rats remained constant during follow-
up. Unilateral nephrectomy led to a significant reduction of the G FR, which was 
about 80% of that in native rats at the first measurement, 4 weeks post-
transplantation. Transplantation of one kidney did not lead to a further 
reduction: the GFR of isografts did not differ from UNx rats at week 4 post-
transplantation. After the initial reduction ofGFR in UNx and isografts, it did not 
further change during the next 48 weeks follow-up (Figure 2). 
The diastolic and systolic BP measured at week 52 did not differ between the 
isografts, UNx-group and native controls (Table r). 
Table I. 
group 11 Diastolic BP Systolic BP 
BN 5 87 ± 5 117 ± 6 
BN-UNx 8 86 ±4 117 ± 3 
BN-isografts 5 8o±4 II5±3 
Systemic blood pressure in native, unilaterally nephrectomized rats and rats with a 
syngeneic kidney transplant, measured intra-arterially at week 52 after 
transplantation 
Kidney weight/body weight ratio 
A 50% reduction of the nephron number by nephrectomy led to compensatory 
hypertrophy of the remaining kidney: At week 52 ' the relative kidney weight of 
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the UNx-group was similar to that of native controls (0.53±0.06 vs 0.53±0.03g 
kidneY/loog BW). Kidney transplantation led to the same degree of 
compensatory hypertrophy: Isografts had a relative kidney weight which did not 
differ from that of UN x-rats (0.48±0.04 vs 0.53±0.06g kidneY/IOog BW). 
Figwe I. 
Morphology 
40 
weeks post-transptantation 
Proteinuria in renal isografts ( • ), unilaterally nephrectomized ( ~ ), and native 
controls ( 0 ). Isografts had a stable proteinuria during follow up, and the excretion 
was similar to that of UN x rats. 
Renal isografts had a few focal mononuclear cell infiltrates that were also present 
in UNx and native kidneys. At week 52, the isografts demonstrated very mild 
glomerular changes. About 8% of the glomeruli were sclerotic whereas 
mesangial matrix expansion with basement membrane thickening was evident 
in about 25% of the nonsclerotic glomeruli (BANFF: 1.4 ±0.5). In all isografts, 
some areas of tubular atrophy were seen (BANFF: 1.0 ±o). Interstitial fibrosis 
and intimal hyperplasia was not observed. The total BANFF score for isografts 
was 2.4 ±0.5. UNx-kidneys demonstrated an identical morphology: 7% of the 
glomeruli were sclerotic and a quarter of the nonsclerotic glomeruli showed 
glomerulopathy (BANFF: I.3±0.5). As in the isografts, some tubules were 
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atrophied, leading to a total BANFF score of 2.2 ±o+ Native control kidneys 
showed significantly less glomerulosclerosis (5%) but the percentage of 
nonsclerotic glomeruli having mesangial matrix increase did not significantly 
differ from UNx-rats_ In some kidneys minimal areas of tubular atrophy were 
present. Interstitial fibrosis and intimal hyperplasia was not seen in the controls. 
The total BANFF score was I.5±0.6. 
Figure 2. 
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Tx 
weeks post-Irnnsplantation 
Relative glomerular filtration rate in renal isografts ( • ), unilaterally 
nephrectomized (UNx)( ..... ) and native controls (D). Isografts and UNx had similar 
GFRs, which were about 80% of that in native controls. * = P<0.05 vs UNx at the 
same timepoint; Tx = transplantation. 
Immunohistology 
Native BN-kidneys showed some CD4+ cells and ED-I+ macrophages, 
predominantly located in the interstitium (Table 2)_ MHC class II was expressed 
on the proximal tubules, and by infiltrating cells. ICAM-I expression was present 
on the glomeruli, the peritubular capillaries, and on some cells located in the 
interstitium. TI,e numbers and patterns of infiltrating cells and the cell surface 
molecules in UNx-kidneys were comparable to the native kidneys. On the 
contrary, the numbers of both CD4+ cells and macrophages in kidney isografts 
were significantly higher, which was predominantly (70%) due to infiltration in 
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the glomeruli. Concurrently, MHC class II expression was seen and [CAM-, 
expression was upregulated in the glomeruli. In the interstitium, MHC class II 
expression was upregulated. 
Table 2. 
Isograft UNx Native control 
CD451eucocytes 24 ± 3 * 14 ± I * 14 ±3 
CD4 TeeUs 20 ± 3 * 13 ± 1 II ± 2 
CD8 T-cells 4 ±1 3 ±1 4 ±1 
EDI macrophages 12 ± 3 * 6 ± I 5 ±1 
MHC dass II 1.5 1.0 1.0 
ICAM'1 2.0 * 1.0 1.0 
Cellular inftltrates, MHC II and ICAM-I expression in renal isografts, unilaterally 
nephrectomized (UNx) and native controls_ Cells counts are expressed as mean ± 
celis/o.lmm2 ; MHC II and ICAM'I expression were quantified on a 0-4 scale. *= 
P<o.05 vs. UNx and native controls. 
Discussion 
Both the etiology and pathophysiology of CTD are poorly understood. Recently, 
attention has been directed to non.allogeneic stimuli causing similar functional 
and morphological changes as seen in allogeneic ones. To further understand the 
importance of these alloantigen-independent factors, we investigated the impact 
of the transplantation procedure per se on the development of CTD in a single, 
syngeneic kidney transplant. 
The main finding of the present study is that transplantation of a kidney in 
itself does not lead to late functional and morphological changes. At week 52, 
proteinuria, GFR, and a systemic BP were similar in isografts and UNx rats. 
Renal morphology was comparable: minor glomerulosclerosis, some 
glomerulopathy and tubular atrophy, without interstitial fibrosis and intimal 
thickening, although the infiltration with CD4+ cells and macrophages was 
significantly higher in isografts. These findings conflict with those Tilney and co· 
workers, who reported that after 32 weeks Lewis renal isografts developed 
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functional and morphological changes, including marked intimal hyperplasia, 
thereby resembling CTD.' These changes appeared to be induced mainly due to 
ischemia. Clamping the renal vessels of a unilaterally nephrectomised Lewis rat 
caused functional deterioration at r year identical to the isografts, whereas a 
nephrectomy in itself resulted in minimal late changes. In concordance with our 
data, other investigators did also not observe intimal thickening after syngeneic 
kidney transplantation using DA or AS rat strains,'" although the observation 
period was not as long as ours. Since there appear to be no differences in surgical 
procedures, it is conceivable that both ischemic injury and the subsequent 
response are strain dependent; a phenomenon which has been demonstrated by 
Ibrahim et a/: 60 minutes ischemia in kidneys of different rat strains led to 
different numbers of infiltrating T·cells and macrophages and different 
expression of MHC class II on hlbular epithelial cells.4 
This study also demonstrates that a 50% reduction in nephron number by 
nephrectomy did not lead to progressive deterioration of function and 
morphology of the remaining kidney. Since glomerular filtration was 80% of that 
in native EN-rats and thus hyperfiltration occurred, hyperfiltration was not 
associated with late renal injury. As renal injury in a hyperfiltrating kidney only 
develops when accompanied by glomerular hypertension, it is presumable that 
the hyperfiltrating EN-kidney preserved a normal glomerular pressure. Since 
UNx Lewis rats showed increased protein excretion, increased I CAM -r and MHC 
class II expression at week 52,' this could reflect different susceptibilities to 
hyperfiltration. Kingma et al. demonstrated different glomerular hemodynamics 
in response to subtotal renal ablation in Lewis and Fisher rats." Also, the age at 
time of nephrectomy and the dietary protein intake have been demonstrated to 
be important determinants for the lifespan of a single kidney." In the light of the 
results of the present study, the suggestion that glomerular changes seen in 
human kidney isografts could be the result of the transplant procedure per se 
needs to be revised. 
In conclusion, transplantation of a kidney subjected to merely 30 minutes 
ischemia does not lead to late renal injury. The EN-kidney may be an important 
in further unravelling the pathophysiology of CTD: Its relative resistance to 
perioperative ischemic injury enables to differentiate clearly between 
alloantigen-driven processes and the contribution of non-alloantigen-specific 
factors to the development of CTD. 
Kidney Tnmsplcmtation Procedure {lnd Chronic Transplant Dysfunction 
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Summary 
Background: The present study was devised to elucidate the influence of 
prolonged cold ischemia on the development of chronic transplant dysfunction 
(CTD) in kidney isografts (BN-BN), and in kidney allografts (BN-WAG) under 
temporary Cyclosporine (CsA) therapy. 
Methods: To induce ischemic injury, BN-donor kidneys were preserved for 2.4 hr 
in 4°C University of Wisconsin solution before transplantation. Renal function 
(proteinuria), histomorphology according to the BANFF criteria for CTD, and 
infiltrating cells were assessed. Grafts were examined both early at day 2., 3, 6, 
and 10, and late at week 2.6 (allografts) or at week 52 (isografts). 
Results: Non-ischemic isografts preserved a normal function and morphology. 
Ischemic isografts developed a progressive proteinuria over time, and 
demonstrated significantly more glomerulopathy with macrophage (M<f» 
inftltration and intimal hyperplasia than non-ischemic controls at week 52. 
During the initial 10 days, there was an increased infiltration ofMHC class II+ 
cells, predominantly CD4+ cells and M<f>, coinciding with upregulated IcAM-I 
expression. CsA-treatment in ischemic isografts inhibited infiltration of MHC 
II+ cells in the early stage which was accompanied by significantly less renal 
damage at week 52 compared to untreated controls (proteinuria: 59±S vs 
I34±I9mg/2.4h; BANFF score: 2..S±o-4 vs 4.3±I.O). 
Under CsA therapy, 2.4h cold ischemia of the allograft did neither affect the onset 
or progress of proteinuria, nor the histomorphology (BANFF score: 7.S±2..4 vs 
7.3±I.9). In both ischemic and non-ischemic allografts, ICAM-I expression and 
mononuclear cell infiltration (CD4, CDS, M<f» was abundantly present during 
the first IO days, and function deteriorated rapidly. 
Conclusions: Prolonged cold ischemia plays a role in the induction of CTD, but 
its deleterious effect can be successfully inhibited by CsA. Therefore, the 
alloantigeneic stimulus is the overriding component in the multifactorial 
pathogenesis of CTD. 
Ischemia and Chronic Transplcmt Dysfunction 
Introduction 
Late failure of renal allografts is largely attributable to the poorly understood 
process of chronic transplant dysfunction (CTD). The cardinal histopathological 
characteristic of CTD is intimal hyperplasia;' the chronic dysfunctioning kidney 
graft also shows less specific features as glomemlar sclerosis, tubular atrophy 
and interstitial fibrosis. The mechanisms leading to CTD are unknown. '., Clinical 
data suggest that the host alloimmune responsiveness plays an important role in 
the development of CTD: Acute rejection is the most consistent risk factor for 
CTD.' Nonetheless, there are indications that ischemia/reperfusion injury 
inducing a non-alloantigen specific response, could be implicated in the 
pathogenesis also: The United Network for Organ Sharing as well as some single 
centres reported that prolonged cold ischemia of the cadaveric kidney shortens 
late graft survival.'·' Moreover, the superior late graft survival rates ofliving-donor 
transplants, both related and unrelated compared to that of cadaveric kidneys 
could reflect diminished cold ischemia/reperfusion injury.' 
However, it is not clear whether cold ischemia per se is a risk factor, or only in 
an interplay with other pathogenic factors.' Experimental non-transplant studies 
showed that renal ischemia in itself causes late lesions resembling those seen in 
allografts with CTD.' TI,e impact of cold ischemia on kidney CTD or on other 
organ transplants in an allogeneic environment is less obvious."'" Comparison 
of these sh,dies are hindered by a variety of used preservation solutions, storage 
methods, type of immunosuppressive therapy in the initial phase, as well as 
donor status. 
Therefore, the objectives of the present sh,dy were to investigate the effect of 
prolonged cold ischemia of a donor kidney on the development of CTD in a 
syngeneic and in an allogeneic setting. To prevent acute rejection in the 
allografts, Cyclosporine A was administered. 
Materials and methods 
Animals 
Male rats of the inbred Brown Norway (BN)(RTIll) and WAG/Rij (RTIU) strains, 
were purchased from Harlan, Austerlitz, The Netherlands. The rats weighed 
200-250 g and were 2-3 months of age at the beginning of the experiment. All 
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animals were kept under standard conditions and given access to standard 
commercial rat chow (AM II; Hope Farms, Woerden, The Netherlands) and tap 
water acidified to pH 3, ad libitum. TI,e experimental protocols were approved by 
the committee on animal research of the Erasmus University, Rotterdam. 
Kidney transplantation 
Transplantations were performed using a modification of the technique 
described by Fisher and Lee." The animals were anaesthetised with ether. After 
an intravenous injection of heparin (100 IU), the left donor kidney was flushed 
ill situ via the aorta with 5 ml University of Wisconsin (UW) solution of 4 ·C at a 
rate of 2 ml Imino TI,e kidney was excised and stored in UW solution prior to 
implantation. In the recipient, the kidney graft was transplanted heterotopically; 
donor renal artery and vein were anastomosed end-to side to recipient aorta and 
vena cava, respectively, using continuous 9-0 prolene (B Braun, Melsungen, 
Germany). During surgery, the graft was wrapped in a gauze moishlrised with 4 ·c 
phosphate buffered saline (PBS). The perioperative ischemic time was 30 
minutes. After revascularization, the ureter was anastomosed end-to-end to the 
distal third part of the recipient's ureter using interrupted ro-o or II-O prolene 
suhlres. TI,e left, native kidney was removed at time of transplantation, whereas 
the contralateral one was excised 3 weeks later. 
Cold ischemia period 
The donor kidney was stored at 4 ·C for either 10 minutes, i.e. the minimal time 
in which the recipient is anaesthetised and prepared for implantation of the graft, 
or 24 hours. The 10 minutes cold ischemia will subsequently be referred to as 
non-ischenlia. 
Immunosuppressive regimen 
Immunosuppression consisted ofintramuscular Cydosporine A (CsA; Novartis, 
Basel, Switzerland) at a dosage OflO mg/kg at day 0, I, 4 and 7 and subsequently 
at a dose of 5 mg/kg, 3 times a week for 2 weeks. In a pilot-study this CsA 
schedule was able to overcome acute rejection in allografts and allowed for the 
development of CTD. If untreated, EN-WAG allografts develop a fatal acute 
rejection in 8-10 days." 
IsclJemia and Clironic Trallsp/(lllt Dysfimctioll 
Experimental design 
The experimental groups are enumerated in Table I. n,e effect of 24 hours of 
cold ischemia on the BN donor kidney, was studied in BN and WAG recipients.' 
The effect of cold ischemia in BN-BN isografts (group 2) was compared to non-
ischemic isografts (group r). Simulating the situation that occurs during clinical 
kidney transplantation, the effect of 24 hr cold ischemia was also studied in an 
allogeneic environment. WAG animals in group 6 received BN allografts that 
were subjected to 24 hr cold ischemia and compared to non-ischemic allografts 
(group 5). To reverse acute rejection in these allografts, a shOlt course ofCsA was 
administered. 
To compare the effect of cold ischemia between isografts and allografts, CsA was 
given to isografts, with and without cold ischemia (groups 3 and 4). 
Group Strain Cold iscilcmia Crclosporine Organ removal 
combination pre-kidney Tx (days) (weeks) 
BN---7BN no 2,3,6,10 52 
2 BN---7BN 24 hr no 2,},6,1O 52 
J BN---7BN yes 2,3,6,10 52 
4 BN->BN 24 hr yes 2,),6,10 52 
BN---7WAG yes 2,3,6,IO 52 
6 BN---7WAG 24 hr yes 2,3,6,10 52 
Table I. Ex-perimental design 
Morphological and immunohistological evaluations of kidney specimens of all 
groups were performed at day 2, 3, 6, and IO post-transplantation (n~3 
animals/group/timepoint). For functional, late morphological and 
immunohistological evaluations, the isograft-groups were followed until week 52 
after transplantation (Iso grafts: n~5; Isografts, 24 hr cold ischemia: n~I2; 
Isografts, CsA: n~5; Isografts, 24 hr cold ischemia, CsA: n~5). The allograft-
groups were sacrificed at week 26 because of end-stage graft failure. (Allograft, 
CsA: n~I2; Allograft, 24 hr cold ischemia, CsA: n~7). 
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Functional studies 
Urine was collected monthly by placing the rats individually during 24 hr in metabolic 
cages. Protein excretion was measured colorimetrically by addition of pyrogallol red." 
Semm creatinine was determined using the Jaffe method without deproteinization. 
Histology 
Kidneys were harvested under ether anesthesia, fIxed by immersion for 48h in a 
3.6% buffered formaldehyde solution after longitudinal bisection, and 
embedded in paraffIn. Sections (3 flm) were stained with hematoxylin. eosin, 
periodic acid Schiff and Goldner and were evaluated for chronic transplant 
dysfunction according to the BANFF·criteria" by 2 independent investigators 
(E.A.K and U.H.). Briefly, glomerulopathy, interstitial fIbrosis, hlbular atrophy 
and intimal hyperplasia were separately determined with a score ranging from 0 
~ normal, I ~ up to 25% affected, z~ moderate, affecting z5'5o% , and 3~ more 
than 50% changes. The total BANFF score is the sum of the 4 individual scores. 
Immunohistology 
Representative portions of all kidneys were stained on 5 flm cryostat sections by 
a three· layer immunoperoxidase technique. After fIXation with acetone for ro 
minutes, endogenous peroxidase activity was blocked by incubation for 10 
minutes in methanol/o.03% H2 0 2 , after dehydration through graded alcohols. 
After rehydration the non.specifIc binding was blocked by preincubation with 
ro% Normal Rabbit serum (Dako, Copenhagen, Denmark), in PBS/Bovine 
serum Albumin 5%. This was followed by one hour incubation with primary 
monoclonal antibodies (Serotec, Oxford, United Kingdom) for identifIcation of 
CD45+ leucocytes (OX'I), CD4+ cells (W3/25), CD8+ cells (OX.8), monocytes 
/macrophages (ED'I), major histocompatibility complex (MHC) class II antigens 
(OX·6), and intercellular adhesion molecule I (ICAM.'). After each incubation, 
slides were washed in PBS·Tween 20, 0.1%. A second layer, rabbit anti· mouse 
IgG (Dako) was then applied for 30 minutes and after washing, slides were 
incubated with the third layer, mouse peroxidase·anti peroxidase (Dako) for 30 
minutes. After washing in PBS, the reaction was developed by the addition of 
Diaminobenzidine substrate (Dako) and slides were counterstained in Mayer's 
hematoxylin for 40 sec, washed, dehydrated and mounted. 
The analysis was done blindly as to the experimental group. Positive cells were 
counted at 400 x magnifIcation using a calibrated micro·ocular grid in >16 fIelds 
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of view and expressed as number of positive cells /0.1 mm2 • The intensity of 
IeAM'I expression on endothelium and hlbules was quantified on a o-to-3 scale 
(0 ~ none, I ~ mild, 2 ~ moderate, 3 ~ dense). Expression of IeAM-I on 
infiltrating cells was not involved in the grading. 
Statistical analysis 
Statistical analysis was performed using Kruskal-Wallis one way ANOYA 
followed by Mann-Whitney test for the ordinal data from histology and leAM-I 
expression. One way ANOYA followed by a NewMan-Keuls test was used for the 
data from function and immunohistology. Statistical significance was 
established at P<0.05. TI,e results are expressed as mean ± SD in the text and 
tables, and as mean ± SEM in the figures. 
Results 
Function 
Cold ischemia in Isografts 
Recipients of a non-ischemic isograft had a stable protein excretion during the 
whole observation period of 52 weeks (Figure IA). 24 hr cold ischemia led to a 
significant, progressive increase of proteinuria from week 18 onwards compared 
to non-ischemic isografts. By 52 weeks, protein excretion had increased to 
r34±66 mg/24h versus 27±romg/24h (P~0.005). esA treatment in non-
ischemic isografts led to a minor, but significant increase of proteinuria 
(P~0.03). Interestingly, esA therapy in ischemic isografts led to significantly less 
proteinuria compared to the untreated controls (Figure rAj. 
group t I week---7 4 S 12 IS 26 }6 44 52 
Isograft 67±} 67"'1 65±5 6}±5 64"'1 6}±4 66"'1 65±6 
Isograft, ischemia 86±I9* 72±9 68±9 69±6 7I±S 68±6 73±IZ 8S±I9* 
Isograft,ischemia,CsA 79±) 68±l 68±4 67±} 64±5 70 ±2 76±8 77±Il 
Isograft,CsA 8o±7 -j- 7)±9 67±2 6)±4 6z±6 67±2 67±6 68±5 
Table zA. Serum creatinine levels(~lmol/l} in non·ischemic and ischemic kidney isografts, 
with and without Cyclosporine A treatment. * =P<O.02 vs Isograft; t =p<o.oS vs Isograft. 
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As shown in Table 2A, ischemic isografts and esA treated isografts had both a 
significantly higher serum creatinine level at the first measurement, 4 weeks 
after transplantation than their controls. Thereafter, levels were comparable in 
the 4 groups until week 44. Than, the serum creatinine again increased in rats 
with an ischemic kidney isograft. 
Cold ischemia in Allografts 
Rats with a non-ischemic kidney allograft developed obvious proteinuria by week 
IO and excreted progressively increasing amounts thereafter (Figure IB). At week 
22, some rats in tl,is group were found to have uremia as consequence of end 
stage graft failure. Therefore, all animals were sacrificed at week 26, although 3 
out of 12 rats had only a slightly increased protein excretion at tl,is timepoint. 
Prolonged cold ischemia (24 hr) in the allografts did not affect the onset or 
progression of proteinuria compared to the non-ischemic allografts (Figure IB): 
at week 26, the protein excretion was I65±82 vs 182±57 mg/24hr. 
As in the syngeneic setting, ischemic allografts had a higher serum creatinine at 
4 weeks post-transplantation compared to the non-ischemic controls (Table 2B). 
TIlereafter, levels were comparable. 
group J- / week ~ 4 8 12 18 22 26 
Allograft,CsA 8o±rS 68±9 67±IO 67±II SI±34 96±57 
Allograft, ischemia,CsA 99±18* 80±I8 SO±I6 83±23 92±25 I09±3° 
Table 2B. Semm creatinine levels (~lmol/1) in kidney allografts subjected to cold ischemia 
under Cyclosporine A therapy. * =P<o.o5 vs Allograft,CsA. 
Histology 
Cold ischemia ifl Isografts 
Exposure of the donor kidney to 24 hr of cold ischemia led to swelling of the 
endothelial cells of intra parenchymal arteries, and to tubular necrosis with 
oedema ofthe interstitium. Moreover, hlbule cells contained lysosomal enzymes 
and the hlbules were ftIled with protein casts at day 2 and 3 after transplantation, 
which was not seen in the non-ischemic isografts. After one year, these ischemic 
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Histologic CTD in kidney iso- and allografts subjected to 24h cold ischemia. 
Isografts preserved for 24h demonstrated more glomemlopathy and intimal 
hyperplasia than non-ischemic isografts at 52 weeks post-transplantation (# = 
p<o.os). CsA-therapy in the ischemic isografts inhibited the development of 
glomerular lesions versus untreated ones (* = p<o_Os), whereas it did not affect the 
degree of tubular atrophy or intimal hyperplasia. 
CsA immunosuppressed kidney allografts subjected to 24h cold ischemia 
demonstrated more intimal hyperplasia- than non-ischemic allografts at 26 weeks 
post-transplantation. (**= p<o.Os). The allografts showed all signs of CTD 
moderately, whereas isografts under the same immunosuppressive regimen showed 
only minimal glomerulopathy and tubular atrophy (## = p<o.oS). 
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isografts had more glomerulopathy (p~o.or) and intimal hyperplasia (P~0.03) 
than non-ischemic controls (Figure 2): the total BANFF scores were 4-3±I.O and 
I.8±0.4, respectively (P~0.004). By week 52, CsA-treatment in ischemic isografts 
resulted in less glomerulopathy, but did not affect the degree of intimal 
hyperplasia. The total BANFF score was significantly lower than that in untreated 
ones: 2.8±0.4 the vs 4-3±I.O (p~o.or). 
Cold ischemia ill Allografts 
At week 26, both ischemic and non-ischemic allografts demonstrated the 
histologic characteristics of renal CTD. Apart from more prominent perivascular 
infiltrates and intimal hyperplasia, prolonged cold ischemia did not affect the 
severity of the parenchymal lesions (total BANFF score 7.8±2.4 vs 7.3±I.9 in non-
ischemic allografts). 
Immunohistology 
Cold ischemia ill Isografts 
The type and number of infiltrating cells is depicted in Figure 3, adhesion 
molecule expression in Figure 4. Significantly higher numbers of CD45+-
leucocytes had infiltrated the interstitium of ischemic isografts from day 2 
compared to non-ischemic controls. TI,e number of MHC class 11+ cells were 
higher, representing CD4+ cells and EDr+ macrophages. CD8+ lymphocytes did 
not appear to playa role in ischemic injury. A further increase of these 
infiltrating cells coincided with increased expression of ICAM-r in the 
peritubular capillaries at day 3. Thereafter the cell populations remained stable 
until day ro. One year post-transplant, the ischemic isografts still showed 
significantly more CD4+ cells and EDr+ macrophages, with a considerable 
number present in the glomeruli. 
Whereas CsA treatment did not affect number and pattern of infiltrating cells 
in non-ischemic isografts, it inhibited cell infiltration of ischemic isografts 
(Figures 3A and B). The number ofMHC class 11+, CD4+ cells and macrophages 
were lower compared to non-treated controls (Figure 3A). One year post-
transplant, they had significantly less EDr+ macrophages, predominantly as 
consequence of a virhlal absence of these cells in the glomeruli (2.4± 0.6 vs 
7.8±I.2 cells/glomerulus). 
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Figure 3A. Cell infiltration into 24 hrischemic kidney isografts (.) is increased from day 2 onwards 
compared to non-ischemic controls (.), except CD8+ lymphocytes. Treatment with esA in ischemic 
isografts (D) inhibits this early influx. CD45 = pan leucocytes, OX·6= MHC class II. # =P<o.o5 vs 
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Figure 3B. Mononuclear cell inHltration under CsA therapy in non-ischemic allografts ( ..... ) was 
abundantly present by day 2. At first CD4+ cells invaded the graft, shortly followed by CD8+ 
lymphocytes and ED-I+macrophages. Hundred eighty days post-transplant, the allograft was mainly 
inftltrated by CD4+ cells and ED-I+ macrophages. Subjection of the renal allograft to 24h of cold 
ischemia (f:::..) did not change the onset or severity of the cellular infiltration. CsA 
immunosuppressed, non-ischemic isografts ( * ) served as controls. # = P<o.o5 vs isograft,CsA 
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ICAM-I expression in kidney iso·and allografts, subjected to 24h of cold ischemia. 
The intensity on the endothelium and tubules was measured semiquantatively on a 
0-3 scale (0= none, r= mild, 2= moderate, 3= dense). # = P<o.o5 vs isograft; * = 
P<0.05 vs isograft,24h ischemia; ## =P<o,o5 vs isograft,CsA 
Cold ischemia in Allografts 
Under CsA treatment, non· ischemic allografts demonstrated significantly 
higher expression of ICAM·r (Figure 4) and more MHC class 11+ cells at day 2 
compared to isografts (Figure 3B), and the number of these cells progressively 
increased until day 6. These MHC II+ cells mainly consisted of CD4+ cells and 
EDr+ macrophages at day 2 and 3, and from day 3 on of CD8+ cells and EDr+ 
macrophages, while numbers of CD4 + cells decreased. By week 26, the extent of 
MHC class II infiltration had diminished, predominantly due to a reduction of 
CD8+ cells. CD4+ cells and macrophages were localised primarily in the 
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glomeruli, peritubularly and around vessels. Also, some CD8+ cells were seen in 
the glomeruli and perivascularly. 
Twenty four hours ischemia of allografts did not affect the onset or 
progression of cell infiltration in the first IO days. At week 26, there were still no 
significant differences in cell numbers between in both groups. 
Discussion 
In unravelling the etiology of CTD, some clinical studies on cadaveric donor 
kidneys demonstrated that prolonged cold ischemia shortened ·late graft 
survival.'·' Another indication that cold ischemic preservation injury is implicated 
in the process leading to CTD is the superior long-term survival ofliving donor 
transplants, both related and unrelated compared to that of cadaveric donor 
kidneys.' Since reliable comparisons between clinical studies are hindered by a 
variety of used preservation solutions, storage methods, immunosuppressive 
regimens as well as a different donor status, we studied the effect of prolonged 
cold ischemia in an experimental kidney transplantation model in the rat, both 
in a syngeneic and allogeneic setting. 
Our study demonstrates that 24 hours of cold ischemia induces CTD in 
syngeneic kidney transplants. Three days after transplantation, endothelial cells 
were swollen and tubular damage was evident. Concurrently, the adhesion 
molecule ICAM-I was upregulated on endothelial and tubular cells and coincided 
with an increase of MHC class 11+ infiltration, mainly consisting of CD4+ T 
lymphocytes and macrophages. After a functional recovery, the ischemic 
isografts showed from week 18 onwards a progressive proteinuria. One year 
posttransplant, these kidneys demonstrated more glomerulopathy and had, in 
contrast with non-ischemic isografts, intimal hyperplasia. The degree of tubular 
atrophy and interstitial fibrosis was comparable. 11,ese observations concur with 
findings in a non-transplant rat model, showing that renal warm ischemia led to 
late functional and morphologic changes.' The significance of the infiltration of 
T lymphocytes and macrophages after ischemia/reperfusion in our study needs 
further investigation. Azuma et al. already demonstrated in the ischemic non-
transplanted kidney that both cell types were activated, producing cytokines and 
growth factors like IL-I, TNF-C(, PDGF, and TGF-j3.' Several of these molecules 
may contribute to tissue injury, repair and the late fibrotic changes. 
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In order to understand the relevance of cold ischemic injury versus donor-
recipient histoincompatibility, the BN donor kidney subjected to 24 hours of cold 
ischemia was transplanted into the WAG recipient, a fully MHC-mismatched 
combination_ Non ischemic BN-WAG allografts immunosuppressed for 3 weeks 
with a relatively low dose of CsA developed in 26 weeks histopathological 
alterations that are compatible with CTD both in man' and rat.""'" Exposure of 
the donor kidney to 24 hr of cold ischemia in the allografts, however, did not affect 
the onset and progression of proteinuria and parenchymal lesions: The degree of 
glomerulopathy, tubular atrophy and interstitial fibrosis was comparable to that 
in non-ischemic allografts_ In the first ro days after engraftrnent, these ischemic 
kidneys showed similar, abundant numbers oflymphocytes and macrophages as 
non-ischemic controls, These observations conflict with data from Yilmaz et al. 
who showed in the DA-WF kidney allograft model that 60 minutes ischemia led 
to higher creatinine levels and more glomerular and vascular pathology than 30 
min ischemia." A likely explanation for this difference is that the cold ischemic 
insult was much greater after perfusion and storage with normal saline, as used 
in their study, than with uW-solution. 
The apparent different outcome of ischemic injury on isografts and 
allografts appeared to be related to CsA treatment. Administering the same 
immunosuppressive regimen to ischemic isografts led to inhibition of cold 
ischemia induced late renal dysfunction. Long-term function and 
histomorphology were similar in both ischemic and non-ischemic CsA treated 
isografts. While CsA protects against ischemic induced early dysfunction in 
organs, as liver, small intestine, heart and brain:"" the benefit of CsA in 
ischemic kidneys has not yet been reported. Some experimental studies showed 
that the early function and morphology of a warm ischemic kidney worsens after 
administration of CsA in a dose dependent way.')." In our study, the relatively low 
dose of CsA did not necessitate to extend the 3 weeks period of support by the 
recipient's own kidney. In fact, CsA lowered the influx of CD45+ leucocytes 
(CD4+ lymphocytes and macrophages) in the post-ischemic kidney, a feature 
which is also observed by Ysebaert et al." The mechanism of action ofCsA in this 
non-alloimmune mediated inflammation is poorly known. A decrease of 
trans endothelial migration of leucocytes" possibly by inhibition of adhesion 
molecule expression."'" are reported effects of CsA. In our model, CsA also 
tended to inhibit the increased ICAM-I expression after cold ischemia. Blockade 
of adhesion-molecules in the ischemic kidney is known to prevent the 
Isdlemia and Chronic Tnmsplcmt Dysfunction 
inflammatory cascade and late dysfunction." CsA could also act in ischemia-
reperfusion injury both through direct action on T-cell infiltration and activation. 
Takada et al demonstrated that ischemia-induced late renal dysfunction was 
prevented by blockade of the T-cell CD28-B7 costimulation which inhibited T cell 
and macrophage infiltration and activation." Thus, it seems that CsA inhibited 
the ischemic mediated response-to-injury in the allografts, but could not prevent 
the far greater alloimmune mediated response. 
In conclusion, prolonged cold ischemia causes late kidney graft dysfunction, 
which is effectively inhibited by CsA. Under CsA treatment, prolonged cold 
ischemia does not appear to increase the immunogenicity of the allografts. The 
much earlier onset and progression of CTD in allografts than in isografts with 
prolonged cold ischemia reflects the major importance of the alloantigenic 
stimulus in the process. 
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Chapter 5 
Summary 
Background: We recently demonstrated that prolonged cold ischemia did not 
influence the onset or progress of chronic transplant dysfunction (CTD) in 
kidney allografts under Cyclosporine therapy, whereas extended ischemic times 
in untreated isografts led to CTD. To study whether Cyclosporine was 
responsible for this effect, the aim was to investigate the impact of ischemia on 
the immune response in rat kidney BN-WAG allografts and WAG-WAG 
isografts, both in the absence of immunosuppression. 
Materials and Methods: To induce ischemic injury, donor kidneys were preserved 
for 24 hr in 4"C University of Wisconsin solution before transplantation. The 
histomorphology according to the BANFF criteria for acute rejection, and 
infiltrating cells (CD4- and CD8-cells, macrophages (M<I>)), MHC class II and 
adhesion molecule expression (P-selectin, ICAM-I) were assessed. Grafts were 
examined at day I, 2, 3, 4, 6, and 8. 
Results: At first cell infiltration of the interstitium accompanied by tubulitis was 
found, and later glomerulitis and vasculitis developed. In the allografts, exposure 
of the kidney to ischemia led to a significantly earlier onset of interstitial cell 
infIltration and htbulitis compared to non-ischemic allografts: BANFF score of 
interstitial cell infIltration was I±O vs o.25±o.29 (day 3) and 2±O vs I.25±o.25 (day 
4)- Ischemic isografts showed oedematous endothelium and tubular damage 
from day 2 to 40 which was not observed in non-ischemic ones. From day 6, the 
histologic differences between ischemic and non-ischemic allo- and isografts 
disappeared. Ischemia led to more intense expression of P-selectin (day I), 
ICAM-I (day 2), and MHC class II on endothelium and proximal hlbular cells 
(day 2). Concurrently with the upregulated ICAM-I and MHC expression, 
significantly more CD4+ cells and M<I> infIltrated the ischemic allografts at day 2 
and 3- In isografts, exposure to prolonged ischemia also led to a higher influx of 
CD4+ cells and M<I> than in non-ischemic isografts. Nonetheless, at day 2 and 3, 
the difference in number ofMHC class IJ+, and CD4+ cells between ischemic 
and non-ischemic allografts was significantly greater than between both groups 
in the syngeneic setting. 
Conclusion: Cold ischemia augments allogeneic mediated cell infIltration in rat 
kidney allografts. The earlier onset of acute rejection in these allografts may be 
prevented by better preservation, or by more adequate immunosuppressive 
therapies. 
IscJJemia altd Allogenicity 
Introduction 
Prolonged cold ischemia has been inconsistently identified as a risk factor for 
chronic transplant dysfunction (CTD) in human solid organ transplantation.'" 
Using a syngeneic kidney transplantation model, we recently demonstrated that 
prolonged ischemia is an independent factor for the development of CTD.' It has 
also been suggested that ischemia predisposes to acute rejection, the latter being 
the most consistent risk factor for CTD.' Some clinical studies demonstrated that 
organ grafts subjected to prolonged cold ischemia or with delayed function, a 
parameter which correlates with the ischemic period""" experience more often 
an early acute rejection episode than grafts which functioned immediately."""" 
Some centres indicate tl,at the effect of ischemia on CTD takes only place via this 
route: Troppmann et al. showed that delayed graft function in the absence of 
acute rejection did not affect long-term outcome." Therefore, it has been 
hypothetised that ischemia initiates an inflammatory response that provokes 
increased host immunological reactivity, possibly by upregulated MHC 
expression on graft tissue after ischemia." One recent experimental study 
showed that prolongation of the ischemic insult from 4 hours to 24 hours 
resulted in higher MHC class II antigen expression and more severe rejection of 
lung allografts in immunosuppressed dogs." In contrast, in our kidney 
transplantation model, prolonged cold ischemia did neither affect adhesion-
molecule and MHC antigen expression, and histomorphology during the first IO 
days in Cyclosporine-treated allografts, nor did it influence the onset or progress 
of CTD." It may be speculated that the absence of the deleterious effect of 
prolonged ischemia may be due to treatment with Cyclosporine. 
To investigate this, the aim of present study was to study the impact of 
ischemia on the immune response to renal allografts and isografts in the absence 
of immunosuppression. 
Materials and methods 
Animals 
Male rats of the inbred Brown Norway (BN}(RTI") and WAG/Rij (RTIU) were 
purchased from Harlan, Austerlitz, The Netherlands. The rats weighed 200-250 
g and 2-3 months of age at the beginning of the experiment. All animals were 
97 
Clzapter 5 
kept under standard conditions and given access to standard commercial rat 
chow (AM II; Hope Farms. Woerden. The Netherlands) and tap water acidified 
to pH 3. ad libitum. The experimental protocols were approved by the committee 
on animal research of the Erasmus University. Rotterdam. 
Kidney transplantation 
Kidney transplantation was performed using a modification of the technique 
described by Fisher and Lee." The animals were anaesthetised with ether. After 
an intravenous injection of heparin (roo IU). the left donor kidney was flushed 
in situ via the aorta with 5 ml University of Wisconsin (UW) solution of 4 ·C with 
a rate of 2 ml Imin. The kidney was excised and stored in UW solution prior to 
implantation. In the recipient. the kidney graft was transplanted heterotopically; 
donor renal artery and vein were anastomosed end-to side to recipient aorta and 
vena cava. respectively. using continuous 9-0 prolene_ During surgery. the graft 
was wrapped in gauze moisturised with 4·C phosphate buffered saline (PBS). 
The perioperative ischemic time was 30 minutes. After revascularization. the 
ureter was anastomosed end-to-end to the distal third part of the recipient's 
ureter using single II-O prolene sutures. The ipsilateral native kidney was 
removed at time of transplant. whereas the contralateral one remained 
untouched until sacrifice. The mean survival time for kidney allografts without 
immunosupression in a bilaterally nephrectomized recipient in this strain 
combination is ro±2 days_ 
Cold ischemia period 
The donor kidney was stored at 4·C for either ro minutes. i.e. the minimal time 
in which the recipient is anaesthetised and prepared for implantation of the graft. 
or 24 hours. The ro minutes cold ischemia will subsequently be referred to as 
non-ischemia. 
Experimental groups 
The impact of prolonged cold ischemia on the development of acute rejection 
was studied in BN-WAG donor-host combination without use of 
immunosuppression. Non-ischemic BN-WAG allografts. and ischemic and non-
ischemic WAG-WAG isografts served as controls to determine the relationship 
between ischemia and allogenicity. 
Representative specimens of kidney grafts were removed and snap frozen in 
Iscllollia and Allogmicity 
liquid nitrogen for immunohistology. Kidney specimens were also placed in 
}G% buffered formaldehyde for histomorphology. 
Morphological and immunohistological evaluation was performed at day I, 2, 3, 
4, 6, and 8 post-transplantation (n~5 animals/group/timepoint for allografts, 
n~3 animals/group/timepoint for isografts). 
Macroscopy 
At the time of sacrifice, the ureter was inspected for its diameter. The kidney 
transplants were examined for signs of acute rejection: swelling, haemorrhage 
and infarction. Kidney grafts with early hydronephrosis or pyelonephritis were 
excluded from the Shldy. 
Histology 
Paraffin-embedded 3 J.lm sections were cut and a haematoxylin/eosin, a periodic 
acid Schiff (PAS) and a Jones-staining was perfoffiled. Histological analysis was 
performed using the BANFF criteria for acute rejection" in a blind fashion. 
Immunohistology 
Representative portions of all kidneys were stained on 5 1,m cryostat sections by a 
three-layer immunoperoxidase technique. After fixation with acetone for 10 
minutes, tissues were dehydrated through graded alcohols to block endogenous 
peroxidase activity by incubation in methanol/o.03% H20 2 for IO minutes. After 
rehydration the non-specific binding was blocked by preincubation with IO% 
Normal Rabbit serum (Dako, Copenhagen, Denmark), in PBS/Bovine serum 
Albumin 5%. This was followed by one hour incubation with primary monoclonal 
antibodies (Serotec, Oxford, United Kingdom) for identification of CD45+ 
leucocytes (OX-I), CD4+ cells (W3/25), CD8+ cells (OX-8), monocytes 
/macrophages (ED-I), Natural Killer cells (P.3), major histocompatibility complex 
(MHC) class II antigens (OX-G), and intercellular adhesion molecule I (ICAM-r). 
After each incubation, slides were washed in PBS-Tween 20,0.1%. A second layer, 
rabbit anti-mouse IgG (Dako) was then applied for 30 minutes and after washing, 
slides were incubated with the third layer, mouse peroxidase-anti peroxidase 
(Dako) for 30 minutes. After washing in PBS, the reaction was developed by the 
addition of Diaminobenzidine substrate (Dako) for 8 minutes and slides were 
counterstained in Mayer's hematoxylin for 40 sec, washed, dehydrated and 
mounted. In order to stain the rabbit polyclonal antibody P-selectin (Pharmingen, 
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San Diego, CAl the preincubation was done with Normal Swine serum (Dako), and 
after staining the sections were incubated with swine·anti rabbit IgG (Dako) and 
subsequently with rabbit peroxidase.anti.peroxidase (Dako). 
The immunohistochemical analysis was done in a blind fashion by two 
observers. Positive cells were counted in at least 8 fields with a 400X 
magnification and expressed as number of positive cells/o.r mm'. P·selectin and 
ICAM expression was analysed semiquantatively in different cortical regions: 
glomerulus, peritubular, perivascular, and intravascular. A scale was made 
ranging from 0 (none), I (very mild), 2 (mild), 3 (moderate), to 4 (dense). 
Statistics 
For statistical analysis of ordinal data (macroscopy, histopathology and adhesion· 
molecule expression) Kruskal·Wallis·one way ANOVA followed by Mann· 
Whitney test was performed. One way ANOVA followed by a NewMan Keuls test 
was used for the data ofinfiltrating cells. A 95% confidence interval for difference 
between means was calculated for cell infiltration in ischemic and non·ischemic 
kidneys both in the allogeneic and syngeneic groups. Then, the confidence 
interval of the allogeneic groups was compared to that of the syngeneic groups: 
When the maximum level of one group did not reach the minimum level of the 
other group, the intervals were defined to be significantly different. Statistical 
significance was established at P<o.o5. The results are expressed as mean ± SD 
in the text, and as mean ± SEM in the figures. 
Results 
Macroscopical appearance 
In both the ischemic and non· ischemic allografted groups, the ureters had a 
normal calibre, with no signs of obstruction or leakage throughout the 8 days 
follow·up. Until day 4, the ischemic kidney allografts had a normal appearance. 
Six days after transplantation, however, 5 out of 7 rats were found to have a 
swollen kidney, with diffuse haemorrhages in the parenchyma. The renal artery 
was open in all cases; the ureter had a normal calibre. In non· ischemic allografts 
only lout of6 kidneys showed the same changes at day 6. (p~o.o6) Two days 
later, no differences between both groups could be observed: All kidneys in both 
groups were rejected. The ureter and kidney from both ischemic and non· 
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ischemic isografts had a normal appearance at all timepoints studied. 
Histology 
The results analysed according to the BANFF criteria are depicted in Figure 1. 
The histologic course in the allografts was as follows: At first infiltration of the 
interstitium is observed, and thereafter tubulitis, glomemlitis and vasculitis are 
found. Exposure of the donor kidney to 24 hr of cold ischemia led to an earlier 
onset of the interstitial cell infiltration and tubulitis (Figures I and 2). At day 2, 
some ischemic allografts showed infiltrating cells and tubulitis, and at day 3 all 
of these grafts had grade I interstitial cell infiltration, which was significantly 
higher than that in non-ischemic allografts. Four days after engraftment, the 
degree of tubulitis was significantly higher in the ischemic allografts. From day 
6, the interstitium ofischemic as well as non-ischemic allografts was.completely 
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Figure I. Severity of histopathological lesions in ischemic kidney allografts 
a 
a 
Allografts preserved for 24 hr (.) demonstrated a higher degree ofinterstitial cell infiltration at day 
3 and 4 after transplantation than non-ischemic allografts (0) (* = P<o.o5). In addition, the onset 
of tubulitis was earlier, which attained a significance at day 4 (* = P<o.o5). In isografts, ischemia 
led to minimal histologic changes: both in ischemic and non·ischemic isografts, the BANFF scores 
were 0. 
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Figure 2. A) Nonnal tubulointerstitium of a kidneyisografts. B) Lysosomal enzymes in tubulus cells 
of a 24 hr preserved kidney isograft at day J. C) Mild hlbulitis and cellular inftJtration in a kidney 
allograft at day 3. D) Moderate to severe tubulitis and cellular infIltration in a 24 hr preserved kidney 
allograft at day 3. E)A normal intra parenchymal artery in a kidney allograft at day 4- F) Endothelial 
swelling and perivascular cell infIltration in a 24 hr preserved kidney allograft at day 4. 
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infiltrated with host mononuclear cells. By day 6, glomeruli and vessels were 
becoming involved in the process, leading to a full blown acute rejection at day 8 
with haemorrhagic infarctions in at least 70% of the kidney, sometimes with 
thrombi in the midsize intraparenchymal arteries. Interestingly, 2 out of 7 
ischemic allografts had beginning fibrosis in the interstitium, which was not 
seen in the non-ischemic group. 
Non-ischemic isografts showed no histologic changes during this period, 
whereas ischemic isografts showed some endothelial and tubular damage at day 
2 to 4- The endothelium was oedematous and some hlbules had protein casts and 
lysosomal enzymes, observations that did not change the BANFF score in the 
ischemic isografts compared to the non-ischemic ones. From day 6 and onwards, 
no difference could be observed between ischemic and non-ischemic isografts. 
Immunohistology 
In the non-ischemic allografts, the adhesion molecule P-selectin increased 
progressively in the peritubular capillaries during the first 6 days. By day 6, the 
glomeruli and the endothelium of intraparenchymal arteries also expressed P-
selectin. Exposure of the kidney to 24 hr of cold ischemia did increase P-selectin 
expression, although it did not reach significance the allogeneic setting. (Figure 
2). In addition, in ischemic kidneys the expression of adhesion molecule ICAM-
, was upregulated by day 2 (Figure 2). Thereafter, in the allografts ICAM 
expression increased progressively, but the intensity between ischemic and non-
ischemic grafts was comparable. From day 2 and onwards, ischemia also induced 
expression of MHC class II antigens on the peritubular endothelium, and 
increased its expression on the proximal tubular cells, in iso- and allografts to a 
similar degree. Concurrently with the upregulated ICAM-, and MHC class II 
expression on graft tissue, significantly higher numbers of CD45+ leucocytes 
infiltrated the ischemic allografts at day 2 and 3 (Figure 3). Many of these 
leucocytes were MHC class II+ cells, CD4+ cells and ED,+ macrophages (Figure 3). 
Although the number ofMHC class IJ+ cells did not change after day 4, the ratio 
ofT lymphocytes CD4 and CD8 subsets were quite different between ischemic 
and non-ischemic allografts. While the ischemic grafts had a maximal 
infiltration of CD4+ cells at day 3, with a rapid decline thereafter, the non-
ischemic allografts showed the highest number at day 4. Whilst the number of 
CD4+ cells declined, the number of infiltrating CD8+ T lymphocytes 
progressively increased. ED,+ macrophages infiltrated the ischemic graft in 
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higher numbers, but after day 3 the difference in number between ischemic and 
non-ischemic allografts disappeared. NK-cells infiltrated the grafts at the late 
stage of acute rejection. By day 6 some cells were present, both in ischemic and 
non-ischemic kidneys, 23±I7 and '5±5 NK cellsjo.1mm', respectively (P~0'42). 
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Figure 2. P·selectin and ICAM'I expression in ischemic kidney iso· and allografts. 
The immunohistochemical intensity of the adhesion molecule expression was measured 
semiquantatively on a 0'4 scale. (O=Ilone, I=vety mild, 2=mild, 3=moderate, 4=dense). At day I, p. 
selectin was increased after ischemia in isografts (* = p<o.oS). In allografts. the expression of p. 
selectin was higher than in isografts (# = p<o.oS). Ischemia did not affect P·selectin expression in 
allografts. ICAM'I expression increased at day 2 after ischemia (* = p<o.oS) in isografl:s. (## p<o.oS 
vs isograft.24hr ischemia) 
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Figure 3. Cell infIltration in ischemic kidney iso- and allografts. 
In allografts, subjection of the kidney to 24 hr of cold ischemia (.) led to an increase of cell 
infiltration compared to non-ischemic controls (D).ln the first 3 days, CD45+ leucocytes consisted 
mainly ofMHC class ll+, CD4+ cells and ED-I+macrophages. The peak ofCD4+ cells was one day 
earlier, and the number of cytotoxic CD8+ T cells was higher at day 4- By day 6, the difference in cell 
infIltration between both groups disappeared. Cell infIltration into ischemic isografts (.) is also 
increased from day 3 and onwards compared to non-ischemic isografts (0), except for CD8+ T-cells 
(# = P<o.o5 ). The increase of infiltration of MHC class II+ and CD4+ cells after ischemia was 
significantly higher in allografts than in isografts at day 2 and 3 post-transplantation, when compared 
to their non-ischemic counterparts. (X = in 95% the maximum confidence interval between the 
means of ischemic and non-ischemic isografts do not reach the minimum confidence interval 
between the means of ischemic and non-ischemic allografts_) 
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In isografts, exposure to prolonged ischemia led also to a higher influx ofCD45+ 
leucocytes, mostly consisting of CD4 + cells and ED,+ macrophages than in non-
ischemic isografts. Nonetheless, at day 2 and 3, the difference in number of 
CD45+, MHC class II+, and CD4+ cells between ischemic and non-ischemic 
allografts was significantly greater than between both groups in the syngeneic 
setting. 
Discussion 
In the present study, we demonstrate that prolonged cold ischemia results in an 
earlier onset oftl,e histological and immunological features of rejection in kidney 
allografts. The mechanism through which ischemia increases the allogeneic 
immune response is not fully understood. Whilst in isografts, 24 hour of 
ischemia led to an increase of the early adhesion molecule P-selectin at day rand 
ICAM-I at day 2 on peritubular capillaries, in allografts ischemia did not furtller 
affect their expression: expression of these adhesion-molecules was persistently 
increased in both ischemic and non-ischemic allografts. Increased P-selectin and 
ICAM-I expression could be due to proinflammatory cytokines released by 
ischemia activated endothelium. This may mediate the selective migration of cell 
populations across endothelial barriers of the graft. Cytokines (IL-I, IFN-y) of 
recruited and activated CD4+ cells, which numbers dramatically increased after 
day I in allografts, could be responsible for the ongoing endothelial cell 
expression of adhesion molecules in allografts. 
In our study both ischemic allo- and isografts had an induced expression of 
MHC class II on vascular endothelium and increased expression ofMHC class 
II on the proximal tubular cells from day 2 and onwards. Shoskes et al. also 
demonstrated that transient ischemia in a non-transplant kidney led to an early 
upregulation ofMHC class I and II mRNA transcripts and protein expression on 
tubular cells." This observed MHC class II hyperexpression - triggered by release 
of IFN -y and other mediators ".,' -, led to the hypothesis that ischemia could 
increase the immunogenicity of a organ graft. Recently, this suggestion has been 
fortified in an experimental lung allograft model: Lung allografts with prolonged 
cold ischemia had an increased expression of MHC class II antigens on the 
vascular endothelium and bronchial epithelium and a more severe rejection 
compared to allografts with a short ischemic period.'] Since ischemic lung 
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isografts were not included in this study, the higher degree of histological 
rejection in ischemic lung allografts cannot be exclusively attributed to increased 
allo-immunogenicity by ischemia: Ischemia induced histologic damage could be 
superimposed on allogeneic mediated damage_ Our data indicate that ischemia 
augments the alloimmune response, since the increase of inflitration of MHC 
class 11+ and CD4+ cells was significantly higher in allografts then in isografts at 
day z and 3 post-transplantation, when compared to their non-ischemic 
counterparts_ In addition, in ischemic allografts interstitial cellular infIltrates and 
tubuli tis developed earlier in the process of histological rejection, whereas 
ischemia in isografts led to only minimal histologic changes: oedematous 
swelling and hlbules Witll protein casts and lysosomal enzymes_ 
Interestingly, the increased CD4+ T cell inflitration at day z and 3 in allografts 
did not correlate with the degree of MHC class II antigen expression on graft 
tissue, since allografts had a similar expression as isografts_ Moreover, in 
contrast to tl,e MHC class II antigen expression on endothelial cells that together 
with costimulatory molecules activate CD4+ T cells," the relevance ofMHC class 
II hyperexpression on hlbular epithelium is less clear. Epithelial cells do not 
seem to activate CD4+ cells,"'" because they miss costimulator molecules, such 
as B7. Nevertheless, even in a non-allogeneic setting, ischemia appears to activate 
CD4+ T cells: It has been found that blocking the CDz8-B7 co stimulatory 
pathway ofT cells inhibits early and late ischemic kidney injury effectively." 
In conclusion, ischemia augments allogeneic mediated cell inflitration, which 
relevance in terms of cytokine expression is currently under investigation. The 
earlier onset of acute rejection in these allografts may be prevented by better 
preservation, or by more adequate immunosuppressive therapies. 
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Chapter 6 
Summary 
Purpose: To investigate whether the type of surgical techniques of ureter 
reconstruction could have an impact on late function in kidney transplants, the 
uretero-neocystostomy (U-B) and uretero-ureterostomy (U-U) were compared. 
To rule out alloantigeneic mediated effects on late graft dysfunction, we 
transplanted kidneys syngeneically. 
Materials and methods: Rat kidney isografts were transplanted with either a U-B 
or a U-U. Unilaterally nephrectomised (UNx) rats served as controls. At 8 weeks 
post-transplantation, the intrapelvic pressure was measured under basal 
diuresis, after intravesical, and after intrapelvic infusion. Albuminuria was 
determined monthly until sacrifice at week 52. Histomorphological analysis 
included the degree of glomemlopathy, hlbular atrophy, interstitial fibrosis and 
intimal hyperplasia. CD4+-, CD8+T cells and macrophages (M<1») were identified 
using immunohistochemistry. 
Results: At 8 weeks, the intrapelvic pressure under basal diuresis and after 
intrapelvic infusion was significantly increased in U-B isografts compared to U-
U isografts and UNx rats, whereas intravesical infusion did not change the 
pressure in any of the groups. During follow-up Ualb in U-U did not differ from 
UNx. In contrast, Ualb significantly increased in U-B isografts from week 36 
onwards. At week 52, the ureter and kidney of U-U transplants and UNx had a 
normal appearance, whereas all ureters in the U-B group were dilated. 
Nevertheless, 6 out of 8 U-B kidneys had a normal appearance. However, the 
histomorphology of U- B transplants demonstrated significantly more interstitial 
fibrosis and more CD-8+ T-cells and m compared to U-U isografts. 
Conclusions: The U-B surgical technique for restoring the urinary tract after 
kidney transplantation contributes to the development of long-term functional 
and histological renal changes. A partial obstruction may be the cause of this 
renal impairment. 
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Introduction 
Despite progressive improvement in r year graft survival rates - mainly due to 
progress in treating acute rejection episodes-, beyond r year the annual rate of 
kidney graft loss has not changed over the last 3 decades,'" Late failure of kidney 
allografts is largely attributable to chronic transplant dysfunction (CTD), which 
histomorphology consists of glomerulopathy, tubular atrophy and interstitial 
fibrosis.'The pathogmonic characteristic is intimal hyperplasia, which can 
frequently not be assessed in biopsies because of absence of arteries.' The 
histomorphology of other causes of late dysfunction, like obstuctive 
nephropathy, can easily overlap with the non-specific kidney changes seen in 
CTD. Some clinical transplant shldies demonstrate that urologic complications 
may have long-term effects on graft function.' 
The continuity of the urinary tract in clinical renal transplantation is usually 
restored by uretero-neocystostomy. Notwithstanding the surgical technique of 
uretero-neocystostomy applied, the incidence of urologic complications has been 
reported to range from r -ro%.',7 The majority of these complications occur within 
the first month after transplantation. Late complications are predominantly 
ureteral obstruction and vesicoureteral reflux.' 
A severely dilated pyelum is known to impair renal function and morphology, 
finally resulting in end stage renal disease.' Some clinical transplant studies have 
shown that mild dilation of the pelvicalyceal system occurs frequently, although 
it does not affect allograft function significantly,"'" However, negative effects of 
the surgically restored urinary tract on renal function and morphology in clinical 
transplants could be masked by overwhelming allogeneically mediated damage. 
Therefore, to study the impact of such a factor in a isolated fashion, an animal 
model in which can be transplanted in the absence of an allogeneic response, is 
necessary. 
To investigate whether the type of ureter anastomosis could has an impact on 
late functional and morphological changes in the kidney transplants, we 
performed two different techniques of ureter reconstruction. The clinical most 
widely used uretero-neocystostomy and the uretero-ureterostomy. 
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Materials and methods 
Animals 
Male rats of the inbred Brown Norway strain (BN; RTIIl) were purchased from 
Harlan, Austerlitz, The Netherlands. The rats weighed 200·25og and were 2'3 
months of age at the beginning of the experiment. All animals were kept under 
standard conditions and given access to standard commercial rat chow (AM II; Hope 
Farms, Woerden, The Netherlands) and tap water acidified to pH 3, ad libitum. The 
experimental protocols were approved by the committee on animal research of 
the Erasmus University, Rotterdam. 
Transplantation technique 
Kidney transplantation was performed from BN to BN using the technique 
described by Fisher and Lee." The animals were anaesthetised with ether. After 
an intravenous injection of heparin (100 JU), the donor kidney was flushed in 
situ via the aorta with 5 ml University of Wisconsin (UW) solution of 4 °C at a 
rate of 2 ml jmin. The kidney was excised and stored in UW solution (4°C) for 
about 6 minutes prior to implantation. The kidney graft was transplanted 
heterotopically, donor renal artery and vein were anastomosed end·to side to 
recipient aorta and vena cava, respectively, using continuous 9.0 prolene 
sutures. The total perioperative ischemia time was 30 minutes. Two methods of 
restoring the continuity of the urinary tract were compared. 
Experimental groups 
Croup 1 
BN.BN-kidney transplants with uretero·neocystostomy (U-B; n = 13). The U-B 
was performed as described by Fisher and Lee." In brief, the donor ureter was 
directly inserted into the bladder and flxed with one 8.0 stitch to the dorsal vesical 
wall about 3 mm from ti,e incision made at the apical site of the bladder. 
Croup 2 
BN-BN·kidney transplants with uretero-ureterostomy (U-U; n = IO). The U-U 
was performed as described by Oesterwitz et al." In brief, the ureter of the donor 
was anastomosed end-to· end to the distal third part of ti,e recipient's ureter using 
4 interrupted IO-O prolene sutures, WitilOUt the use of a stent. 
In both groups, the left native kidney was excised at the time of transplantation. 
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Nephrectomy of the contralateral kidney was performed 3 weeks after 
transplantation. 
Group 3 
Unilaterally nephrectomised (UNx) BN rats (n ~ '3) served as controls. 
The follow.up period was 8 weeks for intrapelvic pressure measurements (n ~ 5 
for each group) and 52 weeks for functional and morphological studies of the 
kidney. 
Intrapelvic pressure studies 
Intrapelvic pressure was determined in all 3 groups at 8 weeks post-
transplantation. Under ether anaesthesia, a midline abdominal incision was 
made. A 20 gauge catheter was introduced into the upper pole of the kidney graft 
and then pushed up towards the renal pelvis. The catheter was initially advanced 
into the upper ureter with visualisation of the catheter tip, then relocated in the 
renal pelvis for continuous pressure monitoring by a Uniflow pressure transducer 
(Baxter, United Kingdom). The zero· calibration of the pelvic pressure was done at 
the level where the catheter inserted the pyelum. Then, a 20 gauge catheter was 
placed into the ventral side of the bladder for bladder emptying. Renal pelvis and 
bladder were examined for leakage after placement of the catheters. 
Vesico·ureteral reflux was tested by examining the ureter for retrograde flow 
of Evans blue: after emptying the bladder, it was filled with 0.7 ml phosphate 
buffered saline (PBS) with Evans blue, the maximum volume before spontaneous 
voiding occurred. The intrapelvic pressure was recorded concomitantl!' 
To detect ureter obstruction, the bladder was emptied and the intrapelvic 
pressure was measured. Subsequently, the pelvis was ftIled with 0.1 ml PBS ,vith 
Evans blue via the renal catheter and the intrapelvic pressure was measured 
continuously for 30 min. 
Renal function 
Urine was collected monthly by placing the rats individually in metabolic cages 
for 24 hours. Protein excretion was colorimetrically by addition of pyrogallol red. 
Serum creatinine was determined using the Jaffe method without 
deproteinization. 
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Macroscopy 
The kidney transplants were examined for hydronephrosis and pyelonephritis. The 
ureter was inspected for its diameter, its vascularisation and for fibrotic thickening. 
Histology 
At 52 weeks post-transplantation, kidneys were harvested, fixed by immersion for 
48h in a 306% buffered formaldehyde solution after longitudinal bisection, and 
embedded in paraffin for histopathological studies. Sections (311m) were stained 
with hematoxylin-eosin (H&E), periodic acid Schiff (PAS) and were evaluated for 
glomerulopathy, tubular atrophy, interstitial fibrosis, and intimal thickening 
using the BANFF-score formulated for CTD:' Briefly, these 4 criteria were 
separately determined with a score ranging from 0 ~ normal, I ~ to 25% affected, 
2~ moderate, affecting 25-50%, and 3~ more than 50% changes. 
Immunohistology 
Representative portions of all kidneys were stained on 5 11m cryostat sections by 
a three-layer immunoperoxidase technique. After fixation with acetone for 10 
minutes, endogenous peroxidase activity was blocked by incubation for 10 
minutes in methanol/o.03% H,O" after dehydration through graded alcohols. 
After rehydration the non-specific binding was blocked by preincubation with 10% 
Normal Rabbit serum (Dako, Copenhagen, Denmark), in PBS/Bovine serum 
Albumin 5%. This was followed by one hour incubation with the primary 
monoclonal antibodies W;'/25, OX-8, and ED-I (Serotec, Oxford, United Kingdom) 
for identification ofCD4+-, CD8+T-cells and macrophages, respectively. After each 
incubation, slides were washed in PBS-Tween 20, 0.1%. A second layer, rabbit 
anti-mouse IgG (Dako) was then applied for 30 minutes and after washing, slides 
were incubated with the third layer, mouse peroxidase-anti peroxidase (Dako) for 
30 minutes. After washing in PBS, the reaction was developed by the addition of 
Diaminobenzidine substrate (Dako) and slides were counterstained in Mayer's 
hematoxylin for 40 sec, washed, dehydrated and mounted. The analysis was 
done in a blind fashion by two observers. Positive cells were counted and 
expressed as number of positive cells /0.1 mm'. 
Statistics 
Statistical analysis was performed using Kruskal-Wallis one way ANOVA followed 
by Mann-Whitney test, p < 0.05 was accepted to be significant. The results are 
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expressed as mean ± SD in the text and tables, and as mean ± SEM in the figures. 
Results 
Intrapelvic pressure 
ullder basal diuresis 
At 8 weeks post-transplant U-B isografts had significantly higher intrapelvic 
pressures than U-U isografts and UNx rats (Table I). 
BN-UNx BN-BN, uretero- BN-BN, uretero· 
ureterostomy neocystostomy 
Intrapelvic pressure 1.4 ± 0·4 2.1 ± 0.9 
(em H 2 0) 
Table I. Intrapelvic pressure at basal diuresis *=P<o.05 vs BN-BN, uretero·ureterostomy and 
EN·UNx. 
after illtravesical infosion 
In isografts with either U-B or U-U and UNx, injecting 0.7 ml Evans blue into 
the bladder did neither lead to any dye in the ureter nor to an increase of the 
intrapelvic pressure. 
after intrape/vic infosion 
Infusion of 0.1 ml PBS intrapelvicaBy led to a significant rise of the intrapelvic 
pressure in aB experimental groups. The pressure in the isografts ,vith U-B was 
significantly higher than in the otl,er 2 groups. Moreover, the pressure in the U-
B transplants returned to normal basal diuresis value after 30 minutes, whereas 
in the U-U kidney transplants and in the UNx group it normalised at IO minutes 
after infusion (Figure I). 
Renal function 
The excretion of protein of kidney isografts with U-U did not differ from UNx 
during the I year follow-up (Figure 2). Also, serum creatinine did not change in 
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u-u compared to UNx (Figure 3). In contrast, isografts with U-B had 
significantly increased proteinuria from 36 weeks after transplantation and 
beyond and serum creatinine levels from week 44 and onwards compared to the 
isografts with U-U and UNx. (Figures 2 and 3). 
Figure I. 
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In syngeneic kidney transplants with either a uretero-ureterostomy (D) or a uretero-
neocystostomy (B)and unilaterally nephrectomized BN rats (~), the intrapelvic 
pressure was monitored after infusion of 0.1 ml PBS intrapelvically as described in 
the Materials and Methods. * I ** = P<o.o5 vs the intrapelvic pressure of the uretero-
neocystostomy at basal diuresis (-I minutes). ** = P<O.02 vs the intrapelvic pressure 
ofthe uretero-ureterostomy-group and the UNx-group immediately after infusion (0 
minutes). # = P<O.02 vs the intrapelvic pressure ofthe uretero-ureterostomy at basal 
diuresis (-I minutes). + = P<O.02 vs the intrapelvic pressure of the Unx at basal 
diuresis (-r minutes) 
At sacrifice, the ureter in kidney transplants with U -U had a normal calibre and 
vascularizatiOI .. At the side of anastomosis no fibrosis or stenosis could be 
detected. FurtJ .ermore, they did not demonstrate any sign of hydronephrosis or 
pyelonephritis. In contrast, all renal isografts with U-B had a dilated ureter, the 
ureteric wall was thickened and poorly vascularized. Nevertheless, only 2 out of 
the 8 kidney transplants showed signs of hydronephrosis. The other kidney 
transplants had a normal appearance. The ureters and kidneys in the UNx rats 
did not show any abnormalities. 
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Histology 
Isografted kidneys with U-U demonstrated some damage at week 52, which did 
not differ from that in BN-UNx; Banff-score was 2.6 ± 0.5 and 2.7 ± 0.8 
respectively. As depicted in Figure 4, the lesions consisted of some 
glomerulopathy and tubular atrophy. Interstitial fibrosis and intimal thickening 
were not seen in any of the kidneys. In contrast, isografts with U-B had a mean 
BANFF score of 4.3 ± La which is significantly higher than that of the other 2 
groups: The most striking difference was the presence of interstitial fibrosis in 
the U-B transplants (Figure 4). As in the kidneys ofisografts with U-U and UNx, 
intimal hyperplasia was not seen, except minimal lesions in one kidney 
transplant. 
Figure 4. 
Dg!omerulopa\hy 
Dlubo!aratrophy 
• interstitial fibrosIs 
Dlntimal hyperplasia 
BN UNx BN.BN,uretero-ureleroslomy BN-BN, uretero-neocystostomy 
Histopathology of kidney isografts with 2 types of urinary tract reconstmction: 
uretero·neocystostomy and uretero-ureterostomy, and of unilaterally 
nephrectomized rats using the BANFF·criteria for chronic transplant dysfunction. * 
"" P<o.o5 vs isografts with uretero·ureterostomy and UNx. 
Immunohistology 
UNx-kidneys showed a few infiltrating CD4+ and CD8+ T-cells and ED-I 
macrophages (M<t», mainly localised peritubularly. Renal transplants with U-U 
had a similar distribution and quantity of the T cell-subsets and m. In isografts 
with U-B, there was a significant increase of CD4+ and 8+ cells and m in the 
interstitium (CD4: 44±I2 vs 2o±3 cells/o.Imm2 ; CD8: I5±6 vs 4±Icells/0.Imm2 ; 
m: 25±8 vs I2±3 cells/0.Imm2). 
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Discussion 
In unravelling the etiology oflate kidney graft failure, some clinical studies 
indicate that urologic complications may have an impact on late graft function 
and morphology. Until now little attention has been directed to the long-term 
effects of the surgical technique of ureteric anastomosis. Therefore, we studied 
the possible impact of 2 types of urinary tract reconstruction, the clinically most 
widely used uretero·neocystostomy (U-B) and the uretero·ureterostomy (U-U) on 
late kidney function and morphology. 
The main finding of the present study is that the U-B induces late graft 
dysfunction in rat renal isografts, whereas the U-U does not. After an initial 
normal function, transplants with U-B demonstrated from week 36 onwards a 
progressive decline of renal function and significantly more interstitial fibrosis 
at week 52. Although it is generally known that urinary tract dysformities can lead 
to nephropathy, the U·B as the standard technique for reconstruction appeared 
to be reliable. The few clinical transplant studies on this subject could not 
demonstrate long·term adverse effects of the U-B per se on graft function. Even 
in dilated urinary collecting systems without obVious obstruction by antegrade 
pyelography, the serum creatinine did not differ from that in non·dilated renal 
allografts." On the other hand, obstructed kidney allografts which were 
reconstructed secondary had serum creatinine levels at 3 months and 1 year 
which were significantly higher than in non·obstructed allografts." 
Although 6 out of8 transplants with U-B had a normal appearing kidney and 
only 2 showed macroscopical signs of obstruction, the intrapelvic pressure under 
basal diuresis and after antegrade intrapelvic infusion was significantly 
increased. Therefore, a partial ureteric obstruction of the U-B isografts appeared 
to be the cause of renal impairment. This simultaneous occurrence of elevated 
intrapelvic pressure and normal pyelocalyceal system has also been observed in 
patients, in which it was indicated as cause of nephropathy. ",' 
In contrast to acute ureteral obstruction ,vith basal intrapelvic pressures of 
>20 cm H20 causing immediate renal impairment," in our study the increased 
intrapelvic pressure (8 cni) did not deteriorate renal function immediately. This 
was also found by others in an experimental model of partial ureteric obstruction, 
in which the glomerular Hltration rate was not affected after 3 weeks, but was 
reduced by 60% after 1 year.'" 
The kidney isografts with U-B showed some glomerulopathy and tubular 
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atrophy, and significantly more interstitial fibrosis and interstitial infiltration of 
CD4+ and CD8+ T-cells and macrophages. These histologic and inflammatory 
feahlres resemble the chronic tubulointerstitial nephritis in non-transplanted 
kidneys exposed to chronic urinary obstruction." 
With the present results, we show that the uretero-neocystostomy as method 
of restoring the urinary tract after kidney transplantation contributes to the 
development oflong-term functional and histological renal changes. Although 
we used the BANFF criteria for CTD to analyse the morphology, the absence of 
intimal hyperplasia in the present study presumes a different pathophysiological 
origin. On the other hand, the aspecific changes - tubular atrophy and interstitial 
fibrosis - seen after uretero-neocystostomy could contribute to the overall 
histopathology in biopsy-proven CTD, thereby in fact overscoring the severity of 
CTD in allografts. Moreover, this study demonstrates that a non-dilated urine 
collecting system in kidney transplants does not guarantee appropriate urine 
outflow and that a partial obstruction can lead to late deterioration of kidney graft 
function. 
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Summary 
Introduction: Chronic transplant dysfunction (CTD) is the major cause of late 
organ graft loss. Since some transplant studies suggest differences in kidney 
graft outcome due to ethnicity, intrinsic genetic factors of the kidney may 
contribute to CTD. 
Purpose: Therefore, the aim of the present study was to investigate possible 
differences in genetic susceptibility for CTD in a rat model. By transplanting 
different donor kidneys into a normotensive, histocompatible recipient, the 
kidneys were exposed to the same blood pressure profiles, metabolic and 
hormonal environment. 
Materials and methods:Kidneys from young adult hypertensive fawn-hooded 
(FHH),a strain showing early onset chronic renal failure, normotensive August 
x Copenhagen. Irish (ACI) and (ACI x FHH)F, donors were transplanted into 
male F, recipients. The native kidneys of the recipients were removed r week 
after transplantation. The results were mutually compared and to their 
unilaterally nephrectomised Iittermates. Systolic blood pressure (SBP) and 
albuminuria (Ua V) were determined at the time of transplantation and at 8 and 
r6 weeks. The histomorphological analysis included the incidence of focal 
glomerulosclerosis (FGS), and determination of CTD according to the BANFF 
criteria. 
Results: A negative impact of the transplantation technique in this syngeneic 
situation could not be detected as F, transplants did not differ functionally and 
morphologically from their UNx controls. Transplanting an ACI kidney did not 
result in significant changes ofSBP, UaV and incidence ofFGS compared to F, 
transplants and ACI-UNx. In contrast, FHH kidneys did show a progressive 
increase ofUaV and glomerulosclerosis and a significant higher BANFF score, 
whereas the SBP did not differ from F, transplants. The moderate hypertension 
seen in FHH did not travel with the kidney. Compared to the FHH-UNx, 
transplantation of a FH H kidney did significantly attenuate the rise of Ua V and 
FGS. 
Conclusions: The susceptibility of the donor kidney appears to be an important 
factor for the development of CTD. 
Susceptibility of Donor Kidneys for Cilronic Transp/ant Dysfilllction 
Introduction 
Chronic kidney transplant dysfunction (CTD) is the major cause of graft loss one 
year post-transplantation." The etiology and pathophysiology of CTD are poorly 
understood_ Generally, alloantigen-dependent factors as acute rejection are 
thought to be the main risk factors for CTD_ However, alloantigen-independent 
factors also appear to contribute to functional and histopathological changes_ 
Several donor- and recipient-related factors, such as age, renal mass, cold 
ischemia and hypertension have been implicated," but an intrinsic genetic 
susceptibility of the donor kidney to renal damage may also be involved_ End 
stage renal failure (ESRF) is a condition that shows great similarity to CTD bO.th 
functionally and histopathologically. Several clinical studies analyzing the causes 
of ESRF suggest that genetic factors may play an important role in the risk of a 
hypertensive patient to develop ESRF. Hypertensive African-Americans, for 
example, have an 8- to 25-fold higher risk of developing ESRF than Caucasians, 
which cannot be explained by the severity or the treatment of hypertension.,·6., 
Even more indicative for intrinsic genetic factors of the kidney are the findings 
of some transplant studies, which suggest differences in graft outcome due to 
. donor ethnicity: Kidneys from African-American and Asian-American donors 
had significantly worse outcome than those from Caucasians.'" 
In an animal model, Churchill et al. clearly demonstrated that susceptibility 
of the kidney to hypertension-induced damage is genetically based. By exposing 
a transplanted Brown Norway (BN) kidney and one native kidney in a BN 
compatible-spontaneously hypertensive rat (SHR) to the same high blood 
pressure and metabolic environment, BN kidneys were found to be more 
susceptible to develop damage than SHR kidneys." 
Apart from a genetic susceptibility of the kidney to hypertension-induced 
damage, experimental transplantation studies also demonstrate that even in a 
normotensive environment the susceptibility of the graft to develop CTD appeared 
to be strain-dependent. Tullius & Tilney demonstrated significant proteinuria at 
week 52 in syngeneic Fisher rat transplants compared to unilateral nephrectomized 
Fisher rats," whereas we did not observe any increase using BN isografts." 
Genetic factors influencing the development and progression of renal damage 
have been suggested, but specific genes have not emerged. Recently, we have 
found genes in the hypertensive Fawn-hooded (FHH) rat that determine 
susceptibility of a kidney to develop damage, independent from loci coding for 
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hypertension," In contrast to the susceptible FHH kidney, the August x 
Copenhagen-Irish (ACI) rat strain was resistant to develop hypertension-induced 
renal damage." (FHHxACI)F j rats were also quite resistant to renal damage 
indicating the resist nature of this trait,"'" However, in the previous studies the 
kidneys functioned in different environments_ Thus the question remains 
whether these differences in susceptibility to CTD are intrinsic to the kidney or 
are related to metabolic, hormonal or other factors, such as the level of blood 
pressure. 
To test the hypothesis that in a normotensive environment, the susceptibility 
of the donor kidney to develop CTD is strain-dependent, we transplanted three 
types of donor kidneys, the FHH, ACI and the Fj of both strains into a 
histocompatible, normotensive Fj recipient. In this setting, the donor kidneys 
were exposed to the same blood pressure profile, metabolic and hormonal 
environment. 
Materials and methods 
Animals 
Inbred male rats, 16 weeks old and weighing 260 to 350 g at the start of the study, 
were used. Hypertensive FHH and normotensive ACI strains and (FHH x ACI) 
Fj were derived from our breeding colony, maintained at the Erasmus University 
Medical School. All animals were kept under standard conditions and given 
access to standard commercial rat chow (AM II; Hope Farms, Woerden, The 
Netherlands) and tap water acidified to pH 3, ad libitum. 
Kidney grafting 
The left donor kidney was flushed ill situ with cold phosphate buffered saline 
(4 'C), removed, cooled, and heterotopically positioned in the recipient. The 
donor renal artery and vein were anastomosed with 9-0 Prolene end-to-side to 
the recipient's infrarenal aorta and caval vein, respectively. The total ischemic 
. time was less than 45 minutes. The donor and recipient ureter were anastomosed 
end-to-end with 10-0 Prolene sutures. The 2 native kidneys of the recipient were 
removed: the homolateral kidney at time of transplantation and the contralateral 
kidney 1 week after transplantation. 
Susceptibility of DOllor Kidneys for Chronic Transplant Dysfuliction 
Experimental groups 
To study the effect of the donor kidney's susceptibility to develop CTD, three 
strains of kidney donors were used: FHH (n ~ 6), ACI (n ~ 7), and (ACI x FHH) 
FI (n ~ 6). 11,e (ACI x FHH) FI rats were used as recipients. Weight-matched 
unilaterally nephrectomised (UNx) FHH (n ~ 8), ACI (n ~!O) and Fr (n ~ 9) rats 
served as controls. 
Functional measurements 
Body weight, systolic blood pressure (SBP) and urinary albumin excretion (UaV) 
were determined before transplantation and at week 8 and ,6 postoperatively. 
Systolic blood pressure was measured by tail· cuff plethysmography (IITC Life 
Science, Woodland Hills, CAl in awake, restrained animals. Twenty-four·hour 
urine was collected by placing the rats in metabolic cages. Actual measurements 
were done on 2 consecutive days for assessment of albumin excretion, which was 
measured with bromocresol green (Merck, Darmstadt, Germany). At week ,6 
post-transplantation, the plasma creatinine was analysed with the Jaffe method 
without deproteinization. 
Tissue processing 
Kidneys and hearts were harvested under ether anesthesia and weighed. 
Recipients without complications of grafting (pyelonephritis or hydronephrosis) 
were included in the study. The kidneys were fIxed by immersion for 48 hr in a 
3.6% buffered formaldehyde solution after longitudinal bisection, and 
embedded in paraffIn for histopathological studies. ParaffIn sections (3 ~m) were 
stained with periodic acid Schiff and hematoxylin/eosin counterstain. 
The kidney sections were microscopically examined for the presence of focal 
glomerulosclerosis (FGS). In a single kidney section, 50 glomeruli were 
examined in the inner and outer cortical region and the number of sclerotic 
glomeruli was determined. FGS was defIned as previously described:' In 
addition, kidney sections were evaluated for chronic transplant dysfunction 
using the BANFF-criteria." Briefly, glomerulopathy - determined in nonsclerotic 
glomeruli -, interstitial fIbrosis, tubular atrophy and intimal thickening were 
separately determined with a score ranging from 0 ~ normal, , ~ up to 25% 
affected, 2 ~ moderate, affecting 25'50%, and 3 ~ more than 50% changes. The 
sum of the individual scores of the 4 criteria is given as the total BANFF score. 
Sections were evaluated as 'blind' to group. 
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Statistical analysis 
All statistical analyses were performed using one way analysis of variance 
followed by the Student-Newman-Keuls test. The results are expressed as mean 
± SD in the text and tables, and as mean ± SEM in the figures; probability of p < 
0.05 was accepted as significant. 
Results 
The susceptibility for CTD was studied by using 3 different types of donors, 
transplanted into the histocompatible, normotensive FI recipient. 
FI transplants 
The SBP ofF1 kidney Iransplants did not differ from that in UNx controls, both 
having a stable SBP during the follow-up (Figure I). Heart and kidney weight 
were identical (Table I). A negative impact ofthe transplantation procedure on 
the development of CTD could not be observed. F 1 transplants had a stable renal 
function. UaV varied between 10 to 16 mg/day during follow-up, and did not 
Donor-Rec 
PI - PI 
ACI·F, 
FHH-FI 
PI UNx 
ACI UNx 
FHH UNx 
Table I. 
'3° 
n 
6 
7 
6 
9 
10 
8 
week 0 
BW·donor KW·donor BW-rec 
332 ± 22 1375 ± lOS 340 ±27 
266 ± n* 996 ± 59* 334 ±20 
331 ± 17 1349 ± 190 342±26 
344 ± 40 
271 ± 191" 
351 ± 24 
1380 ± 86 
IOOS± 70t 
1387 ± 197 
BW 
40S ± 22 
397 ± 36 
402 ± 13 
388 ± 47 
289 ± 25 
375 ± 30 
week 16 
KW HW/loog 
1995± 22 232 ± 9 
2131 ±169 240 ± 31 
1955 ±136 251 ± 16 
1920 ±IIS 
1387 ±84 
2475 ±487 
254 ± 14 
24S ± 10 
285 ± 19# 
Body, kidney and heart (absolute or relative) weights at time of transplantation and 
at autopsy. Ree, recipient; UNx, unilaterally nephrectomized; BW, body weight in g; 
KW, wet kidney weight in mg; HW/lOog, wet heart weightfloog BW. Values are 
given as mean ± SD. * = p< 0.05 AC[ body weight vs FI and FHH body weight; t = 
p< 0.05 ACI kidney weight vs FI and FHH kidney weight; # = p< 0.05 FHH UNx VS 
FHH.F1 
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differ from FI,UNx (Figure 2). They also demonstrated a similar degree ofFGS 
and BANFF score as their UNx controls (Fignre 3). 
ACI transplants 
Transplanting an ACI kidney into the FI did not influence the recipient's SBP: 
At 16 weeks, the blood pressure did not differ from that in FI,FI combination, 123 
± 8 vs 121 ± 9 mm Hg, respectively (Figure I). In addition to the SBP 
measurements, the relative heart weight was equal in both groups (Table I). At 
the end of the experiment, the relative and absolute kidney weight of ACI and F I 
transplants was similar. Because the absolute kidney weight of the ACI donors 
at time of transplantation was significantly lower than that of FI donors, renal 
hypertrophy was most profound in ACI transplants (Table I). 
Apart from the blood pressure profile and renal mass, function determined 
by UaV (Fignre 2) and plasma creatinine (Table 2) of transplanted ACI kidneys 
did not differ from that of FI transplants. Both ACI and FI kidney grafts 
Figure I. 
170 
160 
""" ";;=~== 
~ -- :::::::=:.---:: 
F~UN,:---
T' 
110 ACI UNx 
100 
o 8 16 
weeks post-transplantation 
Tail cuff systolic blood pressure (SBP) in millimeters of mercury in awake (ACI x 
FHH) Fr recipients with transplanted kidneys from the hypertensive Fawn-hooded 
(FHH)(D), the normotensive ACI(.} strain and from the FI (. ) of both strains and 
in awake unilaterally nephrectomized (UNx) FHH, ACI and F I rats. Values are given 
as mean ± SEM. * = p< 0.05 vs FHH UNx, at 8 and 16 weeks post-transplantation 
'3' 
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demonstrated a minimal degree of damage: 14 ± 7 and IO ± 6 % sclerosed 
glomeruli. The BANFF score was also identical in ACI and F, transplants, and 
was mainly based on some glomerulopathy and tubular atrophy (Figure 3). 
ACI transplants versus ACI·UNx 
The SBP of ACI transplants was significantly higher at 8 weeks than that of ACI· 
UNx, 129 ± 9 vs IIO ± 6 mm Hg, respectively. However, at 16 weeks no significant 
difference in SBP could be detected anymore (123 ± 8 and II5 ± 6 mm Hg). 
Renal function (Figure 2, Table 2) did not change after transplantation: At 
week 16, UaY of ACI transplants was 24 ± 12 mg(24hr, which was not 
significantly different from 8 ± 5 mg(24hr of ACI·UNx. There was no difference 
in degree ofFGS, glomerulopathy, tubular atrophy or interstitial fibrosis in both 
groups (Figure 3). 
Figure 2. 
132 
400 
350 
300 
:2 
fi 250 
~ 
5 
.~ 200 
, 
c 
'E 150 , 
D 
" 100 
50 
0 a 16 
weeks post-transplantation 
Urinary albumin excretion in mg/24h in (ACI x FHH) FI recipients with the Fawn· 
hooded (FHH)(.), the (ACI)(O) strain and the F, (D) of both strains as donor and 
in unilaterally nephrectomized (UNx) FHH, ACl and FI rats. Values are given as 
mean ± SEM. * = P < 0.05 vs FI-FI and FHH·UNx, at 8 and r6 weeks post-
transplantation. 
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FHH transplants 
Grafting an FHH kidney to the F, did not change the SBP of the F, recipient 
(Figure I). Similarly, the relative heart weights of both groups were equal (table I). 
The absolute and relative kidney weight of both groups was similar, both at time 
of transplantation and at the end of the experiment (Table I). Despite comparable 
blood pressure profiles and renal mass, the severity of CTD differed significantly 
between FHH and F, transplants. Renal function was impaired. FHH kidney 
grafts excreted significantly more UaV than F, transplants, 234 ± 58 vs 25 ± 30 
mg/24 hr, respectively, at week 16 (Figure 2). Plasma creatinine, a less sensitive 
marker, did not differ between both groups (Table 2). The histomorphology also 
demonstrated a striking difference between both groups. Whereas F, transplants 
had minimal degree of damage, FHH grafts demonstrated moderate FGS (10 ± 6 
vs 39 ± 12%, respectively; p < 0.05). 
Evaluation of renal damage before transplantation demonstrated that kidneys 
from FHH, ACI and F, had minimal FGS at the time of transplantation, although 
FHH kidneys with 8 ± 5% had significantly more damage than ACI and F, 
kidneys with I ± I and 2 ± 2%, respectively. 
ACf.F, ACI UNx FHH UNx 
Creatinine (l-tmol/L) 59 ± 6 60 ± 5 74±17* 60±8 66±7 102 ± 50 
Tablc2. Plasma creatinine levels in kidney transplants at week 16. * = p < 0.05 vs FHH UNx. 
FHH transplants versus FHH UNx 
Comparing the transplanted FHH kidney to the hypertensive FHH UNx, the SBP 
and the relative heart weight of the FHH-F, were significantly lower (Figure I, 
Table I). The rise of UaV (Figure 2) in FHH transplants was significantly 
attenuated. At week 16, UaVwas 234 ± 58 compared to 379 ± 86 mg/24 hrin the 
FHH- UNx. In addition, the transplanted FHH kidney had significantly lower 
plasma creatinine levels compared to FHH-UNx (Table 2). Besides a less 
impaired function, transplanting an FHH kidney into tl,e F, also resulted in a 
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significantly lower incidence of FGS and lower BANFF score with significantly 
less glomerulopathy, tubular atrophy, and interstitial fibrosis compared to that 
observed in FHH-UNx, whereas the degree of intimal hyperplasia did not differ 
between both groups (Figure 3). 
Figure 4a. 
Figure 4b. 
'34 
12 
10 
§ 
~ 
~ 
~ 
2 
0 
ACI-Fl ACI-UNx Ft-Ft Fl-UNx fHH·F1 FHH·UNx 
The histopathological degree of chronic transplant dysfuction according to the 
BANFF·criteria in kidneys of Fawn-hooded (FHH), ACI and the FI of both strains 
transplanted into the histocompatible FI recipient, and in unilaterally 
nephrectomized (UNx) kidneys of the 3 strains. The 4 different criteria· I) 
glomerulopathy in nonsclerotic glomeruli, 2) tubular atrophy, 3) interstitial fibrosis 
and 4) intimal hyperplasia were separately analyzed as described in the Methods, and 
the sum of the individual scores of the 4 criteria is given. Values are given as mean 
± SEM. * = P<o.o5 vs Fr·F I and FHH UNx. 
3 Dglomerulopathy 
Dtubular atrophy 
o interstitial fibrosis 
m Intimal hyperplasIa 
ACI·F1 ACI·UNx 
• 
F1-F1 Fl·UNx FHH·Fl FHH-UNx 
The histopathological degree of chronic transplant dysfunction differentiated by the 
4 criteria: r) glomerulopathy in nonsclerotic glomeruli, 2) tubular atrophy, 3) 
interstitial fibrosis and 4) intimal hyperplasia. Values are given as mean ± SEM. *, 
#, ** = P<o.o5 vs FI,PI and FHH UNx. 
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Discussion 
To test the hypothesis that in a normotensive environment, the susceptibility of 
the donor kidney to develop CTD is under genetic control, we transplanted 
kidneys of two strains (FHH and ACI) and their FI into the normotensive, 
histocompatible FI recipient. In this setting, the donor kidneys were exposed to 
the same blood pressure profLle, metabolic and hormonal environment. 
The main finding of this study was that genetic factors of the donor kidney 
contribute to the development of CTD. Transplanting an ACI kidney into a 
normotensive FI rat resulted in a normal renal function that was comparable to 
that of FI transplants. In contrast, kidneys from hypertensive FHH donors 
transplanted to FI demonstrated a significant rise in albuminuria and 
glomerulosclerosis compared to ACI or F I transplants, whereas the systolic blood 
pressure was similar in the three transplant groups. The normotensive status of 
the FI with different donor kidneys is directly based on tail· cuff SBP 
measurements at two time points after transplantation. Although the sensitivity 
of the indirect measurement of SBP is restricted, even with measuring it five 
times, additional evidence for normotensive profLles comes from the finding that 
absolute and relative heart weights were equal. Thus, factors other than 
hypertension have to be related to the differences in susceptibility for CTD 
between the FHH and ACI rats. 
The ACI donor weighed less than the FI recipient at time of transplantation, 
hence the ACI kidney was transplanted into an unmatched recipient. At the end 
of the follow· up, the kidney weight of ACI transplants was similar to that of FI 
transplants. Even with this compensatory hypertrophy to fully adapt to the 
heavier recipient, the ACI did not demonstrate features of impaired function or 
altered morphology, which emphasizes its genetic resistance to develop renal 
damage. On the other hand, the susceptibility ofFHH kidneys was not related to 
differences in relative or absolute kidney weight since FHH and FI had equal 
values. Furthermore, the increased susceptibility of the FHH could not be 
attributed to a difference in number of glomeruli. At a age of '3 weeks FHH and 
ACI kidneys both have 33.000 ± 3800 glomeruli (Provoost AP, van Aken M, 
unpublished data)." 
From previous shldies in the FHH rat, we know that the susceptibility of the 
FHH to develop glomerulosclerosis is associated with elevated intraglomerular 
pressure. Simons et at. demonstrated glomerular capillary hypertension in 
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moderately hypertensive FHH rats,'" which suggests that the autoregulation of 
the kidney does not function properly. Therefore, it might be that the systolic 
blood pressure of the FI was still too high for the FHH kidney. Previously, we 
demonstrated in FHH-UNx that after decreasing the SBP to "5 mm Hg with 
angiotensin converting enzyme inhibitors the incidence of glomerulosclerosis 
was lower than we observed in the transplanted FHH kidneys." On the other 
hand, decreasing the SBP of the FHH UNx to the level of the FHH transplants 
by irbesartan caused much less glomerulosclerosis than observed in our FHH 
transplants." However, such pharmalogic intervention reduces SBP, but 
additional effects directly protecting the kidney cannot be excluded. 
The degree of CTD could also be related to a genetic susceptibility of kidneys 
to ischemia-reperfusion injury. Such early events have been demonstrated to 
induce or accelerate CTD."·" Because transplantation of an ACI or FI donor 
kidney into the FI recipient did not affect urinary excretion of albumin or renal 
morphology compared to UNx controls, we are able to transplant kidneys without 
impairing renal function. In addition, during a I-year period our transplantation 
technique does not lead to functional and morphological changes in syngeneic 
BN kidneys." Therefore, the renal impairment of the FHH transplants could 
reflect susceptibility for ischemia-reperfusion injury. Using the same 
transplantation technique, kidneys from the WAGjRo strain are much more 
susceptible for damage than BN kidneys. WAG jRo kidneys demonstrate a 
delayed function, whereas BN kidneys produce urine immediately after 
anastomosing the renal vessels." To verify this hypothesis, FHH should be 
transplanted into the FHH. However, surgery with vascular anastomosis is 
technically impossible because of the genetic bleeding disorder of the FHH rat. 
Another approach to resolve this question is by temporary clamping the renal 
artery in unilateral nephrectomized FHH and ACI, both treated with 
antihypertensive drugs. 
One compromising factor in unraveling the mechanism of susceptibility 
could be the donor kidney morphological status. At time of transplant, FHH 
kidneys showed somewhat more glomerulosclerosis than ACI kidneys, which 
could influence the outcome. To exclude this, treatment with antihypertensive 
drugs in FHH and ACI rats early after birth until transplantation could prevent 
any hypertension-induced renal damage. 
The present study confirms previous findings" that hypertension has to be 
associated to the genetic susceptibility of the FHH kidney, as damage could be 
Susceptibility of DOHor Kidneys for Chronic Transplallt Dyif/mctiofl 
attenuated by transplanting it into a normotensive F I recipient. This result 
supports the idea that a proper control of blood pressure in kidney transplant 
patients will reduce the progression ofCTD, as demonstrated earlier by Paul et al. 
in the Fisher to Lewis rat transplantation model. ') 
Besides the observed differences in susceptibility to CTD, this transplantation 
study confirms phenotypically the previous finding that susceptibility for renal 
disease and hypertension are under independent genetic control in the FHH rat.') 
Because the FI recipients remained normotensive after transplantation, the 
moderate hypertension of the FHH rat strain did not travel with the kidney. This 
makes the FHH strain a hypertensive rat strain in which hypertension does not 
appear to travel with the kidney. Experimental studies with genetically hypertensive 
rat strains as the Milan hypertensive," the Dahl·S hypertensive,"'" and the SHR 
strain" demonstrated that hypertension is transferable. Also, some clinical studies 
suggest that hypertension of the donor could contribute to post-transplant 
hypertension in recipients:"" However, results of our study clearly demonstrate 
that hereditary hypertension does not always have its origin in the kidney_ 
In summary, the genetic susceptibility of the donor kidney is important in the 
development of chronic transplant dysfunction. The responsible genes for this 
susceptibility and the pathophysiological mechanisms are currently under 
investigation. 
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Summary 
Background: Our aim was to develop a model of chronic rejection (CR) in small 
bowel allografts, and to study the changes occurring in these grafts. 
Methods: Small bowel transplantation was performed using the DA to AS rat 
strain combination. Short-term (5 mg/kg intramuscular, from days -2 to +9), or 
long-term cyclosporine treatment (5 mg/kg, 3 times a week until day 50) was 
given to prevent acute rejection. Controls were untreated allografts, DA isografts 
with and without cyclosporine, and normal DA and AS rats. They were followed 
for 50 and 100 days after transplantation. 
Results: Recipients of a syngeneic graft lost weight during the first week after 
transplantation, but started to regain weight and kept growing thereafter. 
Histology showed normal bowel architecture with normal mesenteric lymph 
nodes and Peyers patches. Vigorous acute rejection occurred in the untreated 
allografts. Animals had persistent weight loss, and were killed between 6 to 13 
days after transplantation. No clinical signs of graft-versus-host disease were 
seen. Histology showed end-stage acute rejection. In both cyclosporine treated 
allografted groups the postoperative course was as in the isografted animals. 
However, all animals had histologic signs of CR by 50 and 100 days after 
transplantation. Changes were most prominent in the mesentery. Serositis with 
increased vascularity, inflammation with sclerosis, and patchy myointimal 
proliferation with endothelialitis of the mesenteric vessels were found. Changes 
in the bowel were patchy and included some thickening of the muscle coat, crypt 
hyperplasia, scattered necrotic cells in the crypts, slight blunting of villi and loss 
of goblet cells. Infiltrating cells in the mesentery and bowel consisted mainly of 
CD4+ cells, CD8+ T-cells and monocytes/macrophages. Lactulose-mannitol 
urinary excretion ratio was significantly increased in short-term cyclosporine 
treated allografts at days 50 and roo posttransplant. Semm albumin levels were 
significantly lowered in this group at both time points examined. 
Conch<sions: We have developed two models in which CR occurs after small bowel 
transplantation. Long-term cyclosporine treatment delayed the development of 
CR, since functional abnormalities were only seen in the animals that were 
treated with short-term cyclosporine. 
Chronic Transplallt Dysfunction in Intestinal Allografts 
Introduction 
Small bowel transplantation (S BT) is potentially an improved treatment modality 
for patients suffering from irreversible short-bowel syndrome, who are currently 
fed using total parenteral nutrition (TPN). In specialized centers, SBT has 
evolved over the last decade from a cumbersome procedure with unacceptably 
high morbidity and mortality to a more acceptable therapy for those with 
permanent intestinal failure. Patients that qualify for SBT are those with 
irreversible dependency on TPN and a poor long-term prognosis related to 
progressive difficulties with the administration ofTPN (venous access), catheter 
associated sepsis, and liver failure.'" 
A major problem hampering the long-term success of SBT is the vigorous 
acute rejection, requiring high doses of immunosuppression. A major 
improvement in the results ofSBTcame in the early '990-ies when the powerful 
immunosuppressant tacrolimus replaced cyclosporine. Although the outcome of 
SBT is still mainly determined by acute rejection and lethal infections, the long-
term results are nevertheless improving.1 Because of this, new problems that 
arise in the longer term are encountered. Of these, dysmotility, eating disorders, 
post transplant lymphoproliferative disease, late acute rejection episodes and 
chronic rejection (CR) are of special concern. 
Little is currently known about CR following SBT, although some 
experimental and clinical data show that CR may develop after SBT.l4 The clinical 
characteristics reported on CR are diarrhoea and weight loss. Histologically, total 
villous atrophy, apoptosis of crypt cells with inflammatory infiltrate, and 
arteriosclerosis of the mesenteric vessels are described.,·6 
The aim of the present study was to develop a model in which CR of the small 
bowel allograft would develop in a reproducible manner that would allow us to 
Shldy the changes occurring in those grafts. 
Materials and methods 
Animals 
Inbred adult male Dark Agouti (DA) (RT1avI) and Albino Surgery (AS)(RT1I) rats 
were obtained from Monash Animal Services, Victoria, Australia. All 
experimental procedures involving animals conformed to the National Health 
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and Medical Research Council Code of Practice and were approved by Monash 
Medical Centre Animal Ethics Committee B and the Monash Standing 
Committee on Ethics in Animal Experimentation. 
Small bowel transplantation 
SBTwas performed as described previously.' In brief, the total small bowel, from 
the Ligament ofTreitz to the terminal ileum was transplanted on a vascular 
pedicle consisting of the superior mesenteric artery and portal vein. In the 
recipient, end·to·side anastomoses were made between the recipient infra·renal 
aorta and donor superior mesenteric artery, and recipient caval vein and donor 
portal vein. After resection of the recipient small bowel, the graft and recipient 
remnant bowel were anastomosed end-to-end. 
Experimental design 
The following groups were studied: I) DA to DA, no treatment, 2) DA to DA, long-
term cyclosporin (ICsA), 3) DA to AS, no treatment, 4) DA to AS, short-term 
cyclosporine (sCsA), and 5) DA to AS, long-term CsA. sCsA treatment consisted 
of 5 mg/kg intramuscularly from day -2 to +9 relative to transplantation. ICsA 
treatment consisted of 5 mg/kg intramuscularly three times a week until day 50. 
Normal DA or AS rats were used as controls. Animals were killed 50 and roo 
days after transplantation, or when they demonstrated 30% weight loss. 
Functional parameters 
Serum albumin was measured using the bromocresol green method on a Cobias 
bio autoanalyser. Results are given as mean ± sd in gil. Lactulose mannitol 
urinary excretion test: Animals were fasted during the day. 400 mg/kg D-
lactulose and roo mg/kg of D-mannitol were dissolved in I mL of water. This 
solution was given orally by gavage. Each animal was placed in a metabolic cage 
and urine was collected overnight. The amount of urine produced was recorded, 
and samples were stored at -20 ·C until analysis. Both lactulose8 and mannitol' 
concentrations (mmol/l) were measured colorimetrically on a Cobias Bio 
Autoanalyser. TIle results are expressed as mean ± SEM lactulose: mannitol ratio. 
Macroscopic appearance of the graft 
The small bowel graft, its mesentery, the Peyers patches, mesenteric lymph 
nodes, and spleen were inspected for signs of CR at the time of organ retrieval. 
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Samples of the graft were prepared for histology and immunohistochemistry. 
Histology 
Samples of graft ileum were fIxed in 10% neutral formalin. After dehydrating 
and embedding in paraffIn. 3'4 11m thick sections were cut and stained with 
hematoxylin and eosin (H&E). They were scored by two observers. The incidence 
of the following features was recorded for each of nine high power fIelds (400 X); 
Blunting of villi and loss of goblet cells. crypt hyperplasia and crypt cell necrosis 
muscularis thickening. cellular inHltration. vascular involvement (ie myointimal 
proliferation. endothelialitis. adherence of leucocytes to the endothelium. and 
perivascular inHltration). and sclerosis in the mesentery. Scores of o. 1. 2. or 3 
were assigned if features were observed in o. 1/3. 2/3. or all fIelds respectively. 
Results for each feature were added up. and histologic grades were assigned as 
follows: 0 points ~ none (0). "3 points ~ very mild (grade 1). 4.6 points ~ mild 
(grade 2). 7'9 points ~ moderate (grade 3). and 10·12 points ~ severe (grade 4). 
Immunohistochemistry 
Tissues were embedded in OCT and snap frozen. Cryostat sections of711m thick 
were cut. These sections were fIxed in PLP. and stained using a three·layer 
peroxigase technique.'" In brief. sections were pre incubated for 10 minutes in 
10% Normal Swine Serum (NSS; Dako. Christchurch. New Zealand) /10% Fetal 
Calf Serum (FCS) in phosphate buffered saline (PBS) with o.or% NaN) (Az) to 
avoid non·specifIc binding of the primary antibodies. Slides were drained. and 
incubated at room temperature for 1 hour with primary mouse antibody diluted 
in 1% NSS / 1% FCS with 0.01% Az. They were washed 1 x in PBS for 5 minutes. 
taken through graded alcohols. and incubated at 4 "Celcius for 10 minutes in 
methanol/ 0.03% H 2 0 2 to block endogenous peroxidase activity. Thereafter they 
were reversed through graded alcohols and washed 2X in PBS. Rabbit anti· 
mouse·peroxidase conjugate (Dako). was applied and incubated for 30 minutes 
at room temperature. 
After washing 1 x in PBS. the third step. swine anti·rabbit·peroxidase conjugate 
(Dako). was applied and incubated for 30 minutes at room temperature. Sections 
were then washed in PBS 2 x. and colour was developed using metal· enhanced 
DAB substrate (Pierce. Rockford). Finally. slides were counterstained wit Harris' 
haematoxylin. delfydrated. and covered using glass slips. 
The following mouse·anti·rat monoclonal antibodies were used: OX,l (CD45). 
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OX-8 (CD8), W3/25 (CD4), OX-6 (MHC class II), OX-33 (B-cells), ED-I 
(monocytes, free and tissue macrophages), ED-2 (tissue macrophages), ED-3 
(lymphoid macrophages) (ED-I, 2, and 3 are a kind gift of dr C.D. Dijkstra, 
Amsterdam, The Netherlands), and 3-2.3- (NK cells). 
The %-area OX-I positive cells was measured using a "Video Pro" image 
analysis system. OX-8, W3/25, ED-I, OX-33 and 3.2.3 were counted using a 
graticule at a magnification of 400 X. Six separate fields were measured 
corresponding to an area of 0.1 mm2. For the submucosa, an area corresponding 
to 0.02 mm2 was measured and then multiplied by 5. The other markers were 
scored semiquantitatively. 
Statistics 
Statistical analysis of the nutritional parameters, histology and 
immunohistochemistry was done with the Kruskal Wallis analysis of variance, 
followed by a Mann-Whitney U-test, using SPSS for Windows. A p-value <0.05 
was considered statistically significant. 
Results 
Postoperative recovery 
Recipients of a syngeneic graft (groups I and 2) lost weight during the first week 
post transplant, but started to regain weight and kept growing thereafter. 
Untreated allografts demonstrated vigorous acute rejection. Animals had 
persistent weight loss and developed diarrhoea from day 4 onwards. They were 
killed between days 6 and 13 after transplantation. No signs of graft-versus-host 
disease were seen. Histopathological analysis showed end stage acute rejection. 
CsA treated allografts (groups 4 and 5) seemed to lag behind in growth. No 
statistically significant differences between allografted, and syngeneically 
transplanted animals were demonstrable however, since the variation between 
the animals in the different groups was considerable (Figure I). Since no 
diarrhoea or weight loss was observed at the time points studied these models 
may be considered as representing subclinical CR. 
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Figure I. Weight changes after small bowel transplantation 
Nutritional parameters 
10 12 
Serum albumin levels were significantly lowered in sCsA treated animals at both 
time points as compared to normal AS rats (28.I±4.9 and 27.2±2.3 vs. 34.8±0.8 
gil, p~0.02 and p~0.006, respectively). At day 50, the lachllose·mannitol urinary 
excretion ratio in sCsA allografts was significantly higher than that in lCsA 
allografts and normal DA controls (Figure 2). Thereafter, the ratio further 
increased. Hundred days after engraftment, the sCsA allografts had significantly 
higher ratios than tl,e lCsA treated ones, isografts and normal DA controls. There 
were no significant differences between control rats and syngeneically 
transplanted groups. CsA treatment in the isografts did not affect the excretion 
of both urinary lachllose and mannitol. 
The lactulose·mannitol excretion significantly correlated to the histological 
degree of chronic rejection (R~0.35, p ~ 0.047, n ~ 33). 
Macroscopic appearance of the grafts 
Fifty and 100 days after transplantation isografts showed a normal macroscopic 
bowel architecture with normal mesenteric lymph nodes and Peyers patches. 
Signs ofCR were observed in 67% of sCsA treated animals and 33% oflCsA treated 
animals by 50 days, and all sCsA and 67% of lCsA animals by 100 days post 
transplant. 
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Figure 2. 
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Intestinal function of small bowel transplants was measured by the urinary excretion 
of orally administered lactulose and mannitol.' The ratio lactulose / mannitol was 
calrulated and results are expressed as mean ± SD. ** =p <0.05 vs DA-AS,lCsA and 
DA-DA at the same timepoint, and vs DA-AS,sCsA at day 50; * =p <0.02 vs DA-
AS,lCsA and DAat the same timepoint. Nannal DA, DA:DA +j-ICsAdid not differ, 
and are depicted as 'Jlonnal range bar'. 
Macroscopic signs were: sclerosis and enlargement of the MLN, sclerosis of the 
mesentery and serosa, thickening of the bowel wall, splenomegaly, and 
enlargement of the cecum (both 1.5-3 times their normal size). In most allografts 
the Peyers patches were atrophied, sometimes to a degree that they were no longer 
visible. In other allografts Peyers patches had become enlarged and hemorrhagic. 
In advanced CR, the MLN had become a large, sclerotic and sometimes 
hemorrhagic mass. The mesentery and serosa were rigid due to the extensive 
sclerosis. None of these abnormalities were found in the syngeneic groups. 
Histology 
At 50 days post transplant, a pericapillary infiltrate was usually the first 
indication ofCR (Figure 3). Other early features were cellular depletion and active 
infiltration of the graft MLN. Serositis with increased vascularity, florid 
mesenteric inflammation with sclerosis and patchy myointimal proliferation 
with endotilelialitis of the mesenteric vessels were found later in the course of 
Chronic Transplant Dysfunction in IntestiHal Allografts 
Figme J. 
a) DA to DA isograft 100 days post transplant showing normal bowel architechlre. b) Mesentery of 
the graft shown in fig. p c) Pericapillary infiltrate in the mesentery of a long· term cyclosporine 
treated allograft at day 50 pos'ttransplant with mild chronic rejection. d) Allograft treated with long-
tenn cyclosporine at day 100 post transplant showing moderate chronic rejection with blunting of 
villi, loss of goblet cells, crypt hyperplasia, hypertrophy of the muscle coat, and sclerosis of the 
mesentery. e)High power magnification of an allograft treated with short-term cyclosporine at day 
50 post transplant showing moderate chronic rejection with blunting of villi, loss of goblet cells, crypt 
hyperplasia and thickening of the muscularis. 
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CR. Changes in the bowel were patchy, and included some thickening of the 
muscle coat, crypt hyperplasia, scattered necrotic cells in the crypts, sclerosis 
between the crypts, slight blunting of the villi and loss of goblet cells (Figure 3). 
Apart from an increase in mononuclear cells, the lamina propria between the 
crypts also contained mast cells and eosinophils. The degree of CR could vary 
from very mild to moderate within a group (Table raj. At day 50, ICsA treated 
animals had significantly less chronic damage compared to sCsA treated animals 
(I.3±0.5 vs. 2.8±0.5, p~o.oor)(Table rb). However, this difference had 
disappeared by day roo after transplant.None or very mild changes were seen in 
the syngeneically transplanted grafts (Figure 3). 
Table la. 
Table lb. 
Short·tenn CsA Long-teml CsA 
GradeJ./daY----7 dano (n~9) dapoo (n~5) dano (n~6) dapoo (n~6) 
none (0) 0 0 0 0 
very mild (I) 0 20 67 '7 
mild (2) 33 40 33 50 
moderate (3) 67 40 0 33 
severe (4) 0 0 0 0 
Histopathological analysis of chronic rejection after small bowel transplantation. 
Percentage of animals per group with a chronic rejection grade. Histopathological 
chronic rejection grades were assigned according to the severity of the lesions (see: 
Materials and methods). 
Group 
short-term CsA, day 50 
short·term CsA, day roo 
long·term CsA, day 50 
long. term CsA, day 100 
Histopathological rejection grade 
(mean ± sd) 
2·7 ± 0·5 
2.2 ± 0.8 
1.3 ±0·5* 
2.2 ± 0.7 
Chronic rejection grades after small bowel transplantation. Histopathologic 
rejection grades were assigned according to the severity of the lesions (see materials 
and methods).*: short·ternl CsA vs.long·tenn CsA at day 50, p=o.OOI. 
Figure 4. 
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Distribution of!: CD45 (OX-I), 2: CDB (OX-B), 3: CD4 (OX-4), 4: MHC class II (OX-
6).5: macrophages (ED-I), and 6: NK cells (323) in isografts (a) and allografts (b) roo 
days post transplantation. 
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Figure). Cell infiltration in normal DA (fZI). isografted (El),isografted with CsA (~) and 
allografted bowel(sCsA: • ; ICsA: D ).The increased infiltration by CD45+ leucocytes in the 
chronically rejecting allografts consisted mainly ofT lymphocytes and EDr+ macrophages. CsA 
therapy delayed the influx of these cells in the allografts. B lymphocytes and NK cells appeared to 
playa minor role in chronic rejection. Isografts with or without CsA therapy had a comparable 
numbers of mononuclear cells as nonnal DA controls. Results are expressed as mean ± SEM.* = 
P<o.05 vs DA·DA and DA·AS,lCsA at the same timepoint; **:=; P<o.o5 vs DA·DA at the same time 
point; # = P<o.o5 vs DA·DA,ICsA and DA·DA at the same timepoint. 
Analysis ofinfiltrating cells 
The numbers, types, and distribution ofleucocytes demonstrated in the different 
compartments of the ileum (i.e. villi, crypts, submucosa, and muscularis) are 
depicted in Figures 4 and 5. As can be seen in the figures, no significant changes 
were detected in cell numbers in either of the isograft groups when compared to 
nonnal DA rat controls. In some isografts however, a focal infiltrate around single 
crypts was seen. This was never observed in non-transplanted controls. In 
general, in the mucosa of small bowel grafts, the highest density of cells was 
found atthe base ofthe crypts, showing a gradual decrease up the crypt-villus axis. 
In allografts, the number of infiltrating cells (CD45+) was significantly 
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increased. These consisted mainly of CD4+" CD8+ T·cells and ED·I+ 
macrophages. Long·term CsA treatment delayed the infiltration of the allografts, 
since at day 50 significantly less cells were present in the ICsA than in sCsA 
treated animals. 
CD4+ cells were present in constitutively high numbers in normal ileum and 
isografts (Figure 4-3a). A significant increase was observed in the crypts of 
allografts at both time points. CD8+ cells were significantly increased in the 
crypts and muscularis of sCsA treated allografts, and in the crypts oflCsA treated 
allografts at day 100. Changes in number of ED· 1+ macrophages were evident in 
all compartments, \vith a significant increase in the crypts and submucosa. In 
the muscle layer, which is normally devoid ofED,,+ cells, a significant influx was 
observed at day 100. 
The absolute number of OX'33+ B·cells was low in all groups (Figure 5). No 
differences among the groups were found except for a significant increase in the 
muscularis of sCsA treated allografts at day 100. The number and distribution of 
NK cells was comparable in all groups (Figures 4.6b and 5). ED'2+ tissue 
macrophages were markedly increased in the submucosa and muscularis of 
allografted animals. Many cells were situated at the border between the 
longitudinal and circular muscle layers, i.e. in close association with the 
myenteric plexus. Very low numbers ofED'3+ lymphoid macrophages were seen 
in the crypts, submucosa, and muscularis. These numbers were comparable in 
all groups sh,died. 
Discussion 
Chronic rejection is the major determinant that hampers long.term graft survival 
of solid organ grafts."'" With the improving results after seen after SBT,' CR will 
also emerge as an obstacle to long·term survival. Although its pathophysiology 
seems in part similar in different types of grafts, organ specific feahlIes are also 
apparent. Aspecific features that predominate are thickening of the intima of the 
blood vessels in the graft, and fibrosis." Specific features are unique to the 
anatomy and physiology of the graft, and include h,bulointerstitial damage in 
kidneys," loss of bile ducts in liver grafts," and blunting of villi in the small 
bowel.' Because we wished to sh,dy the specific pathophysiology of CR following 
SBT, the aim of the present study was to develop a model for CR after S BT. 
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The macropathological findings of our study are grossly comparable to the 
findings published previously by Langrehr et a/.,' namely: enlargement of the 
MLN and involvement of the Peyers patches, fibrosis of the mesentery and in a 
later stage the serosa. Histological findings were quite similar also: cryptitis, 
blunting of villi, loss of architecture and cellular depletion of the MLN. Loss of 
goblet cells was not reported. In their study, however, these changes progressed 
rapidly after the discontinuation of CsA, whereas w~ found that CR had 
developed in all animals 50 days posttransplant, but did not rapidly progress over 
the next 50 days. This difference may be explained by the fact that we killed the 
animals at the time points of evaluation and did not take consecutive biopsies of 
the graft, as did Langrehr et aI., These successive laparotomies and biopsi,s of the 
graft cause multiple episodes of wound healing with the release of growth factors 
that may accelerate fibrotic changes in the graft and evoke multiple adhesions. 
No histological, and only very minimal inflammatory changes were found in 
the isografted groups. There was no difference between CsA-treated or untreated 
animals. This is in accordance with previous findings in syngeneic small bowel 
grafts,"" but contrasts with recent observations in syngeneic kidney transplants 
where significant changes may be seen in the absence of alloantigenic 
stimulation," and shows that the pathophysiology of CR in different organs may 
vary considerably. 
The earliest histologic signs of CR in our small bowel transplants were loss of 
architecture and cellular depletion of the MLN and Peyers patches together \vith 
a pericapiUary infiltrate of the mesenteric vessels. These changes were also 
observed in allogeneic SBT models in which no morphologic or functional 
changes were seen more than one year after grafting." This underscores the 
highly immunogenic nature of these lymphoid structures and the mesentery. 
Mucosal ischemia may be important in the development of CR since 
arteriosclerosis, which may lead to ischemia, is one of the characteristics observed in 
this study. The small bowel has an enormous regenerative potential after ischemic 
damage." 111is regeneration starts in the crypts which respond with an increase in 
proliferating cells (crypt hyperplasia). These proliferating cells, which constitutively 
express MHC class II antigens may be primary targets for acute and chronic 
rejection. This may explain the high density of infiltrating cells seen in the crypts. 
Rejection of the small bowel is not a generalised process. Acute rejection is 
patchy,"" and may be easily missed when taking biopsies. Here we show that CR 
is also a very patchy process, in one graft both normal appearing bowel and severe 
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lesions may be found. This may also explain the variation found within the 
groups with respect to histologic score, numbers of infiltrating cells, and 
lactulose: mannitol excretion. Therefore, early detection of CR in human SBT 
will be possible only when histology is combined with immunohistochemistry 
and functional evaluation. 
This is the first comprehensive phenotypic analysis of cells involved in 
chronic rejection after small bowel transplantation. The increase in CD45+ 
leucocytes in the graft was mainly due to an increase in T.lymphocytes and ED-
1+ macrophages. These cells are also dominant in acute rejection episodes of the 
small bowel in man. '0." Pericryptic T cell infiltration preceeds histologic overt 
acute rejection and seems an early marker for acute rejection.'o The focal 
pericryptic infiltration with CD8+ cells in the present study again indicates that 
the crypts are an early target for both alloantigen-independent (syngeneic grafts) 
and alloantigen-dependent destruction. How these infiltrating cells damage the 
enterocytes is not clear. However, in several suspected immune-mediated small 
intestinal disorders crypt hyperplasia and villus atrophy are observ.ed. It has been 
shown recently that activated macrophages can directly inhibit the proliferation 
of rat intestinal epithelial cells. Mediators produced by macrophages may be 
involved, and both nitric oxide and TNF-o: have been show to be involved in this 
cytostatic effect." Eosinophils and mast cells were observed in the allografts also. 
These cells are found in inflammatory diseases of the bowel, such as celiac 
disease" and Crohn's disease' Their possible contribution to CR in our model 
is intriguing, and deserves further study. 
In the muscle layer of allografts significant infiltration with macrophages 
(both ED-I+ and ED-2+) was seen. These cells may contribute to the thickening 
of the muscle wall observed, and to the loss of contractile activity reported by 
others." This by secreting cytokines and by activating the myocytes and cells in 
the myenteric plexus to produce cytokines, which may exacerbate the process. 
B lymphocytes and NK cells did not appear to be involved in the development 
of chronic rejection: There was no significant difference in the numbers of OX-
33+ B cells and 3.2.3+ NK cells in the different groups. This in contrast to the 
findings by Bauer and co-workers who observed a complete loss of B cells in the 
mucosa" and an increase ofNK cells" of chronically rejecting small bowel grafts. 
Histologic changes in tl,e graft were accompanied by loss of graft function. 
Although we found no statistically significant differences in growth between iso 
and allografts, serum albumin was significantly lowered in the group treated 
Chronic TransplaHt DysjimctioH in Intestinal Allografts 
with short-term CsA. Serum albumin is an important nutritional parameter and 
lowered serum levels indicate that the small bowel graft was unable to normally 
digest and/or absorb nutrients. The lactulose-mannitol test is a widely accepted 
method to test intestinal permeability:' Lactulose is normally not absorbed by 
the intestinal mucosa but under pathologic conditions, it transfers paracellularly 
and is subsequently secreted in the urine. Mannitol is normally absorbed 
transcellularly, and excreted in the urine. Under pathologic conditions its 
absorption is impaired, and its excretion diminished. The urinary excretion ratio 
therefore is a sensitive measure for mucosal integrity. In our model, lactulose-
mannitol ratio was significantly increased in sCsA treated allografts, which 
indicates a compromised epithelial integrity with transcelluar leakage. In 
addition, we hypothesise that the loss of goblet cells, which produce the 
constihlents of the overlying mucus layer, results in loss of this layer. Although 
the role of mucus is not fully understood, there is increasing evidence that both 
glycoproteins and trefoil peptides present in mucus playa role in mucosal repair 
after injury." Together, the loss of integrity of the epithelium, and the loss of 
goblet cells may contribute to the progression of mucosal atrophy by further 
impairing its capability to respond to injury. 
Although it is known that CsA has a profound effect on small bowel function 
even in normal animals" the changes we found seem not attributable to CsA 
toxicity since function and morphologyofisografts treated \vith CsA was normal. 
Long-term CsA treatment delayed the development of CR somewhat. At 50 
days posttransplant 67% of the ICsA group had very mild CR and none had 
moderate CR. In the sCsA group this was the reverse. However, roo days 
posttransplant (i.e. 50 days without CsA in the ICsA group and 93 days in the 
sCsA group) this difference had disappeared. Nonetheless, the mucosal integrity 
in the sCsA allografts, as defined by lactulose/mannitol excretion, had further 
deteriorated at day roo compared to the allografts treated with long-term CsA. 
These findings show we have developed two rat models in which CR develops 
in a reproducible manner. Histologic and inflammatory changes are accompanied 
by loss of function only in· short-term CsA treated animals. Clinical signs of CR 
were not present at the time points shtdied, representing subclinical CR. Long-
term CsA treatment delays the development of CR, but is unable to prevent it. 
Further shldies using this model are currently done to determine the role of 
growth factors in the pathophysiology of CR following intestinal transplantation. 
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Summary 
Background: Long-term survival of small bowel transplants is hampered by 
chronic rejection. Epidermal growth factor (EGF) and transforming growth 
factor 13 (TGF-I3) have opposing, regulatory roles in normal intestinal physiology 
and may be involved in the pathogenesis of chronic intestinal rejection. 
Aims: To investigate the expression of EGF and TGF-l3r in chronically rejecting 
small bowel transplants. 
Methods: Olthotopic small bowel transplantation was performed in the allogeneic 
DA to AS rat combination; Cyclosporin was administered temporarily to prevent 
acute rejection. Controls were DA isografts and normal DA rats. PreproEG F and 
TGF-l3r gene expression was evaluated by Northern blot analysis of the ileum 
RNA and standardized against glyceraldehyde-3-phosphate-dehydrogenase 
expression. 
Results: Allografts demonstrated functional impairment and histological features 
of chronic rejection, whereas isografts appeared normal. EG F: Allografts 
demonstrated a significant reduction of EGF mRNA when compared to DA 
isografts. TGF-l3r: No significant changes were detected in TGF-l3r expression in 
either allogeneic or syngeneic grafts. 
Conclusions: This study demonstrates reduced preproEGF and preserved TGF-l3r 
gene expression in chronically rejecting small bowel transplants. 
Epidermal growth factor and CilYollic Intestinal Transplant Dysfunction 
Introduction 
Chronic rejection is the predominant cause of graft dysfunction and failure of 
solid organ transplants, such as heart, kidney, liver and lung, which survive the 
first year post-transplantation,'" The introduction of new potent 
immunosuppressive drugs to treat acute rejection has improved the survival of 
small bowel transplants. Recent clinical evidence demonstrates that the process 
of chronic rejection also hampers the long term survival of small bowel 
transplants, eventually leading to graft loss.'~ Understanding of the mechanisms 
of injury in this pathology is thus imperative for new therapeutic strategies to be 
developed. Chronic rejection of small bowel is characterized clinically by 
refractory diarrhea and weight loss and pathologically by mesenteric 
inflammation with sclerosis, myointimal proliferation of mesenteric vessels, 
hypertrophy of muscularis, scattered necrosis of crypt cells, crypt hyperplasia, 
blunting of villi and loss of goblet cells.'"' 
Epidermal growth factor (EGF) and transforming growth factor-I\ (TGF-Pr) 
have important, opposing, regulatory roles in normal intestinal physiology and 
alterations in their expression have been implicated in the pathophysiology of 
chronic rejection of other organs,lOoll 
EGF, a 53 amino acid peptide, stimulates the proliferation and differentiation 
of epidermal and epithelial cells and is mitogenic for other cell types such as 
fibroblasts and smooth muscle cells in vitro,"'" It regulates absorption of 
electrolytes and nutrients from the small intestine and is thus involved in the 
control of intestinal transport." In the intestine EGF is produced by crypt cells 
and the enterocytes of the lower half of the villi.,6·"-Immunohistochemical studies 
have demonstrated EGF peptide in Brunner's glands of the duodenum and 
Paneth cells of the small intestine of adult rats," EGF is formed as a large prepro 
molecule of I2I7 amino acid residues" and processed to EG F I-53:0 Receptors for 
EGF are present throughout the entire gastrointestinal tract and have been 
localized to the brush border and basolateral membrane."'" 
In contrast to EGF, TGF-Pr inhibits the proliferation of crypt cells and 
stimulates their differentiation to mature enterocytes:"" TG F-Pr also has 
important effects on extracellular matrix deposition, stimulating its synthesis 
and preventing its degradation, induces angiogenesis and plays a role in 
immunomodulation. These features make TGF-Pr one of the main factors 
involved in the development of fibrosis in disease states." 
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TGF-p in the small intestine is predominantly localized to the differentiated, 
non-proliferating cells of the villus tips_''''' Expression ofTGF-p is regulated by 
both pre- and posttranscriptional mechanisms which include viral 
transactivators and growth factors_ It is synthesized as a 39' amino acid residue 
precursor that is proteolytically cleaved to a II2 amino acid residue subunit and 
protein fragments which form a latency-associated peptide_ It is secreted in a 
latent form, and conversion to the active form occurs at the cell surface and in 
the extracellular matrix."'" 
In the small intestine, TG F-P receptor mRNA assessed by Northern blot analysis 
was mainly shown in the non-epithelial compartment Immunohistochemical 
localization demonstrated the TGF-p receptor was mainly expressed in the lamina 
propria and muscularis and to a lesser degree in the epithelium, where it was most 
prominent in the villus and absent in crypt cell.'o 
The aim of the present study was to evaluate the possible involvement ofEG F 
and TGF-Pr in the pathophysiology of chronically rejecting small bowel 
transplants. 
Materials and methods 
Groups 
All experimental procedures involving animals conformed to the National 
Health and Medical Research Council Code of Practice and were approved by 
Monash Medical Centre Animal Ethics Committee B and the Monash Standing 
Committee on Ethics in Animal Experimentation_ 
Chronic rejection model 
The model of chronic rejection after small bowel transplantation has been 
previously described.' In brief, male, adult inbred Dark-Agouti (DA) and Albino-
Surgery (AS) rats were used, obtained from Monash Animal Services_ One-step 
orthotopic total small bowel transplantation was performed, as described 
previously," in the allogeneic DA to AS rat combination. Cyclosporin, 
5mg/kg/day from day -2 until day 9, was administered to prevent acute 
rejection_ Rats were killed at 50 days (n ~ 6) or 100 days post-transplantation (n 
~ 5)- Small bowel grafts were removed and processed for histopathology and 
Northern blot analysis. 
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Isografts 
DA isografts were included to control for non-allogeneic injury. Rats were killed 
and grafts were removed at 50 (n ~ 6) or IOO days (n ~ 5) post-transplantation. 
Normal rat small howe/(DA) 
Four small bowels from normal DA rats were used as controls. 
Intestinal Function 
The function of the intestinal transplants at 100 days post-transplantation was 
investigated using the lachtlose mannitol urinary excretion test. Animals were 
fasted during the day. 400 mg/kg D-Iactulose and roo mg/kg of D-mannitol 
were dissolved in I ml of water. This solution was administered orally by gavage. 
Each animal was placed in a metabolic cage and urine was collected overnight. 
The amount of urine produced was recorded, and samples were stored at -20 ·C 
until analysis. Both lactulose and mannitol concentrations were measured 
colorimetric ally on a Cobias bio analyzer and results are expressed as the 
lachllose: mannitol ratio. 
Processing of the graft 
Small bowel grafts were retrieved under ether anesthesia, and rats were killed 
immediately thereafter. Portions of the ileum measuring approximately I cm 
were fixed in 10 % buffered formalin and embedded in paraffin for 
histopathological studies or snap frozen in liquid nitrogen for RNA extraction. 
Histopathology 
Paraffin sections, stained with haematoxylin and eosin, were assessed in a 
blinded manner by two observers. TI,e incidence of the following features were 
recorded for each of 9 high power fields (400 X): a) blunting of villi and goblet 
cell loss; b) crypt hyperplasia and necrosis; c) thickening of the muscularis; d) 
inflammatory cell infiltrate, vascular damage and sclerosis of the mesentery. 
Scores of 0, I, 2 or 3 were assigned to features not observed, or observed in I/3, 
2/3, or all fields respectively. Results obtained for each feature were added up, 
and added scores of 0 were classified as no damage, 1-3 as very mild (grade I), 4-
6 mild (grade 2), 7-9 moderate (grade 3) and 1O-I2 severe (grade 4). 
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Northern blot analysis 
Total RNA was extracted from 100 mg of snap frozen, full-thickness ileum using 
the RNAzol'mB method (Tel-test, Friendswood, USA). Northern blot analysis was 
performed as previously described." Briefly, the RNA was denaturated with 
dimethylsulfoxide/glyoxal, electrophoresed in a I % agarose gel in phosphate 
buffer (pH 7.4) and blotted onto nylon membrane (Hybond-N, Amersham). 
Hybridization was carried out with a 400 bp mouse preproEGF eDNA probe" or 
a 370 bp TGF-l3r cDNA probe", labeled with pP-dCTP using random primers 
(Megaprime, Amersham). Quantitative variability of either isolation, transfer or 
loading of RNA was controlled for by reprobing the blots with a 720 bp eDNA 
probe for glyeeraldehyde-3-phosphate dehydrogenase (GAPDH)." Blots were 
prehybridized at 42'C. Hybridization with EGF and GAPDH probes was 
performed a142'C and with TGF-l3r eDNA probe at 55'C. Blots were exposed for 
7 to 72 hours to a phosphor imager plate, and the bands ofpreproEGF, TGF-l3r 
and GAPDH mRNA were measured using a Fuji Bio Imager Analyzer. Results 
are expressed as EGF/GAPDH or TGF-l3r/GAPDH ratios. Four normal DA 
ileum samples were run on every blot to enable comparisons between blots, and 
results obtained with normal DA were standardized to represent the value of 1. 
Statistical analysis 
For statistical analysis, the Kruskal-Wallis one way ANOVA followed by Mann 
Whitney U test and the Spearman correlation test were used. The results are 
expressed as mean ± SEM; probability of p < 0.05 was accepted as significant. 
Results 
Histology 
The evolution of histological changes in this model of chronic rejection has been 
described previously.' All allogeneic transplants developed chronic rejection 
although the severity of damage varied between animals from very mild to 
moderate. At 50 days, 4 out of 6 animals had moderate chronic rejection. A 
progression of chronic damage with time was not evident. At one hundred days 
post-transplantation, 2 of 5 rats had moderate changes. All other grafts had mild 
changes. None or very mild (lout of II animals) changes were seen in the 
syngeneic grafts. 
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Intestinal Function 
The lactulose·mannitol urinary excretion ratio was significantly elevated in 
allografts compared to isografts at roo days (Table I). suggesting an impaired 
mucosal integrity in chronically rejecting intestinal transplants. There was no 
significant difference between the syngeneically transplanted group and control 
rats. (p ~ 0.89) 
Table I. 
Nonnal DA n DA·DA n DA·AS n 
Lactulose/ Mannitol ratio 0·37 ± 0.02 (4) 0·54 ± 0.17 (4) 1.34 ± 0.15 * (5) 
Lactulose-mannitol excretion ratio in small bowel transplants 
At 100 days post-transplantation, intestinal function was measured by the urinary 
excretion of orally administered lactulose and mannitol. The ratio lactulose I 
mannitol was calculated and results are expressed as mean ± SEM. * = P <0_05 vs 
DA-DA and normal DA. 
Northern blot analysis ofTGF'~l mRNA 
The results of Northern blot analysis ofTGP·!31 expression are summarized in 
Table 2. No significant changes in TGF.!3, expression were detected in either the 
allogeneic or syngeneic grafts at the time points examined. 
Table 2. 
TGF·0,/GAPDH 
day 50 
day roo 
Nonnal DA n DA·DA n DA·AS n 
1.00 ± 0.08 (4) 1.35 ± 0.09 (6) 1.'7 ± 0.16 (7) 
1.00 ± 0.09 (4) 1.02 ± 0.16 (5) 0.8) ± 0.09 (5) 
TGF-PI gene expression in small bowel transplants. 
Ileum RNA samples were isolated and Northern hybridization was performed with 
preproEGF and GAPDH cDNA probes as described in the Methods. Results are 
expressed as TGF-PdGAPDH ratios, standardized to normal DA. Units are 
arbitrary. Data were analyzed by Kruskall Wallis nonparametric ANOYA, and pairs 
were compared by Mann·Whitney U test. 
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Figure I. 
Figure 2. 
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Ileum RNA samples were isolated and Northern hybridization was performed with 
preproEGF and GAPDH cDNA probes as described in the Methods. Results are 
expressed as EGF/GAPDH ratios, standardized to nonnal DA. At 100 days post-
transplantation, the intestinal function was measured by the urinary excretion of 
lactulose and mannitol after oral administration and expressed as a ratio lactulose I 
mannitol. Data were analyzed with the Spearman correlation test: R = '0.74. p= 0.01, 
n=l4· 
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Northern blot analysis of prepro EGF mRNA 
The results of North em blot analysis of prepro EGF mRNA are depicted in Figure 1. 
Allografts demonstrated a progressive reduction in preproEG F mRNA levels 
over time, which attained significance at IOO days post-transplantation when 
compared to their relevant control. DA isografts (p ~ 0.03). The preproEGF 
expression of DA isografts did not significantly differ from untransplanted, 
normal DA controls (p ~ 0.06). 
The EGF expression was inversely correlated with the lactulose-mannitol 
excretion (-0.74, p ~ o.or, n ~ 14)(Fignre 2). 
Discussion 
Chronic rejection hampers long term survival of organ transplants, including 
small bowel grafts.""" To investigate the pathophysiology of chronic rejection 
after small bowel transplantation, we recently developed a rat model in which 
allogeneic small bowel grafts demonstrated histological features of chronic 
rejection.' The present sh!dy investigates the expression of EGF and TGF-Il, in 
the model of chronically rejecting small bowel transplants. 
PreproEGF gene expression was significantly reduced in chronically rejecting 
small bowel allotransplants IOO days post-transplantation compared to 
syngeneic controls. The reduced preproEGF expression could be the result of 
loss of EGF producing cells through chronic graft injury, or could be the 
response to downregnlatory signals. Ischaemic injury may be an important factor 
resulting in the loss of EG F producing cells in the iniestinal crypts. Since the 
mesenteric vessels of the allografts were found to be partially obliterated in this 
model, the resulting ischaemia may have contributed to the scattered necrosis of 
crypt cells and crypt hyperplasia seen in chronic rejection of small bowel 
allografts. TI,is is consistent with the sequence of events described by Langrehr 
et al. in another model of chronic intestinal rejection in which the early stages 
were characterized by infiammation and endothelialitis of the mesenteric 
vessels, while mucosal·inflammation, apoptosis and cryptitis emerged with 
time.' Furthermore, ischaemia has been identified as a signal resulting in down-
regulation of preproEG F mRNA while the overall RNA transcription is not 
affected." Other factors which may have provided downregulatory signals 
include infiammatory mediators such as interleukin-r and TGF-Il, which have 
Cl1C1pter 9 
been shown to modulate growth factor expression."'" 
Since EGF stimulates the proliferation of crypt cells'" and thus functions to 
maintain mucosal integrity, blunting of villi and loss of goblet cells could be the 
result of or be aggravated by the reduced preproEG F production. In addition, the 
impaired mucosal integrity, as measured by the lactulose·mannitol test, could 
also directly reflect to decreased EG F production: EG F has a cytoprotective effect 
through stimulation of goblet cells to release mucus." 
Administered EGF has been shown to heal and prevent experimentally induced 
gastrointestinal ulcerations in animals."'" In a rat model of acute abdominal 
radiation EGF administration decreased the mucosal ulceration, infiltration of 
polymorphonuclear lymphocytes and maintained the cellular structure." 
Guglietta & Sullivan have described possible clinical applications of EGF" and 
based on the results of our study, administration of exogenous EG F emerges as a 
possible treatment strategy to ameliorate the process of chronic rejection. 
TGF.p, gene expression was not modified in chronically rejecting small bowel 
allografts compared to isografts or normal bowel. This finding was unexpected 
since in other models of chronic organ rejection, using the same rat strain 
combinations, an increase of the TGF.p, mRNA transcripts was found." Using a 
different strain combination, TGF.p, was increased in a model of chronic small 
bowel rejection. H A possible explanation for this discrepancy might be a 
difference in mucosal damage: In our model loss of goblet cells was a consistent 
feature of chronic rejection while this was not described in Walgenbachs model. 
Since the allografts demonstrated a significant increase of ED·, positive 
macrophages/ monocytes 9 which are known to be potential producers ofTGF.p" 
an increased TG F.p, expression by the macro phages and a concomitant decreased 
production ofTGF.p, mRNA by injured enterocytes could explain our finding. 
To investigate the possible role of alloantigen.independent factors such as 
ischemia/reperfusion and surgical trauma on the process of chronic rejection, 
DA·DA isografts were compared to native DA bowel. Isografts preserved normal 
histology, normal function and their expression of EGF and TGF·Il, was not 
significantly different from that of the normal DA controls, although the EG F 
expression in isografts showed a tendency to be lower. Similarly, Sigalet et al. 
found that intestinal transplantation per se had only minimal effects on 
intestinal function." Thus, in contrast to the reported importance of alloantigen. 
independent factors in kidney transplantation," these factors do not seem to play 
a major role in our small bowel transplantation model at the timepoints shldied. 
Hpidermal growth factor and Chronic Intestinal Transplant Dysfunction 
In summary, this study demonstrates reduced preproEGF and preserved TGF-i3J 
gene expression in chronically rejecting small bowel transplants. A possible 
beneficial effect of exogenous administration of EG F to the long·term survival of 
small bowel allografts is currently under investigation. 
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Summary 
Background: Long-term survival orintestinal transplants is hampered by chronic 
rejection (CR). Since transplants with CR demonstrate fibrotic changes, the 
cytokine basic fibroblast growth factor (bFGF) could be involved in the tissue 
remodelling of chronic intestinal rejection. 
Aims: To investigate the bFG F gene and protein expression and distribution in 
chronically rejecting intestinal allografts. 
Methods: Orthotopic small bowel transplantation was performed in the allogeneic 
DA to AS rat combination; Cyclosporin was administered temporarily to prevent 
acute rejection. Controls were DA isografts and normal DA. bFGF gene 
expression was evaluated using RT-PCR of the ileum-RNA and standardised 
against GAPDH expression. bFGF protein was demonstrated using 
immunohistochemistry. To identify the bFGF-positive cell type, stains for cell 
markers were performed on sequential sections. 
Results: Allografts showed histological features of CR, whereas isografts 
preserved normal architecture. bFGF gene expression was present in normal 
ileum and significantly upregulated in allografts. Immunohistochemical 
staining showed a significant increase of bFG F protein compared to isografts. 
Most bFGF+ cells were localised in the submucosa and muscularis, particularly 
around neural plexus. bFGF+ cells appeared to be ED-2+ macrophages, strongly 
suggesting that the site ofbFGF production is the activated macrophage. 
Conclusions: This study demonstrates increased bFGF mRNA and protein in 
chronically rejecting intestinal allografts, which appeared to be produced by 
macrophages. 
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Introduction 
With the improved treatment of acute rejection episodes, intestinal 
transplantation has evolved over the last decade from a cumbersome procedure 
with unacceptably high morbidity and mortality to a more acceptable therapy for 
those with permanent intestinal failure. Although long.term outcome is 
currently mainly determined by uncontrolled acute rejections and lethal 
infections, it is also hampered by chronic rejection,'" which is the leading cause 
oflate graft loss of other organs such as heart and kidney.'· Indeed, some patients 
have already lost their small bowel transplant due to chronic rejection.'" In 
contrast to the knowledge of the nature of the immune response and production 
of cytokines during acute intestinal rejection,' little is known about the 
involvement of cytokines in the pathophysiology of chronic rejection of intestinal 
transplants: The Pittsburgh.group has given some attention to this issue. They 
demonstrated an increased expression of the cytokines IL'4 and interferon·y in 
chronically rejecting intestinal allografts, mainly localised in the thickened 
muscularis externa.'·' To further understand the mechanisms of tissue 
remodelling during chronic rejection of the small bowel, we have recently 
developed a rat model.'" Histomorphological analysis demonstrated mesenteric 
inflammation with sclerosis, myointimal proliferation of mesenteric vessels, 
thickening of the muscularis, crypt hyperplasia, blunting of villi and loss of 
goblet cells, features which have also been found both in humans and other 
animal models. '.n.n Some of these characteristics are consistent with the possible 
involvement of fibrogenic growtll factors such as basic fibroblast growth factor 
(bFGF), as demonstrated for other organs."'" 
bFGF, or fibroblast growth factor'2 (FGF'2), a member of the FGF family, is 
a '33 to I54 amino acid (I7.5 kDa) peptide which is mitogenic for vascular 
endothelial cells, smooth muscle cells, fibroblasts, neural cells and chemotactic 
for macrophages and endothelial cells. It has been involved in wound healing 
and tissue regeneration." bFGF has a high affinity for heparin and heparan 
sulphate proteoglycans, and can thus be found in the extracellular matrix, or 
bound to basement membranes." The binding ofbFGF to heparan sulphate 
proteoglycans, protects it from inactivation by endogenous proteolytic agents. 
In the digestive tract, bFGF peptide has been detected in duodenum,I7 and in 
normal gastric and colonic mucosa. It has been immunohistochemically 
localised to vessels, fibroblasts and macrophages, with epithelial cells and 
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extracellular matrix demonstrating no bFGF immunoreactivity." Heparan 
sulphate proteoglycans act as the low-affinity receptors for bFGF in the 
intestine," forming an FGF-heparin complex, which facilitates the interaction 
between FGFs and their high-affinity cell surface tyrosine kinase receptors, 
identified on various cell types including smooth muscle cells, endothelial cells, 
macrophages and intestinal epithelial cells_'"'" 
The function ofbFGF in the small intestine is not well defined. bFGF failed 
to promote epithelial restitution after colonic mucosal damage in vitro." 
Production ofbFGF in the adult ileum has not yet been described_ However, 
bFGF is known to be produced by activated macrophages, smooth muscle cells 
and fibroblasts,""" and just these sources of bFGF could be important in the 
tissue remodelling processes of chronic intestinal rejection. 
The aim of the present study was to evaluate the possible involvement ofbFGF 
in the pathophysiology of chronic intestinal allograft rejection by analysing gene 
and protein expression and distribution in the course of chronic rejection. 
Materials and methods 
Groups 
All experimental procedures involving animals conformed to the National 
Health and Medical Research Council Code of Practice and were approved by 
Monash Medical Centre Animal Ethics Committee B and the Monash Standing 
Committee on Ethics in Animal Experimentation. 
Chronic rejection model 
The model of chronic rejection after small bowel transplantation has been 
previously described.IO In brief, male, adult inbred Dark-Agouti (DA)(RT-rav') 
and Albino-Surgery (AS)(RT-r') rats were used, obtained from Monash Animal 
Services. One-step orthotopic total small bowel transplantation was performed, 
as described previously,23 in the allogeneic DA to AS rat combination. 
Cyclosporin, 5mg/kg/day from day -2 until day 9, was administered to prevent 
acute rejection_ Rats were killed at 50 days (n ~ 6) or roo days post-
transplantation (n ~ 5)- Small bowel gratis were removed and processed for 
histopathology, immunohistochemistry and reverse transcriptase polymerase 
chain reaction. 
basic Fibroblast grolVth factor and Chronic Intestinal Transplant Dysfunction 
Isografts 
Untreated DA isografts were included to control for non-allogeneic injury. Rats 
were killed and grafts were removed at 50 (n ~ 6) or 100 days (n ~ 5) post-
transplantation. 
Normal rat small howel(DA) 
Four small bowels from age-matched, normal DA rats were used as controls. 
Processing of graft 
Small bowel grafts were retrieved under ether anaesthesia, and rats were killed 
immediately thereafter. Portions of the ileum measuring approximately I em 
were fixed in 10 % buffered formalin and embedded in paraffin for 
histopathological studies or snap frozen in OCT for immunohistochemistry or 
directly in liquid nitrogen for RNA extraction. 
Histopathology 
Paraffin sections, stained with haematoxylin and eosin, were assessed in a 
blinded manner by two observers. The incidence of the following features were 
recorded for each of 9 high power fields (400 X): a) blunting of villi and goblet 
cell loss; b) crypt hyperplasia and necrosis; c) tllickening of the muscularis; d) 
inflammatory cell infiltrate, vascular damage and sclerosis of the mesentery. 
Scores of 0, I, 2 or 3 were assigned to features not observed, or observed in 1/3, 
2/3, or all fields respectively. Results obtained for each feature were added up, 
and added scores of 0 were classified as no damage, !-3 as very mild (grade I), 4-
6 mild (grade 2), 7-9 moderate (grade 3) and IQ-I2 severe (grade 4). 
Immunohistochemistry 
Immunoreactive bFGF was assessed on 4 J.lm cryostat sections post fixed in PLP 
by a four-layer immunoperoxidase technique. Briefly, non-specific binding was 
blocked by preincubation with 10 % normal rabbit serum (Dako, ChristcllUrch, 
New Zealand), in phosphate buffered saline (PBS) with 0.01% sodium azide at 
room temperature. This was followed by overnight incubation with the primary 
mouse anti-bFGF (Upstate Biotechnology Incorporated) and cell surface marker 
ED-2 (a gift by dr.C.D. Dijkstra, Amsterdam, The Netherlands). After each 
incubation, slides were washed in PBS-0.2% gelatine. A second layer, goat anti-
mouse IgG (Sigma, Castle Hill, Australia) was then applied for 30 minutes. 
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Endogenous peroxidase activity was blocked by incubation for ro minutes in 
methanol/o.3% H2 0 2 , after dehydration through graded alcohol. After 
rehydration and washing, the third and fourth layer, rabbit-anti goat 
immunoglobulin (Dako) and goat peroxidase anti-peroxidase (Dako) were 
applied both for 30 minutes. The reaction was developed by the addition of metal 
enhanced Diaminobenzidine substrate (Pierce,) and slides were counterstained 
in Harris haematoxylin, dehydrated, cleared and mounted. 
Negative controls included sections where the primary antibody was omitted 
for every animal. Isotype-specific control monoclonal antibodies (Dako) were 
also used. No staining was observed with these irrelevant antibodies. The 
specificity of the antibodies to bFGF was confirmed by a solid phase absorption 
study, as previously described."' 
The immunohistochemical staining was analysed by two observers, 'blind' as 
to treatment group and time post-transplantation. Positive cells were counted in 
four different compartments of the ileum: villi, crypts, submucosa and 
muscularis, and are expressed as numbers of positive cells/ 0.1 mm2 • 
Semiquantative Reverse Transcriptase Polymerase Chain Reaction 
RNA preparation 
Total RNA was extracted from approximately roo mg of snap frozen full-thickness 
ileum using the RNAzollmB method (Tel-test, Friendswood, USA). RNA was 
quantified spectrophotometrically and samples were diluted to 2.5 flghll. 
cDNA synthesis 
Reverse transcription reactions were set up using I /-II of RNA (2.5 /-Ig), in 20 /-II 
volumes using an MULV RT system (Perkin Elmer, Foster City, CA, USA) 
PCR DNA amplification 
PCR reactions were performed using a PCR amplification kit, with AmpliTaq gold 
(Perkin Elmer). The co-amplification reaction for bFGF and GAPDH genes was 
optimised to ensure that the amplification of both genes was within the exponential 
phase at the end-point of the PCR. Different concentrations of the primer pairs and 
of the Amplitaq gold were tested. Based on optimisation experiments, PCR 
amplification reactions were performed in 25 fll volumes and contained 1.5 mM 
MgCI2 , x r PCR buffer, 1.25 U AmpliTaq gold, 100 nM bFGF, 100 nM GAPDH and 
2.5 fll cDNA. The following primers were used: bFGF sense: Fluorescein (Fl)-
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basic Fibroblast growlll factor and Chronic Intestinal Transplant Dysfunction 
TCACTICGCTICCCGCACTG (549), antisense CCAGCAGCCGTCCATCTT (787); 
GAPDH sense: FI·CCTICATIGACCTCAACTACATG (131), antisense: 
GATGACCTIGCCCACAGCCTT (667). The position of the 5 nucleotide of each 
primer in the published sequences,,·,6 is included in parenthesis. Following an 
activating step for 12 minutes at 94 ·C, 35 cycles were performed with a 
denaturation step of 1 minute at 94 ·C, an annealing temperahtre for 1 minute 
and 30 seconds started at 72 ·C and declining with 0-4 ·C per cycle until 64·C, 
and an extension step of 2 minutes at 72 .c, The resulting PCR products had a 
length of 238 and 536 bp for bFGF and GAPDH respectively. The GAPDH 
primers were designed by Dr P .Aldred and kindly provided by Dr N. Cranswick. 
No interference was demonstrated between primer pairs. 
Analysis of peR products 
The sense primers were labelled with fluorescein at the 5' end for direct detection 
of the PCR product bands using a laser based fluorescence DNA detection system 
(Fluorimager 575·Molecular Dynamics, Sunnyvale, CA, USA). The volume of the 
individual bands was integrated using the ImageQuant software (Molecular 
Dynamics) and ratios between bFG F and GAPD H bands were calculated. Four 
normal DA ileum samples were amplified and nm with each group containing all 
isografts or allografts, at day 50 or day 100 to enable comparisons between each 
group of amplified samples, and results obtained with normal DA were 
standardised to 1. All samples were amplified and run in duplicate. 
Statistical analysis 
All statistical analysis were performed using SPSS for Windows. Kruskal·Wallis 
nonparametric ANOVA followed by Mann Whitney U test and Spearman 
correlations were used. The results are expressed as mean ± SEM; probability of 
p < 0.05 was accepted as significant. 
Results 
Histology 
All allogeneic transplants developed CR although the severity of damage varied 
between animals from very mild to moderate. At 50 days, 4 out of 6 animals had 
moderate chronic rejection (grade 3). A progression of chronic damage with time 
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was not evident. At one hundred days post-transplantation, 2 of 5 rats had 
moderate changes. All other grafts had mild changes. Syngeneic grafts retained 
a normal architecture. 
Immunohistology 
Normal ileum (Figure la, Figure 2) 
The highest density of bFGF protein expressing cells was located in the 
submucosa; a few positive cells were detected in the lamina propria of the villi 
and crypts, whereas epithelial cells were negative. bFGF positive cells were 
present throughout the muscularis, their density being highest between the 
circular and longitudinal layers. Vessels did not show bFGF reactivity. 
Intestinal isografts 
The number and distribution ofbFGF protein expressing cells did not differ 
from normal controls, both at day 50 and day 100 (Figure 2). 
Intestinal allografts (Figure IC, Figure 2) 
The number of bFG F protein expressing cells in allografts was approximately 
doubled compared to isografts and normal DA.(p < 0.05 and p < 0.01, respectively) 
at 50 and roo days. Increased numbers ofbFGF positive cells were seen in all 4 
compartments evaluated. As in normal ileum, most bFGF positive cells were 
localised to the submucosa. Some positive cells were detected in the lamina 
propria of the villi and crypts, whereas no bFGF positivity was seen in epithelial 
cells. As in the controls, the highest number of cells was found between the 
circular and longitudinal muscular layers. None bFGF positivity was seen in the 
vessels. 
We had previously demonstrated increased numbers of monocytes /macrophages 
(EDI-positive cells) and T cells in chronic rejection of small bowel.'o Staining of 
sequential sections was performed to identify the lineage of the bFGF positive 
cells in our model. 
As shown in Figures Ib and I d, many cells expressing bFG F protein appeared in 
sequential sections to be ED-2 positive tissue macrophages. Immunohistochemical 
staining of normal DA ileum with ED-2 antibody demonstrated that the highest 
number of ED-2 positive cells was present in the submucosa. Very few tissue 
macrophages were present in the villi. The density was somewhat higher in the 
crypts. There were some positive cells in the muscularis, vvith accumulation at 
basic Fibroblast grolVtli factor and Cllronic Intestinal Transplant Dysfunction 
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Figure I. a) bFGF protein expression in a normal small intestine b) normal distribution of tissue 
macrophages in small intestine of the DA·rat. c·d)Chronically rejecting intestinal allografts 
demonstrating an increased number of bFGF positive cells and tissue macrophages. TIle highest 
increase was found in the submucosa and in the muscularis, particularly between the circular and 
longitudinal layers (arrow). 
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the border between the circular and longitndinallayer. Isografts did show a 
progressive increase of tissue macrophages over time, which attained 
significance at roo days post-transplantation when compared to normal controls 
(p < 0.05) (Figure 2). This increase was found in all compartments, although it 
did not reach statistical significance in the crypts. Fifty days after transplantation, 
allografts demonstrated a significant increase in ED-2 positive macrophages 
compared to isografts and to normal DA ileum (p < O.OI). Increased macrophage 
numbers were evident in villi, crypts, submucosa and muscularis, with the 
highest density found in the submucosa. Hundred days after engraftrnent, the 
number of ED-2 positive macrophages in allografts was still significantly 
increased compared to isografts and normal ileum (p < 0.01 and p < 0.02, 
respectively), but did not differ significantly from day 50. The same pattern of 
distribution was observed. 
The association between bFGF expression and tissue macrophages was further 
examined by performing a correlation stndy between bFG F protein expressing 
cells and ED-2 positive macrophages. Taking all compartments together, bFGF 
protein expression was found to be significantly correlated with the number of 
tissue macrophages (R ~ 0.86, P < 0.001, n ~ 25). (Figure 3). Furthermore, the 
number of bFGF protein expressing cells was significantly correlated with the 
severity of chronic rejection (R ~ 0.80, P < 0.001, n ~ 21) (Figure 4). 
Figure 4. 
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Histological grade of chronic Intestinal rejection 
bFGF protein and the histological grade of chronic intestinal rejection. The severity 
of chronic changes including blunting of villi and goblet ceUloss, crypt hyperplasia 
and necrosis. thickening of the muscularis. inflammatory cell infiltrate vascular 
damage and sclerosis of the mesentery were classified as no damage (grade 0), very 
mild (grade I), mild (grade 2). moderate (grade 3) or severe damage (grade 4). The 
number ofbFGF protein expressing cells were counted and given as a quantity per 
0.1 mm2. Data were analysed by Speannan correlation: R = 0.80, p < O.OOI,n= 21 
Figwe 2. 
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bFGF protein expression and ED'2 positive tissue macrophages in the course of 
chronic intestinal rejection. Grafts were processed for immunohistology and stained 
for immunoreactive bFGF protein and ED'2 tissue macrophages as described in the 
Methods, Results are expressed as the number ofbFGF protein expressing cells and 
ED'2 positive cells and mean ± SEM are given. * = p < 0.05 vs normal ileum; ** = p 
< 0.01 and p <0.05 vs normal ileum and isografis, respectively: # = P < 0.05 and p < 
0.02 vs normal ileum and isografis, respectively; ## = P<O.OI vs nonnal ileum and 
isografts; x = P<0.02 vs nonnal ileum and isografts. 
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Correlation between the number ofbFGF expressing cells and the number ofED2+ 
tissue macrophages in normal ilewn and intestinal transplants at timepoints studied. 
Grafts were processed for immunohistology and stained for immtu10reactive bFGF 
protein and ED'2 tissue macrophages. The number ofbFGF protein expressing cells 
and ED'2+ cells were counted and given as a quantity per 0.1 mm2 Data were analysed 
by Spearman correlation: R = 0.86, P < O.oor, n = 25. 
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bFGF gene expression in chronically rejecting intestinal allografts 
Ileum RNA samples were isolated and RT·PCR was performed with bFGF and 
GAPDH primers as described in the Methods. Results are expressed as 
bFGFjGAPDH ratio, standardised to nonnal DA ileum and mean ± SEM are given. 
Units are arbitrary. * = p < 0.02 vs normal DA ileum (Kntskal Wallis one way 
ANOVA followed by Mann Whitney U test) 
The bFGF gene was transcriptionally active in normal DA ileum (Figure 5). 
Allografts demonstrated a significant increase in bFGF mRNA levels at 50 and 
roo days post-transplantation, compared to normal controls (p < 0.01 and p < 
0.02 respectively). The bFGF mRNA of isografts was not postoperatively 
modified compared to normal DA controls. bFG F gene expression was correlated 
with the histological grade of chronic rejection (R ~ 0.55, p < 0.02, n ~ 21) 
Discussion 
Long-term survival of intestinal transplants is hampered by chronic rejection, the 
major cause of graft loss of other transplanted organs, such as kidney and heart. l4 
Chronic rejection of transplanted organs is characterised by a inflammatory 
infiltrate, graft arteriosclerosis and fibrosis. Small bowel-specific features 
include thickening of the muscularis externa, crypthyperplasia, and blunting of 
villL'·'o." Because of its effects Oil smooth muscle cells, fibroblasts and the 
extracellular matrix, bFG F is a candidate for being involved in the tissue 
186 
basic Fibroblast growth jactor and Cllronic Intestinal Transplant D}'sfwlctioll 
remodelling of chronic rejection in intestinal transplants. as demonstrated in 
other organs."" Moreover. bFGF has been identified to act as a chemoattractant 
for macrophages." a cell type which has been recurrently demonstrated in 
chronically rejected organs. 
The present study demonstrates that the bFGF gene was transcriptionally 
active in the ileum. This is the first time that bFGF mRNA has been detected in 
the adult intestine. Chowdhury et al. could not detect any signal in normal 
colorectal mucosa using RT-PCR." Shimasaki et al. found that bFGF measured 
by Northern blot analysis could not be detected in the small intestine." Our use 
of the full thickness of the intestine combined with a sensitive RT-PCR protocol 
may explain these differences. The bFG F protein was also present in normal and 
rejecting ileum. 
The main finding of this shldy is that there was a significant increase in bFGF 
mRNA and protein in chronic intestinal allograft rejection. This enhanced bFG F 
expression appeared to be correlated with the histological damage of the 
intestinal grafts. further suggesting a role for this growth factor in the tissue 
remodelling. In contrast. chronic vascular rejection in lung allografts did not 
coincide with bFG F immunoreactivity; bFG F was only markedly upregulated in 
the early phase and restricted to peribronchiolar and perivascular infiltrates." 
Also. bFGF did not correlate with the degree of transplant vasculopathy in 
bioptied heart allografts '9·" and in aorta allografts." Indeed. myoproliferation of 
the intra-intestinal arteries was also not accompanied by enhanced bFGF 
immunoreactivity. Therefore. bFGF appears to be important in organ-specific 
remodelling. i.e. muscular thickening and neuron repair. rather than being 
involved in transplant arteriosclerosis. 
Many of the bFGF expressing cells appeared to be ED-2 positive macrophages. 
Furthermore. the number of bFG F protein and ED-2 positive cells were 
significantly correlated. strongly suggesting that the macrophage is an important 
source ofbFGF. Lee et al. also found that bFGF protein was mainly expressed by 
infiltrating cells. including macrophages. in lung allografts." The production of 
bFGF by macrophages has been unequivocally demonstrated by PCR and 
Nortllern blot analysis of macrophage-mRNA." 
bFGF expressing cells and tissue macrophages in allografts were mainly 
localised to the submucosa and the muscularis. particularly between the 
longitudinal and circular layer. Since the neural plexus are localised in these 
areas. bFGF and macrophages have not only to be associated to the muscular 
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thickening, but also might act in the intrinsic neural plexus, Lee et al. found a 
suppressed neuromuscular transmission during subclinical chronic intestinal 
rejection, which is related to the loss of enteric neurons as a consequence of 
extrinsic denervation." Since bFG F is known to stimulate neurons outgrowth," 
the preferential site ofbFGF expressing cells could reflect an attempt to repair 
the intrinsic neural plexus. We could not detect bFGF protein 
immunohistochemically in epithelial cells of normal intestine, consistent with 
the results of Ohtani et al." Moreover, no staining was seen in the damaged 
mucosa of chronically rejecting intestinal allografts, suggesting that endogenous 
bFGF is not involved in the repair of epithelial damage in CR. 
Although the influx of macrophages in isografts was significantly increased 
when compared to normal ileum, histologically the intestinal grafts were well 
preserved during follow-up. Also, bFGF protein and mRNA remained at non-
transplanted level, further assuming that the macrophages in the isografts were 
inactive. 
Based on the present data, we postulate that bFG F may have important effects 
which contribute to chronic rejection ofintestinal grafts: bFGF is a chemoattractant 
for macrophages, contributing to the persistent increase of macro phages in 
chronic intestinal rejection. Activated macrophages in tum produce bFGF and 
other fibrogenic cytokines, including TGF·beta and PDGF and have been shown 
to have a pivotal role in the process of chronic rejection."'" bFGF also has a 
mitogenic effect on smooth muscle cells, enhancing the hypertrophy of the 
muscularis. The localisation of bFGF also suggests that it may have a positive 
effect on neuron outgrowth. 
To further understand the contribution of bFG F in chronic rejection and its 
relationship with tissue macrophages, studies on the effect of neutralisation of 
bFGF protein and on the effect of a selective inhibition of macrophages should 
be performed. 
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Summary and General Discussion 
Chapter 11 
Summary 
Chronic transplant dysfunction (CTD) is the predominant cause of late graft 
failure. The common histopathological feature in all transplanted organs is 
intimal hyperplasia. accompanied by organ· specific lesions. The knowledge about 
the pathogenesis of CTD is incomplete. There is still no treahnent to prevent CTD 
and retransplantation is currently the only effective therapy. 
The studies described in this thesis were performed to investigate etiological and 
pathophysiological aspects of CTD. with the ultimate goal to obtain new 
therapeutic strategies. 
Clinical and experimental studies suggest that non-alloantigen specific factors 
playa role in the process of CTD. Since a role for ischemia in the process is still 
controversial. our purpose was to clarify its contribution to CTD. At first. we 
studied the effect of prolonged cold ischemia on the development of the cardinal 
feature of CTD. i.e. intimal hyperplasia. in an isolated fashion. Therefore. we 
transplanted aortic grafts in a high-responder allogeneic (WAG-BN) rat strain 
combination. Cold preservation (4"q of the aortic grafts in UW-solution for 24 
hr did not enhance the degree of intimal hyperplasia in this non-
immunosuppressed allogeneic model. Likewise. in BN-BN aortic isografts that 
show minimal intimal hyperplasia at vleek 4 after transplantation. 24 hours 
preservation did not adversely influence its development (Chapter 2). 
The question remained whether cold ischemia affects the parenchyma of a 
graft. In addition. the susceptibility of endothelium to ischemic injury might be 
site-dependent. To mimic clinical organ transplantation. the influence of 
immunosuppression on ischemia also had to be studied. From a clinical point of 
view. the effect of cold ischemia is most relevant in a kidney transplantation model; 
kidney transplants are preserved from 2 hours in living-related programs to up to 
40 hours using cadaveric donors. In syngeneic (BN-BN) kidney transplants. the 
transplant procedure itself. which includes an ischemic time of 30 minutes. did 
not affect function and morphology during a J-year observation period (Chapter 3). 
Kidney isografts subjected to 24 hr cold ischemia. however. developed 
progressive proteinuria from week 18 onwards. and showed I year after 
transplantation histological features of CTD: intimal hyperplasia. 
glomerulopathy. and tubular atrophy. In the first days after transplantation. there 
was an increased infiltration of CD4 + T-cells and macrophages. which coincided 
194 
SItn1mary and Get1eml DisClmioll 
with upregulated ICAM'1 expression on the endothelium. At I year, the numbers 
of these infiltrating cells were still significantly increased compared to those in 
isografts with a minimal ischemic period. Exposure of the donor kidney to 24 hr 
of cold ischemia in allografts (BN.WAG) did not affect the onset and progression 
of CTD. Ischemic and non· ischemic allografts, immunosuppressed with 
Cyc1osporine for 3 weeks developed a similar pattern of CTD in 26 weeks. As in 
ischemic isografts, infiltrating cells mainly consisted of CD4 + T cells and 
macrophages, albeit that their numbers were higher, in particular in the early 
phase. This discrepancy of the effect of prolonged cold ischemia between iso· and 
allografts appeared to be related to Cyc1osporine. Administration of the same 
immunosuppressive regimen to ischemic isografts led to inhibition of cold 
ischemia induced late renal dysfunction (Chapter 4). 
Another indication that Cyc1osporine inhibited ischemic mediated injury in 
long·term allografts comes from observations, described in Chapter 5. In the 
absence ofCyc1osporine ischemia augmented the alloimmune mediated response 
in the BN·W AG allografts: Interstitial infiltrates, consisting mainly of CD4 + T cells, 
and tubulitis occurred earlier in the grafts subjected to 24 hr cold ischemia. 
Experiments described in the Chapters 2 and 6 show that surgery· related 
factors also have an impact on the development of CTD. For example, in the 
syngeneic aorta transplantation model, the mode of suturing influences the 
development of intimal hyperplasia. In the midportion of the I cm aortic 
transplant, continuous suturing of the anastomosis led to more intimal 
hyperplasia than interrupted suturing. Aortic stretch - performed by 
transplanting 8 mm long aorta segments into 12 mm dissected recipients - did 
not influence the degree of intimal hyperplasia, but did decrease medial 
thickness. In the syngeneic kidney transplantation model, we demonstrated that 
an uretero·neocystostomy as surgical technique to restore the urinary tract 
contributes to long·term functional and histological renal changes. As the 
intrapelvic pressure was significantly increased, a partial obstruction appears to 
be cause of the renal impairment. 
Since some transplant studies suggest differences in graft outcome due to 
ethnicity of the donor organs, intrinsic genetic factors of an organ may contribute 
to CTD. Chapter 7 presents the effects of transplanting donor kidneys of different 
rat strains into a histocompatible F,.recipient, allowing these grafts to be exposed 
to the same blood pressure profiles, metabolic and hormonal environment. The 
ACI strain, resistant to hypertension induced renal damage, and the hypertensive 
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FHH rat, susceptible for hypertension. induced renal injury, and the (ACI x FHH) 
F, were used as donors. In the normotensive F, recipient with a F, or ACI 
transplant, function and morphology did not differ from their unilaterally 
nephrectomized controls. In contrast, the FHH kidney showed a progressive 
deterioration of function and histological features of CTD. Genetic susceptibility 
of a donor kidney appears to be an important factor in the etiology of CTD. 
Chapter 8 describes that small bowel allografts developed functional 
abnormalities and histological signs of CTD by 50 and 100 days after 
transplantation. CD4+ " CD8+ T cells and macrophages infiltrated the grafts. B· 
lymphocytes and NK·cells did not appear to be involved. Cyclosporine treatment 
delayed the development of CTD. Specific cytokine analyses were performed. In 
Chapter 9, we showed that the gene expression of the cytokine EGF was 
significantly reduced and that the gene expression ofTGF'~, was unmodified in 
the allografts with CTD. From day 50 and onwards gene and protein expression 
of the fibrogenic cytokine bFGF was increased in the CTD allografts. bFGF 
appeared to be produced by the infiltrated macrophages (Chapter 10). 
Concluding Remarks and Perspectives 
Studies in this thesis show that CTD develops in different organ transplants in a 
similar pattern. In both kidney and intestinal allografts with CTD, the 
predominant infiltrating cells are CD4 + T cells and macrophages. In both organ 
transplants, the mild to moderate degree of intimal hyperplasia assumes that the 
concomitantly organ.specific lesions may not only be a consequence of ischemia 
due to vascular obliteration, but have an own entity in the process. 
Despite the fact that CTD presents itself months to years after transplantation, 
the process is initiated at the moment of graft retrievaL Ischemia per se causes 
long·term functional and histological changes resembling those seen in allografts 
with CTD. In allografts, ischemia augments the alloimmune·mediated response. 
Since adhesion· molecule expression and cell infiltration is qualitatively identical 
during the first days in syngeneic and allogeneic grafts, which both develop CTD 
on the long.term, therapies to minimize this early ischemic injury are the first 
goal of treatment of CTD. At this moment, interference with transcriptional 
factors, such as NF'KB, that activate cytokine and adhesion molecule genes in 
response to ischemic injury, are a promising approach for the field of organ 
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transplantation. In an animal model of myocardial ischemic injury, the transfer 
of NF-KB oligodeoxynucleotides as a 'decoy' binds NF-KB and thus prevents 
activation of genes involved in ischemic injury. This led to reduction of 
myocardial infarction after reperfusion.' Interfering in the process at later stages 
is less effective because of the redundancy and Janus-faced character of several 
individual biologic factors, as clarified by knock-out studies. 
Despite the role for ischemia in the process, alloimmunity is the predominant 
factor that induces and maintains the development of CTD. Allografts developed 
CTD in a much more rapid tempo than isografts. 
Up to now, immunosuppressive therapies are basically related to T and B cell 
inactivation. In the chronic phase, however, macrophages appear to be the main 
producers of fibrogenic cytokines, such as bFGF and TGF-i3. Strategies to 
eliminate or inactivate this cell population should be a point of interest. Also, a 
direct interference with the fibrogenic cytokines might be a future avenue. 
Antagonizing TGF-i3 or bFGF interrupts the fibrotic cascade' 
In order to identify patients at risk for CTD, the significance of gene 
polymorphisms of cytokines, growth factors and metabolic factors has to be 
further clarified. Recently, it has been found that<l high-producerTGF-i31 genotype 
in transplant recipients is associated with CTD.'·' Also, as shown in this thesis, 
donor organs may have their own genetic susceptibility to develop chronic lesions. 
In addition to prevent CTD, to halt the process is another therapeutic strategy. 
Adding antihypertensive and antihyperlipedimic treatment to the 
immunosuppressive protocols appears meaningful to reduce the side effects of 
certain immunosuppressive drugs. In this view, stimulating the atrophied 
epithelium in small bowel and kidney transplants with CTD by mitogenic growth 
factors should be investigated. 
To search for an optimal treatment, a further understanding ofthe pathophysiology 
is essential. Characterization of various cell populations, adhesion molecules, 
cytokines, and growth factors during the course of CTD, as performed in this 
thesis, should be followed by depletion or inactivation ofthe individual substances 
at different stages to understand their role in the process. 
In conclusion, CTD has a multifactorial pathogenesis, in which both 
alloimmune specific and non-alloimmune specific factors are involved. A multiple 
treatment strategy at different stages in the process is likely the best design to 
overcome CTD. 
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Sameflvatting en DisclIssie 
Samenvatting en Discussie 
Ondanks de enorme verbetering van de r-jaars overIeving van orgaan-
transplantaten, met name door effectievere immunosuppressiva, is na r jaar het 
transplantaatverIies gedurende de laatste 20 jaar vrijwel konstant gebleven; de 
gemiddelde overleving van een niertransplantaat bedraagt 7.5 a 9.5 jaar. 
Chronische transplantaat disfunctie (CTD) is de hoofdoorzaak van dit late 
transplantaat-falen. Klinisch uit CTD zich in een langzame achteruitgang van 
orgaanfunctie. Morfologisch is het pathogmonisch kenmerk van CTD circulaire 
arteriosclerose van intraparenchymale bloedvaten; daarnaast is er orgaan-
specifieke pathologie, zoals by. glomerulosclerose, tubulusatrofie en il)terstitiele 
fibrose in de nier. 
De etiologie en de pathofysiologie van CTD zijn grotendeels onbekend. Er is geen 
therapie voorhanden om CTD te voorkomen. Retransplantatie is momenteel de 
enige effectieve behandeling. 
De studies in dit proefschrift zijn opgezet om etiologische en pathofysiologische 
aspecten van CTD te onderzoeken, met als doel dat inzicht in het proces zal 
lei den tot nieuwe therapie strategien. 
Klinisch en dierexperimenteel onderzoek hebben aanwijzingen opgeleverd dat 
naast de immunologische respons van de ontvanger tegen het histo-
incompatibele donor-orgaan ook niet-alloimmunologische factoren bijdragen 
aan CTD. 
Hoofdstnk 2 geeft de resultaten weer van de eerste studie, waarbij het effect van 
langdurige koude ischemie op de ontwikkeling van het pathogmonisch kenmerk 
van CTD, intima hyperplasie, sec werd onderzocht. Om dit te realiseren werden 
aorta transplantaties uitgevoerd in een high responder (BN-WAG) combinatie in 
de rat. Zonder immunosuppressie ontstaat in dit model in 4 weken ernstige 
intima hyperplasie. Koude preservatie (4 0q van de donor aorta's in UW-medium 
gedurende 24 uur veranderde de mate van intima hyperplasie niet. Ook in BN-
BN syngene aorta transplantaten, die minimale intima hyperplasie hebben op 4 
weken na transplantatie, had 24 uur preservatie geen invloed op de ontwikkeling. 
De vraag bleef of koude ischemie invloed had op het parenchym van het 
transplantaat. Daarnaast zou de gevoeligheid van het endotheel voor ischemische 
schade afhankelijk kunnen zijn van locatie. Om de klinische orgaan 
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transplantatie na te bootsen, moest bovendien de invloed van immuno-
suppressie op ischemie worden onderzocht. 
Vanuit een klinisch gezichtspunt, is onderzoek naar het effect van ischemie op 
CTD het meest relevant in een niertransplantatie modeL Immers, 
niertransplantaten worden slechts 2 uur gepreserveerd in familie-nierdonatie 
programma's en tot meer dan 40 uur bij postrnOliale donaties_ 
Hoofdstuk 3 beschrijft de opzet van het niertransplantatiemodel en bespreekt de 
resultaten van het effect van de transplantatieprocedure op late schade in een 
bilateraal genefrectomeerde ontvanger. Dit werd onderzocht in een syngeen 
(EN-EN) modeL De transplantatie procedure per se, waarbij inbegrepen een 
ischemietijd van 30 minuten, leidde niet tot verandering van nierfunktie en 
morfologie gedurende de studieperiode van I jaar. 
Echter, syngene transplantaten die gedurende 24 uur werden gepreserveerd, 
ontwikkelden progressieve proteinurie vanaf week 18, en lieten op I jaar na 
transplantatie de histologische kenmerken van CTD zien: intima hyperplasie, 
glomerulopathie, en tubulaire atrofie. In de eerste dagen na transplantatie was er 
een toename van het aantal infiltrerende CD4+ T-lymfocyten en macrofagen, wat 
samenging met een verhoogde expressie van ICAM-I op het endotheel. Op I jaar 
na transplantatie was het aantal infiltrerende cellen nog steeds verhoogd 
vergeleken met de syngene transplantaten met minimale ischemietijd. In allogene 
transplantaten (EN-WAG) beinvloedde de 24 uurs preservatie van de donornier 
niet het ontstaan en beloop van CTD: Ischemische en niet-ischemische allo-
transplantaten die gedurende 3 weken behandeld werden met Cyclosporine om de 
acute afstoting te onderdrukken, ontwikkelden CTD in 26 weken op eenzelfde 
wijze. Net als in de ischemische syngene transplantaten bestond het type 
infiltrerende celllen voornamelijk uit CD4+ T-lymfocyten en macro fagen, hoewel 
het aantal cellen hoger was, m.n. in de vroege fase. De discrepantie van het effect 
van langdurige ischemie tussen syngene- en allogene transplantaten lijkt 
gerelateerd aan de Cyclosporine therapie. Toediening van hetzelfde 
immunosuppressieve schema aan de ratten met syngene ischemische 
transplantaten leidde tot vermin de ring van koude ischemie geinduceerde CTD 
(Hoofdshlk 4). 
Een andere aanwijzing dat de behandeling met Cyclosporine de ischemische 
schade in allogene transplantaten remt, komt van bevindingen beschreven in 
Hoofdstuk 5. Zonder het gebruik van Cyclosporine versterkt ischemie de 
alloimmuun gemedieerde respons in de EN-WAG allotransplantaten. 
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Interstitiele infiltratie van voornamelijk CD4+ T-Iymfocyten, en tubulitis werden 
eerder waargenomen in de transplantaten die 24 uur gepreserveerd werden_ 
De experimenten die beschreven zijn in de Hoofdstukken 2 en 6, tonen aan 
dat chirurgie-gerelateerde factoren ook een invloed hebben op de ontwikkeling 
van CTD_ In het syngene aortatransplantatie model had de manier van hechten 
van de anastomose invloed op de ontwikkeling van intima hyperplasie_ In het 
middendeel van het I cm lange aortatransplantaat leidde doorlopend hechten tot 
meer intima hyperplasie dan onderbroken hechten_ Rek van de vaatwand -
uitgevoerd door een 8 mm lang aorta segment in een I2 mm gedissecteerde 
ontvanger te implanteren - had geen invloed op de mate van intima hyperplasie, 
maar verminderde weI de dikte van de media_ In het syngene 
niertransplantatiemodel werd aangetoond dat de uretero-neocystostomie als 
reconstructie-techniek van de trachls urinalis, bijdraagt aan lange-termijns 
funktionele en histologische nierafwijkingen_ Daar de intrapelvicale druk 
verhoogd was, lijkt een partitiele obstructie de oorzaak van nierschade_ 
Hoofdstuk 7 beschrijft de effecten van het transplanteren van donor nieren 
van verschillende rattenstammen in een histocompatibele FI-ontvanger. Op deze 
wijze werden de transplantaten blootgesteld aan gelijke bloeddruk, metabole en 
hormonale omgeving_ De ACI rattenstam, resistent tegen hypertensie-
gelnduceerde nierschade, de hypertensieve FHH rat, gevoelig voor hypertensie-
gelnduceerde nierschade, en de (ACI x FHH) FI- De funktie en morfologie van 
een FI of een ACI niertransplantaat in de normotensieve FI ontvanger was gelijk; 
Bovendien verschilde deze niet van hun unilateraal genefrectomeerde ACI en F I 
controles op I6 weken na transplantatie_ Daarentegen ontwikkelde het FHH 
niertransplantaat een progressief verlies van funktie en toonde histologische 
kenmerken van CTD_ Uit deze shldie kunnen we concluderen dat de genetische 
gevoeligheid van de donornier voor schade een factor is in de etiologie van CTD_ 
Hoofdstuk 8 beschrijft de ontwikkeling van een reproduceerbaar CTD-model 
na dunne darm-transplantatie en de daarmee gepaard gaande funktionele, 
histologische en inflammatoire veranderingen_ Funktionele afwijkingen en 
histologische kenmerken ontwikkelden op dag 50 na transplantatie_ Het type 
infiltrerende cellen in het transplantaat bestond voornamelijk uit CD4+ en CD8+ 
T-Iymfocyten en macrofagen_ B-Iymfocyten en NK-cellen lijken niet betrokken in 
het proces_ Cyclosporine therapie vertraagde de ontwikkeling van CTD_ In dit 
model werden de expressie van cytokinen onderzocht: 
Hoofdstuk 9 toont aan dat de genexpressie van het cytokine EG F significant 
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verminderd was in allotransplantaten met CTD. De expressie van TGF-~, was 
ongewijzigd. 
Vanaf dag 50 na transplantatie was de gen- en eiwitexpressie van het fibragene 
cytokine bFGF verhoogd in de dunne darmtransplantaten met CTD. Vit deze 
shldie lijkt de macrafaag de voornaamste bron van bFGF te zijn (Hoofdstuk 10). 
Conclusies en Vooruitzichten 
De shldies beschreven in dit praefschrift tonen aan dat de ontwikkeling van CTD 
in verschillende orgaan transplantaten op analoge wijze verloopt. Zowel in nier 
als dunne darm allotransplantaten met CTD zijn CD4+ T-Iymfocyten en 
macrofagen de belangrijkste typen infiltrerende cellen. De milde tot matige 
intima hyperplasie in beide orgaantransplantaten veronderstelt dat de gelijktijdig 
optredende orgaan-specifieke lesies niet alleen het gevolg zijn van ischemie door 
vasculaire obliteratie, maar ook een eigen entiteit in het proces hebben. 
Ondanks het feit dat CTD pas maanden tot jaren na transplantatie manifest 
wordt, begint het praces op het moment van orgaanuitname. Ischemie sec 
veroorzaakt funktionele en histologische afwijkingen op de lange-termijn, die 
overeenkomen met de afwijkingen in allo-transplantaten met CTD. In allo-
transplantaten versterkt ischemie de alloimmuun-gemedieerde respons. 
Daar de expressie van adhesie-molekulen en celinfiltratie kwalitatief gelijk is 
in syngene en allogene transplantaten gedurende de eerste dagen na 
transplantatie, zijn therapieen gericht op het minimaliseren van deze 
ischemische schade het eerste doel van behandeling van CTD. Op dit moment 
lijkt interferentie met transcriptie-factoren, zoals NF-KB, die cytokine en 
adhesiemolecuul genen activeren in respons op ischemische schade, een 
veelbelovende strategie. In een diermodel van ischemische hartschade voorkomt 
het overbrengen van NF-KB oligodeoxynucleotiden als 'Iokeend' voor NF-KB de 
activatie van genen die betrokken zijn bij ischemie. Dit leidde tot een 
vermindering van het myocardinfarct na reperfusie. Latere interferentie in het 
CTD-praces is minder effectief vanwege het pleiotrope karakter van veel 
biologische factoren, zoals aangetoond met knockout-studies. 
Ondanks de rol voor ischemie in het praces is alloimmuniteit de belangrijkste 
factor die de ontwikkeling van CTD in gang zet en onderhoudt. Allogene 
transplantaten ontwikkelden sneller CTD dan syngene transplantaten. 
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Tot op heden zijn de immunosuppressieve therapien gericht op T- en B cel 
inaktivatie_ In de chronische fase, echter, zijn de macrofagen de producenten van 
fibrogene cytokinen zoals bFGF en TGF-j3. Eliminatie of inaktivatie van deze 
celpopulatie behoort een serieus doel te zijn. Ook direkte interferentie met de 
fibrogene cytokinen is een potentiele invalshoek. Het antagoneren van TGF-j3 of 
bFGF onderbreekt de fibrotische cascade. 
De betekenis van genpolymorfisme van cytokinen, groeifactoren en metabole 
factoren dient verder opgehelderd worden teneinde patienten te identificeren die 
een verhoogd risko hebben op het ontwikkelen van CTD. Recent is aangetoond 
dat een high-producer TGF-j3, genotype in transplantatie-patienten geassocieerd 
is met CTD. Daarnaast kunnen ook de donor organen hun eigen genetische 
gevoeligheid hebben om schade te ontwikkelen, zoals is aangetoond in deze 
dissertatie. 
Naast het voorkomen van CTD is het remmen ervan een optie. Het toevoegen 
van antihypertensieve en antihyperlipidemische medkatie aan de immuno-
suppressive proto collen Iijkt zinvol om de nevenwerkingen van bepaalde 
immunosuppressiva te reduceren. Vanuit dit gezichtpunt is het stimuleren van 
geatrofieerd epitheel in dunne darm- en niertransplantaten met CTD met 
mitogene groeifactoren een mogelijkheid. 
Om de optimale therapie te vinden, is verdere sh!die van de pathofysiologie 
essentieel. Het karakteriseren van verscheidene cel populaties, adhesie-
molekulen, cytokinen en groeifactoren tijdens de ontwikkeling van CTD, zoals 
uitgevoerd in dit promotieonderzoeks, behoort gevolgd te worden door depletie 
en inactivatie van de individuele celtypen en factoren tijdens verschillende stadia 
om zo hun preciese rol te begrijpen. 
In conclusie: CTD heeft een multifactoriele pathogenese, waarbij zowel 
alloimmuun specifieke als niet-alloimmuun specifieke factoren betrokken zijn. 
Een multipele behandelingsstrategie tijdens diverse stadia in het proces is 
waarschijnlijk de beste opzet om CTD te overwinnen. 
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basic fibroblast growth factor 
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chronic rejection 
chronic transplant dysfunction 
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Fawn Hooded 
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